# Machine learning analysis of the UNOS database fails to predict lung transplant outcomes

**Authors:** Lucy Luo<sup>1</sup>, Marcin Możejko<sup>2</sup>, Nikolay S. Markov<sup>1</sup>, Alec Peltekian<sup>3</sup>, Suror Moshin<sup>1</sup>, Mary Carns<sup>1</sup>, Phillip Cooper<sup>4</sup>, Jeffrey Lysne<sup>4</sup>, Anthony Joudi<sup>1</sup>, Alan Betensley<sup>1</sup>, Bradford C. Bemiss<sup>1</sup>, Catherine Myers<sup>1</sup>, Ankit Bharat<sup>4</sup>, Rade Tomic<sup>1</sup>, Ambalavanan Arunachalam<sup>1</sup>, Ewa Szczurek<sup>5,6</sup>, GR Scott Budinger<sup>1</sup>, Alexander V. Misharin<sup>1</sup>, Mrinalini Venkata Subramani<sup>1</sup>

## **Affiliations:**

Abstract: Background: Lung transplantation is the only life-saving therapy for end-stage lung disease. However, lung transplantation has the worst survival among all solid organ transplants. We applied machine learning to a large standardized electronic health record (EHR) dataset from the United Network for Organ Sharing (UNOS) to test whether pretransplant and peri-transplant donor and recipient features can predict one-, three- and five-year survival, or favorable long-term outcomes in lung transplant. Methods: We used data from 43,869 first time lung transplant recipients >18 years old from 1987 to November 2022 for whom one-, three-, and five-year survival outcomes were available. We applied XGBoost or a tabular BERT model called EHRFormer to the UNOS EHR dataset. Results: Using pre-transplant features XGBoost predicted one year mortality with a test AUC = 0.6 [0.57, 0.64] 95% CI. Addition of peri-transplant features only modestly improved AUC for one-year mortality prediction (test AUC = 0.63 [0.60, 0.67] 95% CI and 0.64 [0.63, 0.66] 95% CI for XGBoost and EHRFormer, respectively). Top predictive features of one year mortality using peri-transplant features from each model were length of index stay, transplant type, recipient age, ventilation status during the index stay, and creatinine at the time of transplant. Both XGBoost and EHRFormer performed better when predicting lung function at one-year post-transplant (XGBoost test AUC = 0.74; EHRFormer test AUC = 0.76). Both models identified and used features previously associated with transplant outcomes to inform predictions. Conclusions:

<sup>&</sup>lt;sup>1</sup> Northwestern University Division of Pulmonary and Critical Care

<sup>&</sup>lt;sup>2</sup> University of Warsaw

<sup>&</sup>lt;sup>3</sup> Department of Computer Science, Northwestern University McCormick School of Engineering and Applied Science

<sup>&</sup>lt;sup>4</sup> Northwestern Medicine

<sup>&</sup>lt;sup>5</sup> Al for Health, Helmholtz Munich

<sup>&</sup>lt;sup>6</sup> Faculty of Mathematics, Informatics and Mechanics, University of Warsaw

Despite machine learning approaches identifying known risk factors for transplant outcomes, EHR data collected by UNOS poorly predict one-, three-, and five-year mortality outcomes of lung transplantation. These results suggest caution when using pre-transplant EHR features to predict lung transplant outcomes.

#### Introduction

Lung transplantation is the only viable treatment option that confers improved survival and quality of life for patients with advanced lung disease and respiratory failure. Despite improvements in surgical techniques, immunosuppressive strategies, perioperative management, supportive strategies, and approaches for donor lung allocation over the years, lung transplantation is persistently associated with poor survival relative to other solid organ transplants, with a median survival of 5.8 years (1990-2014)<sup>2</sup> and a mean survival of 9.28 years. Approximately 10-15% of all deaths after lung transplant occur in the first year. Indeed, in patients who survived one year after transplant, median survival is 10.2 years. As a result, one-year mortality is an important, trajectory-defining event and is the focus of public reporting of transplant outcomes. Recently, investigators have suggested that three- or five-year outcomes provide additional data with respect to center-specific transplant outcomes, leading some to suggest these outcomes be publicly reported<sup>5</sup>. We reasoned that early prediction of one-, three- and five-year survival based on factors available early in the transplant course might identify patients who would benefit from targeted interventions. Further, we reasoned that waitlist and peri-transplant factors in the donor and recipient that predict outcomes might include modifiable factors to improve outcomes.

Conventional approaches for analyzing risk factors and predictors for lung transplant outcomes rely on univariate or multivariate statistical approaches applied to selected variables. As such, available predictors of lung transplant outcomes vary by center and perform poorly. A,6-15 Machine learning is a powerful approach to identify predictors of outcomes from clinical data, leading to its growing use in clinical research and care. Despite this promise, the application of historic machine learning techniques to EHR data collected by the United Network for Organ Sharing have been disappointing. As machine learning approaches have dramatically improved since the publication of those studies, we sought to test whether modern machine learning approaches could predict one-, three-, and five-year lung transplant outcomes after training on data extracted from the UNOS database. We found that even the best performing models, including XGBoost and a Bidirectional Encoder Representations from Transformers

(BERT)<sup>19</sup>-based model, EHRformer performed poorly in predicting one-, three-, and five-year mortality and only modestly better when predicting lung function at one year. The predictive performance of the models was further reduced when data collected during the index stay were excluded. The predictions of the models were driven by factors previously reported to be associated with poor transplant outcomes. Our findings suggest that even with state-of-the-art machine learning models, data collected by UNOS poorly predict lung transplant outcomes.

#### **Results**

The UNOS dataset reveals changes in lung transplant practices and outcomes in the US over time.

The UNOS dataset is a standardized, national database that includes clinical and demographic information for candidates listed for lung transplantation.<sup>20</sup> For the purposes of this study, we focused on first-time lung transplant recipients >18 years old. Because the UNOS dataset is cumulative, it reflects overall changes in national lung transplant practice over time. Our exploratory analysis of these patients suggested these changes in practice explain a significant amount of variance in the dataset (Figure 1A, 1B). For example, the proportion of transplants performed for restrictive lung disease has increased relative to those performed for obstructive lung disease. Additionally, ischemic time, age, and FEV1% at transplant have increased over time, reflecting changes in organ storage and allocation, recipient characteristics, and indication type.

An initial exploration of all relevant waitlist, peri-transplant, and follow-up features (at one, three, and five years) yielded 780 features with at least 1 observation (Table S1, Figure S1A). There were distinct patterns of feature presence and missingness in the UNOS dataset (Fig. S1B), coinciding with the introduction of the Lung Allocation Score (LAS) in May 2005<sup>21</sup> and changes in data collection introduced in 2015 (Fig. 1A, S1B). Accordingly, we performed modeling separately for each of these three time periods using all features available within a given period. For the entire time period, we used only shared features. To inform feature selection for machine learning applications, we first performed principal components analysis (PCA) to identify influential features and trends present in the dataset. We included all first-time lung transplant recipients >18 years old (47,864 observations) and all waitlist, peri-transplant, and follow-up features at one, three, and five years for which ≤10% of data was missing (357 features, Fig. S1C, Table S1. Lung transplant type, indication, lung function, and transplant year explain substantial variation in the dataset (Figure 1C-E).

## XGBoost and EHRFormer fail to predict one year mortality

We ran 4 separate models based on waitlist and peri-transplant features present in various time frames illustrated in Fig. 1A and S1B. Briefly, features that were at least 90% complete within each specified time frame were used for the model. For the model encompassing all observations across all years, only features that were at least 90% complete across all years were used. The number of features used in each time period is shown in Fig. 2A. A data dictionary of these features is shown in Table S1. Due to class imbalance, downsampling of the majority class was also applied such that there was a 1:1 ratio of either outcome. Additionally, those who died within 90 days of the index stay were excluded from the initial mortality prediction analysis and analyzed separately (see below) to prevent length of index stay from serving as a model shortcut. A bar graph visualizing the class imbalance of outcomes is shown in Fig 2B. Final test AUCs across all models were uniformly poor, ranging from 0.58 to 0.64 (0.64 for data from all years) for EHRFormer and from 0.62 to 0.63 (0.63 for data from all years) for XGBoost (Figure 2C, S2A, and Table 1). Confusion matrices of both models on the test set are shown in Figure S2B. Figure 2D shows test AUROC, accuracy, F1, precision, recall, and specificity across all models.

Model	1987-2004	2005-2014	2015-now	All years
EHRFormer	0.61 [0.56,0.67]	0.60 [0.56,0.65]	0.56 [0.50,0.62]	0.64 [0.61, 0.66]
	95% CI	95% CI	95% CI	95% CI
XGBoost	0.62 [0.55,0.72]	0.63 [0.58,0.69]	0.62 [0.58,0.66]	0.63 [0.60, 0.67]
	95% CI	95% CI	95% CI	95% CI

Table 1: Test AUROCs for EHRFormer and XGBoost predicting one year mortality across key time periods in the UNOS dataset.

#### XGBoost and EHRFormer fail to predict one-, three-, and five-year mortality

XGBoost and EHRformer predict one-, three-, and five-year mortality with poor performance, with test AUROCs ranging from 0.61 to 0.65 across all tasks and models (Figure 2E). There was significant imbalance in the number of patients belonging to the positive and negative classes for the one-, three-, and five-year tasks that was corrected by downsampling (Figure 2F). Model performance did not change between one-, three-, and five-year mortality prediction (Figure S3).

Model	1-year test AUROC	3-year test AUROC	5-year test AUROC
EHRFormer	0.64 [0.61, 0.66] 95% CI	0.61 [0.60, 0.63] 95% CI	0.63 [0.62, 0.64] 95% CI
XGBoost	0.63 [0.60, 0.67] 95% CI	0.65 [0.63, 0.67] 95% CI	0.63 [0.62, 0.64] 95% CI

Table 2: Test AUROCs for EHRFormer and XGBoost predicting mortality at one, three-, and five-years post-transplant.

XGBoost and EHRFormer modestly predict patients with poor lung function at one year.

We used all waitlist and peri-transplant features (≤10% missing) included in our mortality prediction models to predict one year lung function after downsampling for class imbalance, resulting in 4 separate models (Figure 2A, Table S1, and Figure 3A). XGBoost and EHRFormer predicted one year lung function, with final test AUCs across all models ranging from 0.72 to 0.74 (0.74 for data from all years) for EHRFormer and from 0.74 to 0.79 (0.76 for data from all years) for XGBoost (Figure 3B, 3C, S3A, S3B, and Table 3).

Model	1987-2004	2005-2014	2015-now	All years
EHRFormer	0.74 [0.72,0.78]	0.74 [0.73,0.75]	0.72 [0.70,0.73]	0.74 [0.72, 0.75]
	95% CI	95% CI	95% CI	95% CI
XGBoost	0.79 [0.77,0.81]	0.77 [0.76,0.79]	0.74 [0.73,0.76]	0.76 [0.74, 0.77]
	95% CI	95% CI	95% CI	95% CI

Table 3: Test AUROCs for EHRFormer and XGBoost at across key time periods in the UNOS dataset.

Index stay features have high importance for mortality prediction.

To identify features associated with one-year mortality in our models, we developed two XGBoost models. The first model was trained on features from all years that were available pre-transplant (Figure 4A, Table S1). The second model was trained on features that were available pre-transplant and during the index hospitalization (Figure 4B, Table S1). We then obtained SHapley Additive Probabilities (SHAP)<sup>22</sup> from these two models. The pre-transplant features with high importance for mortality prediction included transplant type, donor ethnicity, PCO2 at the time of transplant, and FVC at the time of transplant (Figure 4A). The pre-transplant features and index hospitalization features with high importance for mortality prediction included length of stay and whether the recipient experienced acute rejection during the index stay (Figure 4B).

Removing index hospitalization features and further subsetting on the Lung Allocation Score (LAS) further reduces model performance

Because index hospitalization features are unavailable when clinicians make decisions to list patients for lung transplantation, we trained another XGBoost model in which we removed the index stay features specified in Table S1. Model performance for mortality prediction at one year was lower when XGBoost was trained on features only available immediately preceding transplant (Figure 4C and Table 4). Similarly, model performance for mortality prediction at one year was significantly decreased when XGBoost was trained on the initial LAS on the waitlist, the end LAS on the waitlist, the calculated LAS, and the match LAS (Figure 4C and Table 4).

All features	Pre-transplant features	LAS
0.63 [0.60, 0.67] 95% CI	0.60 [0.57,0.64] 95% CI	0.53 [0.51,0.55] 95% CI

Table 4: Test AUROCs for XGBoost for predicting 1 year mortality using all features, pretransplant features only, and the LAS.

## Index stay features are highly influential for prediction of lung function

Features important to lung function prediction included whether the transplant performed was single or bilateral, ischemic time, PCO2 at registration, creatinine at registration, recipient age, donor age, days on the waiting list, and O2 requirement at rest at the time of transplant (Figure 4D and Table 5). Features unique to lung function were primarily related to lung function at the time of transplant (FEV1 and FVC at registration), indication type (COPD and cystic fibrosis were associated with better lung function), and recipient BMI (Figure 4D and Table 5).

#### Stratification by transplant type results in a small increase in model performance

After length of stay, transplant type was the most important feature for 1 year mortality. Therefore, we trained separate XGBoost models on all single lung transplant recipients and all double lung transplant recipients. Utilizing all features including those collected from the index stay yielded a test AUROC of 0.67 [0.61, 0.71] 95% CI within single lung transplant recipients vs test AUROCs of 0.63 [0.60, 0.67] 95% and 0.57 [0.52, 0.62] CI for all patients and double lung transplant recipients, respectively (Figure 4E, Table 5). When modeled on pre-transplant features, subsetting on single lung transplant recipients did not increase model performance compared to modeling on both single and bilateral lung transplants. SHAP analysis within the model trained on single lung transplant recipients using only pre-transplant features revealed the importance of donor and recipient age as well as hemodynamic parameters such as

pulmonary arterial pressures. Interestingly, listing center code and center code also emerged as influential features in this model (Figure 4F). Train and test AUROC curves as well as SHAP values for XGBoost models trained on the single and bilateral subsets are shown in Figure S4.

	All features	Pre-tx features
Both	0.63 [0.60, 0.67] 95% CI	0.60 [0.57,0.64] 95% CI
Single transplants	0.67 [0.61, 0.71] 95% CI	0.58 [0.52,0.63] 95% CI
Bilateral transplants	0.57 [0.52, 0.62] 95% CI	0.55 [0.50,0.60] 95% CI

Table 5: Test AUROCs for XGBoost for predicting 1 year mortality using all features or pretransplant features only stratified by transplant type.

EHRFormer permits querying the effect of multiple features simultaneously.

SHAP values for EHRFormer models are not currently accessible. Instead, we can query feature importance by "perturbing" or changing the value of a specified feature or even a set of multiple features and seeing what effect doing so has on the model's output. For example, the probability distribution of mortality by one-year does not change after perturbing transplantation region (Figure 5A) but changes substantially after perturbing long index stay (Figure 5B) or dialysis during the index stay (Figure 5C). One can also perform multiple *in silico* perturbations simultaneously. For example, we set positive flags to the highest quartiles for complicated index stay features, including ECMO at 72 hours, inhaled NO at 72 hours, intubation status at 72 hours, and ventilation duration post-transplant which shifted the mortality prediction towards death at one year (Figure 5D).

Perturbing multiple features simultaneously allows EHRFormer to explain the unexpected influence of long ischemic time on one year mortality in the XGBoost model

Prolonged ischemic time has been historically associated with worse 1-year outcomes<sup>23</sup>. Unexpectedly, longer ischemic times were associated with improved outcomes in our XGBoost models (Figure 3A). We hypothesized that the historic association between prolonged ischemic time and poor outcomes were reversed by improvements of organ handling and storage, including the use of *ex-vivo* lung perfusion (EVLP). Accordingly, we leveraged the ability of EHRFormer to query multiple features at once to investigate perturbation of a feature *conditioned on the value of another feature* - in this case what might happen if we prolong ischemic time when transplant year is set to its lowest quartile (earliest) (Figure 5E). When

setting ischemic time to its highest value alone, we see a paradoxical shift in mortality prediction that is consistent with the direction of the SHAP values seen in XGBoost (Figure 4A and B). However, when setting ischemic time to its highest value when conditioned on setting transplant year to its lowest quartile, the probability distribution reverses in the opposite direction. Additionally, when we subsetted on those whose lungs underwent EVLP prior to transplant, the proportion of those experiencing poor outcomes such as 1 year mortality, ECMO at 72 hours after transplant, and death during the index stay, were significantly reduced (Figure S6).

Features associated with frailty predicted death during the index hospitalization.

Those who died during the index hospitalization were excluded from our initial mortality prediction models. To investigate features associated with mortality in this subset of patients, we performed hierarchical clustering of all features (Figure 6A). Features associated with mortality during the index stay included transplant indication of idiopathic pulmonary fibrosis or restrictive lung disease, recipients of donors of black or African American ethnicity, and life support features such as ECMO, ventilator, and ICU status. A distinct group of features associated with recipient frailty such as functional status at the time of transplant, infection requiring IV drug therapy prior to transplant, and hospitalization status prior to transplant were associated with higher rates of index hospitalization mortality (Figure 6A). When we investigated features associated with a complicated index hospitalization, those who died during the index stay showed much higher oxygen requirements (FiO2), rates of ECMO, rates of inhaled NO, rates of intubation, and rates of reintubation at 72 hours after transplant (Figure 6B). Similarly, we examined additional frailty features associated with higher rates of index hospitalization mortality. Those who died during the index hospitalization had higher O2 requirements at rest, lower six-minute walk scores, as well as higher rates of chronic steroid use, pan-resistant bacterial infection, infection requiring IV drug therapy, and ventilator status at the time of transplant (Figure 6C).

## **Discussion**

Lung transplant is a lifesaving treatment for patients with end stage lung disease. Over the years, lung transplant allocation systems have used prediction models to guide patient eligibility for transplant, organ allocation, and outcome reporting. The role of these models is two-fold: 1) to prioritize organ allocation to patients who have the greatest chance of death due to their underlying lung disease and 2) to direct scarce resources to patients who would achieve

maximum survival benefit from lung transplantation. Achieving these goals requires robust prediction models for post-transplant outcomes. Traditionally, these predictive models have been informed by expert-guided supervised selection of features incorporated into traditional statistical methods such as multilinear regression. Modern machine learning approaches such as language models or gradient boosted decision trees can accommodate non-linear relationships between variables and have the potential to account for the multiplicative risks of comorbidities on lung transplant outcomes. We used two robust machine learning models, XGBoost and EHRFormer, which have performed well in other clinical prediction tasks, to predict one-, three- and five-year mortality and lung function after lung transplantation. Our models were trained on data within the UNOS database up until November 2022. Even after optimization, these models performed poorly as predictors of mortality or lung function after transplant, particularly when data from the post-transplant index stay were excluded.

Despite their attention to known risk factors associated with transplant outcomes, the performance of our machine learning methods in predicting outcomes was poor. There are several possible reasons that might explain this poor performance. This suggests that data features collected by UNOS are not predictive of transplant outcomes and that collection of additional predictive features such as diffusing capacity of the lungs for carbon monoxide<sup>24</sup> is needed. The application of machine learning algorithms to the larger body of EHR data available at individual centers or consortia of centers might identify informative features outside of the UNOS database. Importantly, the models would incorporate molecular features, imaging features, and other modalities outside of EHR data<sup>25</sup>. Second, batch effects in the UNOS data related to differences in data curation, collection, reporting between centers, and changes in practice over time might confound the models. Arguing against this, both models identified features previously associated with transplant outcomes as important for their predictions. Applying these models to EHR data that have been validated by clinician review is a strategy to address this concern at the level of individual centers or consortia. Finally, drivers of transplant outcomes might be largely independent of clinical features present before the procedure. The limited performance of these models suggests caution in using these data for predicting lung transplant outcomes.

Our study highlights the promise of machine learning approaches in identifying risk factors that drive lung transplant outcomes. We observed a high level of concordance between predictors of

poor outcomes identified by our models and those selected by experts for use in supervised models. These included donor and recipient age, length of index stay, and renal dysfunction or failure during the index stay as important predictors of 1 year mortality. Investigation of factors driving our machine learning prediction also revealed biases in the data that would likely be missed in a supervised analysis. For example, the increased risk associated with African American donors likely suggests important risks related to social determinants of health or other factors that would be unlikely to be included in supervised analyses. The failure to include these factors in current models might paradoxically perpetuate these biases in the form of reporting of higher program quality scores for centers in different geographic regions.

XGBoost provides direct measures of the relative weights of features that drive the model. BERT-based models like EHRFormer do not provide explicit information about the factors that drive their predictions. To address this concern, we developed perturbation tools in EHRFormer that allow users to investigate the hypothetical effect of changing variables. We used these to investigate the paradoxical association between prolonged ischemic time and improved mortality after transplantation in the XGBoost models. When we fixed transplant year to the earliest quartile, before procedures such as EVLP were available, increased ischemic time was associated with increased mortality. We show how this tool can be used to perform multiple "perturbations" within EHRFormer simultaneously to query multivariate hypotheses and dependencies. These tools might be helpful to generate hypotheses that can be tested with causal interventions or for individual programs to assess the relative benefits of interventions in the peri-transplant period that can improve outcomes.

#### Conclusion

In summary, despite their ability to identify and use clinical features known to be associated with lung transplant mortality in their predictions, modern interpretable machine learning approaches applied to the UNOS database performed poorly in predicting one-, three- and five-year survival and lung function after lung transplantation. We developed perturbation tools within EHRFormer to simultaneously explore features in the UNOS database that might reflect changes in lung transplant practice and outcomes over time and unexpected biases in the data. Our data suggest caution when using historic UNOS data to inform clinical practice decisions by multidisciplinary lung transplant teams and outcome reporting. The relative ease with which these models can be applied to more comprehensive clinical and laboratory data, and their

demonstrated ability to identify features associated with transplant outcomes, suggest them as powerful approaches to address these limitations.

## Disclosure and data availability statement

All patient-de-identified data was obtained from the United Network for Organ Sharing (UNOS) Standard Transplant Analysis and Research File (SRTR), which is based on the Organ Procurement and Transplantation Network data as of 11/8/2023. All research was approved by the Northwestern Institutional Review Board (STU00221316).

## **Acknowledgements**

This research was supported by the computational resources and staff contributions provided for the Quest high-performance computing facility at Northwestern University, which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. This research was supported in part through the computational resources and staff contributions provided by the Genomics Compute Cluster which is jointly supported by the Feinberg School of Medicine, the Center for Genetic Medicine, and Feinberg's Department of Biochemistry and Molecular Genetics, the Office of the Provost, the Office for Research, and Northwestern Information Technology. The Genomics Compute Cluster is part of Quest, Northwestern University's high-performance computing facility, with the purpose to advance research in genomics. We thank J. Milhans, A. Kinaci, S. Coughlin and all members of the Research Computing and Data Services team at Northwestern for their support.

#### **Competing interest statement**

The authors have no conflicts of interest to disclose.

#### **Methods**

Data preparation, cleaning, and feature encoding

All observations with a transplant date earlier than November 8, 2022 were included. All waitlist (THORACIC\_WL\_DATA), peri-transplant (THORACIC\_DATA), and follow-up features (THORACIC\_FOLLOWUP\_DATA) with at least 1 observation were initially considered, yielding 786 features from the STAR File Data Dictionary. All features were reviewed for outliers and unexpected values with consultation from a committee of transplant pulmonologists. Outlier data

were treated as missing. Binary features were numerically binarized as 0 or 1. Categorical features were ordinalized if they represented a scale or one-hot encoded. Waitlist and follow-up features were collected at various points in time for each patient. For waitlist data only the first and most recent values were collected. Follow-up observations closest to and within +/-3 months of one-, three-, and five-years post-transplant were used.

## Principal components analysis

The features and resultant dataframe obtained from *Data Preparation and Feature Encoding* were further filtered for those that were missing <10% of data, resulting in 363 features. Numerical features were mean imputed while categorical features were mode imputed. With this dataframe, principal components analysis was applied using *scikit-learn*<sup>26</sup> in Python, with the top 50 principal components chosen for initial exploration. *Matplotlib*<sup>27</sup> and *seaborn*<sup>28</sup> were used for data exploration and visualization.

#### Statistical tests

To determine whether continuous variables change with respect to time (transplant date), logistic regression was performed with *statsmodels*<sup>29</sup> to determine R-squared coefficients and p-values. To analyze differences in categorical variables between groups, the chi-squared test (*scipy.stats*)<sup>30</sup> was used with a Benjamini-Hochberg adjustment for multiple comparisons (FDR < 0.05) (*statsmodels*)<sup>29</sup>. To analyze differences in continuous variables between groups, the wilcoxon rank sum test (*scipy.stats*)<sup>30</sup> was used with a Benjamini-Hochberg adjustment for multiple comparisons (FDR < 0.05) (*statsmodels*)<sup>29</sup>. To draw statistical comparisons between the bootstrapped AUROCs between models (50 bootstraps), a Student's t-test was performed after assessing normality with the Shapiro-Wilk test (*scipy.stats*)<sup>30</sup>. A Benjamini-Hochberg adjustment was made for multiple comparisons (FDR < 0.05) (*statsmodels*)<sup>29</sup>.

#### Data preparation for modeling

#### Feature selection and preparation for modeling

Subsets of data were chosen for modeling based on observations from the following time frames (inclusive): 1987-2004, 2005-2014, and 2015-Present. These time-related subsets were chosen due to changes in data collection illustrated in S1. All waitlist and peri-transplant data were included for all modeling tasks. Features were filtered for those that were missing <10% of observations within each time period, resulting in 140, 145, 152 and 140 features for data from

1987-2004, 2005-2014, 2015-Present, and all years. Numerical features were mean imputed while categorical features were mode imputed.

#### EHRFormer feature representation and pretraining

From each of the 4 dataframes generated as described in the previous paragraph, 4 different models were pretrained from a tabular BERT initialized with random weights, available via Huggingface in the transformers package<sup>31</sup>. For the base architecture of this model (EHRFormer), we set the standard Transformer Encoder with three transformer layers, with a layer size of 64, an intermediate layer size of 128, and 4 attention heads. representation of the tabular data, all numerical values were quantile-binned to represent data from a single patient. Binary features were set to either the lowest or highest quartile bin. Following the standard BERT procedure, we added a 64-dimensional learnable CLS embedding at the beginning of the sequence. An additional bin was included to represent the CLS token for each patient as well as an additional bin for missing data. Each bin and each EHR feature was then assigned with a learnable 64-dimensional vector embedding. We later represented a single EHR entry with a sequence of the length of the number of features, where each element of a sequence was a 64-dimensional vector obtained by summing the feature embedding vector and its assigned bin embedding vector for every feature in the training data. In line with the BERT pretraining procedure, we pre-trained EHRFormer using a masked language model objective. The observations were divided into an 80/20 train/test split for pre-training. During this phase, we randomly masked 15% of the values in the 80% train of each entry by replacing the true bin embedding with a learnable MASK embedding. We later equipped EHRFormer with the task of predicting the actual bin values of the masked entries based on the unmasked EHR feature values. None of the observations in the 20% holdout test set were seen during pretraining.

# Modeling one-, three-, and five-year mortality and lung function outcomes Mortality label retrieval

To obtain the correct labels for one-, three-, and five-year mortality, we used the patient's date of death (COMPOSITE\_DEATH\_DATE) to confirm patient death. We then calculated survival in days by subtracting the difference between the patient's date of death and date of transplant (TX\_DATE). Survival time was then used to further identify which patients had died within the one-, three-, and five-year outcomes of interest. To retrieve patients who were alive at one, three, and five years, we used the "patient status", patient status date, and date of death variables (PX\_STAT = "A" for alive, PX\_STAT\_DATE, COMPOSITE\_DEATH\_DATE = NA).

PX\_STAT\_DATE was used to determine total known survival time. We then added this subset of patients to patients who might have died but whose survival exceeded the 1-, 3-, and 5-year outcomes of interest for each task. To further ensure the model was not relying on shortcut features, we removed patients who died during or within 90 days of their index stay. This was determined by filtering out patients whose length of stay (LOS) exceeded survival time by at least 90 days.

## <u>Lung function <70% of predicted label retrieval</u>

To obtain labels for lung function <70% of predicted, we used the follow-up feature FEV\_percent available at 1 year post transplant (+/- 3 months). For patients in which FEV\_percent at 1 year post transplant was unavailable, we used the *spiref*<sup>32</sup> package with GLI-2012<sup>33</sup> reference values to determine a calculated FEV\_percent of predicted based on their absolute FEV1(L) at one year (FEV). Downsampling of the majority class was also applied as described in detail in the subsequent section *EHRFormer fine-tuning and evaluation*.

## **EHRFormer fine-tuning and evaluation**

We used fine-tuning of the pretrained EHRFormer for binary classification of the patient's mortality and lung function at 1 year. Specific outcome retrieval is described above. To perform this task within specific time frames, we used one of the 4 pretrained models that corresponded to these time frames: 1987-2004, 2005-2014, 2015-Present, and all years. With the data and pretrained model from data spanning all years, we also performed identical binary classification of whether the patient was alive or dead at 3 and 5 years. Due to class imbalance for all tasks, the majority class was downsampled at random to result in a 1:1 negative to positive class ratio in both the training and test sets separately.

For each task, following downsampling, hyperparameter tuning was performed using *optuna's*<sup>34</sup> Parzen Tree based estimator (objective = accuracy, direction = maximize, n\_trials = 75), on the 80% train split from pretraining. We searched for optimal hyperparameters within the following space: learning\_rate = [1e-6, 1e-2], per\_device\_train\_batch\_size = [16, 32, 64, 128, 256], and weight\_decay = [1e-4, 1e-1]. With the tuned hyperparameters, we performed 5-fold cross-validation on the 80% train split from pretraining. Splits and performance metrics (accuracy, AUROC, F1, precision, recall, and specificity) were determined using *scikit-learn*<sup>26</sup>. The tuned models were finally evaluated on their performance using the remaining 20% holdout test set that were not seen during pre-training, hyperparameter tuning, or 5-fold cross-validation. To

determine the variability of performance metrics within the test set, 50 random bootstraps were performed on the test set when calculating model metrics.

#### XGBoost evaluation

We similarly used XGBoost for binary classification of the patient's mortality and lung function at 1 year within time frames corresponding to 1987-2004, 2005-2014, 2015-Present, and all years. We also performed identical binary classification of whether the patient was alive or dead at 3 and 5 years. Additional tasks included assessing the performance of XGBoost on all features, features only available at or before the time of transplant, and on the LAS. For these additional tasks, center-specific features were also included (ie. CTR\_CODE, see Table S1). Where center code features were included, the *Catboost Encoder* package was used to perform target encoding of center codes. Finally, XGBoost was also used to determine prediction performance on single and bilateral lung transplant recipients separately. Downsampling of the majority class was done as was done for EHRFormer. Since there is no pre-training process, we divided entire datasets into an 80/20 train/test split at random. 5-fold cross-validation was performed within the training set with scikit-learn. Hyperparameter tuning was performed using a Bayesian optimizer with a Gaussian Process based estimator (scikit-optimize's BayesSearchCV)<sup>55</sup>. The search space was defined as follows: learning rate = (0.01, 1.0), max depth = (2, 12), subsample = (0.1, 1.0), colsample bytree = (0.1, 1.0), reg lambda = (1e-9, 100), reg alpha = (1e-9, 100), min\_child\_weight = (1, 10), gamma = (0, 5), n\_estimators = (50, 1000). To determine the variability of performance metrics within the test set, 50 random bootstraps were performed on the test set when calculating model metrics. For interpretability and insight into XGBoost model decisions, we used SHAP (SHapley Additive exPlanations)<sup>36</sup>.

#### EHRFormer perturbations

To gain model insights from EHRFormer, we developed a pretrained tabular BERT similar to the pretraining process described in the modeling tasks. We specifically included data from all years and included additional features of interest such as transplant year (TX\_YEAR) as well as all the features from the 2015-Present model. The entire dataset was used for pretraining as opposed to setting aside a test cohort. Hyperparameter search was performed within the entire dataset as described previously. We then ran this new model on the fine-tuning binary classification task of 1-year mortality. To understand feature importance, we randomly sampled half of the input observations 10 times. From these sampled observations, we manipulated features of interest by manually changing the bins for one or multiple features in each of the sampled observations.

These new "perturbed" inputs were fed to the model during fine-tuning. This process returned new probabilities of a positive class outcome (ie. 1 year mortality) determined by the model when given a perturbed set of features, visualized here as probability distributions before and after the perturbation was applied.

Hierarchical clustering for length of stay analysis

Hierarchical clustering was performed on all observations using all the features that were used for prediction of 1 year mortality (140 features). Numerical features were mean imputed while categorical features were mode imputed. The ward linkage method and euclidean distance were used. Whether an individual died during their index stay was used as the row annotation feature.

Propensity score matching for creating matched cohorts for length of stay analysis

To examine associations between those who died during the index stay and those who did not, we performed propensity score matching with *psmpy*<sup>37</sup> to generate a matched cohort of controls. 1:5 matching was performed based on patients with similar transplant year, indication grouping, gender, age, and ethnicity. Missing data were imputed prior to matching with a simple mean strategy. KNN matching with propensity logits was performed at a 1:5 case:control ratio to mitigate class imbalance.

#### References:


- 1. Graham CN, Watson C, Barlev A, Stevenson M, Dharnidharka VR. Mean lifetime survival estimates following solid organ transplantation in the US and UK. *J Med Econ*. 2022;25(1):230-237. doi:10.1080/13696998.2022.2033050
- 2. Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. 2016;35(10):1170-1184. doi:10.1016/J.HEALUN.2016.09.001
- 3. Bos S, Vos R, Van Raemdonck DE, Verleden GM. Survival in adult lung transplantation: where are we in 2020? *Curr Opin Organ Transplant*. 2020;25(3):268-273. doi:10.1097/MOT.00000000000000753
- 4. Foroutan F, Malik A, Clark KE, et al. Predictors of 1-year mortality after adult lung transplantation: Systematic review and meta-analyses. *The Journal of Heart and Lung Transplantation*. 2022;41(7):937-951. doi:10.1016/J.HEALUN.2022.03.017
- Valapour M, Lehr CJ, Wey A, Skeans MA, Miller J, Lease ED. Expected effect of the lung Composite Allocation Score system on US lung transplantation. *American Journal of Transplantation*. 2022;22(12):2971-2980. doi:10.1111/AJT.17160

- 6. Inci I, Schuurmans M, Ehrsam J, et al. Lung transplantation for emphysema: impact of age on short- and long-term survival. *European Journal of Cardio-Thoracic Surgery*. 2015;48(6):906-909. doi:10.1093/EJCTS/EZU550
- 7. Allen JG, Arnaoutakis GJ, Weiss ES, Merlo CA, Conte J V., Shah AS. The impact of recipient body mass index on survival after lung transplantation. *Journal of Heart and Lung Transplantation*. 2010;29(9):1026-1033. doi:10.1016/J.HEALUN.2010.05.005
- 8. Ambur V, Taghavi S, Jayarajan S, et al. The impact of lungs from diabetic donors on lung transplant recipients. academic.oup.comV Ambur, S Taghavi, S Jayarajan, S Kadakia, H Zhao, J Gomez-Abraham, Y ToyodaEuropean Journal of Cardio-Thoracic Surgery, 2017•academic.oup.com. 2017;51(2):285-290. doi:10.1093/ejcts/ezw314
- 9. Aramini B, Kim C, Diangelo S, et al. Donor surfactant protein D (SP-D) polymorphisms are associated with lung transplant outcome. *American Journal of Transplantation*. 2013;13(8):2130-2136. doi:10.1111/AJT.12326
- 10. Yoon S, Jang EJ, Kim GH, et al. Adult lung transplantation case-volume and in-hospital and long-term mortality in Korea. *J Cardiothorac Surg.* 2019;14(1):1-8. doi:10.1186/S13019-019-0849-3/TABLES/4
- Whitson BA, Hertz MI, Kelly RF, et al. Use of the donor lung after asphyxiation or drowning: Effect on lung transplant recipients. *Annals of Thoracic Surgery*. 2014;98(4):1145-1151. doi:10.1016/J.ATHORACSUR.2014.05.065
- 12. Tague LK, Scozzi D, Wallendorf M, et al. Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment. *American Journal of Transplantation*. 2020;20(1):250-261. doi:10.1111/AJT.15581
- 13. Hayes D, Black SM, Tobias JD, Higgins RS, Whitson BA. Influence of donor and recipient age in lung transplantation. *Journal of Heart and Lung Transplantation*. 2015;34(1):43-49. doi:10.1016/J.HEALUN.2014.08.017
- 14. Huppmann P, Neurohr C, Leuschner S, et al. The Munich-LTX-Score: Predictor for survival after lung transplantation. *Clin Transplant*. 2012;26(1):173-183. doi:10.1111/J.1399-0012.2011.01573.X
- 15. Kurihara C, Fernandez R, Safaeinili N, et al. Long-Term Impact of Cytomegalovirus Serologic Status on Lung Transplantation in the United States. *Annals of Thoracic Surgery*. 2019;107(4):1046-1052. doi:10.1016/J.ATHORACSUR.2018.10.034
- 16. Gholamzadeh M, Abtahi H, Safdari R. Machine learning-based techniques to improve lung transplantation outcomes and complications: a systematic review. *BMC Med Res Methodol.* 2022;22(1):331. doi:10.1186/S12874-022-01823-2
- Agrawal A, Al-Bahrani R, Russo MJ, Raman J, Choudhary A. Lung Transplant Outcome Prediction using UNOS Data. *IEEE Xplore*. December 2013. doi:10.1109/BigData.2013.6691751
- 18. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. *Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*. 2016;13-17-August-2016:785-794. doi:10.1145/2939672.2939785
- 19. Devlin J, Chang MW, Lee K, Toutanova K. BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding. *NAACL HLT 2019 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human*


- Language Technologies Proceedings of the Conference. 2018;1:4171-4186. https://arxiv.org/abs/1810.04805v2. Accessed July 30, 2024.
- 20. OPTN database OPTN. https://optn.transplant.hrsa.gov/data/about-data/optn-database/. Accessed July 30, 2024.
- 21. Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. *Am J Transplant*. 2006;6(5 Pt 2):1212-1227. doi:10.1111/J.1600-6143.2006.01276.X
- 22. Lundberg SM, Allen PG, Lee SI. A Unified Approach to Interpreting Model Predictions. https://github.com/slundberg/shap. Accessed July 30, 2024.
- 23. Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. *Am J Respir Crit Care Med.* 2005;171(7):786-791. doi:10.1164/RCCM.200409-1248OC
- 24. Darley DR, Ma J, Huszti E, et al. Diffusing Capacity for Carbon Monoxide (DLCO): Association with long-term outcomes after Lung Transplantation in a 20-year longitudinal study. *European Respiratory Journal*. 2021;59(1). doi:10.1183/13993003.03639-2020
- 25. Sage AT, Donahoe LL, Shamandy AA, et al. A machine-learning approach to human ex vivo lung perfusion predicts transplantation outcomes and promotes organ utilization. *Nat Commun.* 2023;14(1). doi:10.1038/S41467-023-40468-7
- Pedregosa FABIANPEDREGOSA F, Michel V, Grisel OLIVIERGRISEL O, et al. Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research*.
   2011;12(85):2825-2830. http://jmlr.org/papers/v12/pedregosa11a.html. Accessed August 27, 2024.
- 27. Hunter JD. Matplotlib: A 2D graphics environment. *Comput Sci Eng.* 2007;9(3):90-95. doi:10.1109/MCSE.2007.55
- 28. Waskom ML. seaborn: statistical data visualization. *J Open Source Softw.* 2021;6(60):3021. doi:10.21105/JOSS.03021
- 29. Seabold S, Perktold J. Statsmodels: Econometric and Statistical Modeling with Python. Proceedings of the 9th Python in Science Conference. 2010:92-96. doi:10.25080/MAJORA-92BF1922-011
- 30. Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat Methods*. 2020;17(3):261-272. doi:10.1038/S41592-019-0686-2
- 31. Wolf T, Debut L, Sanh V, et al. HuggingFace's Transformers: State-of-the-art Natural Language Processing. October 2019. https://arxiv.org/abs/1910.03771v5. Accessed August 27, 2024.
- 32. Spiref: Spirometry Reference Value Calculator KU Leuven. https://kuleuven.limo.libis.be/discovery/fulldisplay?docid=lirias3999656&context=Search Webhook&vid=32KUL\_KUL:Lirias&lang=en&search\_scope=lirias\_profile&adaptor=Searc hWebhook&tab=LIRIAS&query=any,contains,LIRIAS3999656&offset=0. Accessed August 27, 2024.
- 33. Quanjer PH, Stanojevic S, Cole TJ, et al. MULTI-ETHNIC REFERENCE VALUES FOR SPIROMETRY FOR THE 3–95 YEAR AGE RANGE: THE GLOBAL LUNG FUNCTION 2012 EQUATIONS: Report of the Global Lung Function Initiative (GLI), ERS Task Force

- to establish improved Lung Function Reference Values. *Eur Respir J.* 2012;40(6):1324. doi:10.1183/09031936.00080312
- 34. Akiba T, Sano S, Yanase T, Ohta T, Koyama M. Optuna: A Next-generation Hyperparameter Optimization Framework. *Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*. July 2019:2623-2631. doi:10.1145/3292500.3330701
- 35. scikit-optimize/scikit-optimize. doi:10.5281/ZENODO.5565057
- 36. Lundberg SM, Lee SI. A Unified Approach to Interpreting Model Predictions. *Adv Neural Inf Process Syst.* 2017;2017-December:4766-4775. https://arxiv.org/abs/1705.07874v2. Accessed August 27, 2024.
- 37. Kline A, Luo Y. PsmPy: A Package for Retrospective Cohort Matching in Python. Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS. 2022;2022-July:1354-1357. doi:10.1109/EMBC48229.2022.9871333


**Figures** 





**Figure 1:** An exploratory analysis of the UNOS dataset reveals distinct indication-drive groupings and time-associated trends. A. Histogram of the number of lung transplants by year since 1987 split by restrictive indication (red). The timeline schematic below the x axis indicates how many observations were included for modeling for each model across various time frames. B. Hexbin plots showing from top to bottom the relationship of ischemic time (hours), recipient age, and FEV1% at the time of transplant with sorted transplant date. Black dots on the ischemic time plot indicate the yearly median of ischemic time. P values and R-squared values were derived from linear regression on all three variables vs transplant year. C. Principal components contour plots split by single and bilateral transplants, indicated in red. D. Principal components contour plots split by indication (red). E. Principal components scatterplot colored by transplant year with reference contour plot on the right. Early to most recent transplant years are illustrated from dark to light respectively.




#### Test AUROCs for EHRFormer and XGBoost for 1 year mortality prediction












**Figure 2**: EHRFormer and XGBoost predict one-, three-, and five-year mortality with modest performance. A. The number of features used in each of the 4 different models. A data dictionary of these features is available in Table S1. B. The number of patients in each model split by class outcome of 1 year mortality. Teal indicates those who were excluded for modeling if they died within 90 days of their index stay. D. Test set AUROCs for EHRFormer (red) and XGBoost (blue) prediction of 1 year mortality across the 4 models. Error bars indicate 95% CIs based on 50 bootstraps of the test set. D. Heatmap of all test set metrics normalized within each metric (row-wise) including AUROC, accuracy, F1 score, precision, recall, and specificity for EHRFormer and XGBoost across the 4 models. E. Test set AUROCs for EHRFormer (red) and XGBoost (blue) prediction of 1-, 3-, and 5-year mortality. Error bars indicate 95% CIs based on 50 bootstraps of the test set. F. The number of patients split by class outcome of 1-, 3-, and 5-year mortality. Teal indicates those who were excluded for modeling if they died within 90 days of their index stay.

A Number of lung transplant recipients per time period split by lung function at one year




B Test AUROCs for EHRFormer and XGBoost for 1 year lung function <70 percent predicted prediction






**Figure 3:** EHRFormer and XGBoost predict one year lung function with strong performance. A. The number of patients in each model split by class outcome of FEV1 <70% predicted at 1 year. B. Test set AUROCs for EHRFormer (red) and XGBoost (blue) prediction of FEV1p <70% predicted across the 4 models. Error bars indicate 95% Cls based on 50 bootstraps of the test set. C. Heatmap of all test set metrics normalized within each metric (row-wise) including AUROC, accuracy, F1 score, precision, recall, and specificity for EHRFormer and XGBoost across the 4 models.




D

C Test AUROCs for 1 year mortality prediction with XGBoost on all years with various sets of features




values including peri-transplant features on all years

XGBoost 1 year lung function model SHAP



E Test AUROCs for 1 year mortality prediction with XGBoost on all years stratified by transplant type

Feature sets



XGBoost 1 year lung function model SHAP values on all single lung transplants using pre-transplant features only





Figure 4: Index stay features strongly influence 1-year outcomes. A. SHAP values from the XGBoost model predicting 1 year mortality using pre-transplant features. B. SHAP values from the XGBoost model predicting 1 year mortality using pre-transplant and peri-transplant features. C. Test AUROCs from XGBoost models predicting 1 year mortality using all features (pre- and peri-transplant), pre-transplant features only, and lung allocation score. Error bars indicate 95% Cls based on 50 bootstraps of the test set. Statistical comparisons were made using the student's t-test method with correction for FDR <0.05. D. SHAP values from the XGBoost model predicting FEV1p <70% predicted at 1 year using pre- and peri-transplant features. E. Test AUROCs from XGBoost models predicting 1 year mortality by transplant type - all transplants, single, and double lung transplants. Light and dark blue indicate models trained on all features (pre- and peri-transplant features) vs. pre-transplant features only). Highlighted significant statistical comparisons of interest are indicated on the graph. F. SHAP values from the XGBoost model predicting FEV1p <70% predicted at 1 year within single lung transplant recipients using pre-transplant features only.

## Probability distribution of mortality prediction after perturbation



Figure 5: EHRFormer perturbations allow users to query the effect of one or multiple features simultaneously and reveal the paradoxical relationship of ischemic time on mortality. A, B, and C demonstrate probability distribution curves for the model's prediction of 1 year mortality and how they change when an individual feature is toggled. A. transplantation in UNOS region 2; B. whether patient experienced long index stay; C. whether patient experienced dialysis during index stay. D. Changes in probability distribution curves for 1 year mortality when index stay features reflective of complications are toggled. E. Changes in the probability distribution for 1 year mortality when all observations are set to their maximum quartile for ischemic time are shown on the left. Changes in the probability distribution for 1 year mortality when all observations are set to their maximum quartile for ischemic time and set to their lowest quartile for transplant year are shown on the right.








Figure 6: Those who died during their index stay have a higher proportion of flags for life support features, features associated with frailty, and index stay complications. A. heatmap visualization of the hierarchically clustered features used for the prediction tasks. The annotation legend on the left indicates those who died during their index stay (yellow) vs. those who survived the index stay (green). The heatmap also highlights groupings or clusters of features with a higher proportion of those who died during their index stay. Blue box - those whose indication for transplant was idiopathic pulmonary fibrosis; red box - a group of patients highlighted by black donor ethnicity; green box - a set of features associated with life support after transplant; grey boxes - 2 groupings belonging to separate hierarchically clustered "clades" associated with recipient frailty. B. Life support features that were statistically significant in patients who survived the index stay vs. those who died during the index stay, where stacked proportional bar plots were used to represent categorical features (green indicates "yes" and blue indicates "no" for the feature value) and violin plots were used to show continuous features. C. Frailty features that were statistically significant in patients who survived the index stay vs. those who died during the index stay. For graphs in B and C a chi-square (categorical) or Wilcoxon-rank sum (continuous) test was applied with FDR correction <0.05 for multiple comparisons.


## **Supplementary Figures**











**Figure S1:** Heatmaps showing data missingness of features from Table S1. A. Missingness of all waitlist, follow-up, and peritransplant features sorted by transplant date (780 features). B. Missingness of all waitlist, peritransplant features sorted by transplant date that were at least 90% complete and used for modeling. 2005 and 2015 are indicated on the heatmap to demonstrate features that are missing from the time periods used for modeling. Missingness of all waitlist, follow-up, and peritransplant features sorted by transplant date, used for PCA and at least 90% complete (357 features).




Figure S2: Area under the receiver operating curves (A) and test set confusion matrices (B) for the prediction of 1 year mortality using data from 1987-2004, 2005-2014, 2015-present, and from all years. The top row and bottom row in each panel shows the performance in EHRFormer and XGBoost respectively.





Figure S3: Area under the receiver operating curves (A) and test set confusion matrices (B) for the prediction of 1, 3, and 5 year mortality using data from 1987-2004, 2005-2014, 2015-present, and from all years. The top row and bottom row in each panel shows the performance in EHRFormer and XGBoost respectively.

AUROC curves for the prediction of lung function <70% predicted at 1 year in EHRFormer and XGBoost across time frames



Test confusion matrices for the prediction of lung function <70% predicted at 1 year in EHRFormer and XGBoost across time frames





Figure S4: Area under the receiver operating curves (A) and test set confusion matrices (B) for the prediction of FEV1 <70% at 1 year using data from 1987-2004, 2005-2014, 2015-present, and from all years. The top row and bottom row in each panel shows the performance in EHRFormer and XGBoost respectively.

AUROC curves for the prediction of 1 year mortality in single vs bilateral lung transplants using XGBoost



SHAP values for the prediction of 1 year mortality in single vs bilateral lung transplants on **pre-transplant features only** using XGBoost




Figure S5: Area under the receiver operating curves and additional SHAP values for the prediction of 1 year mortality stratified by transplant type using all features vs. pre-transplant features only. A. Area under the receiver operating curves for XGBoost models predicting 1 year mortality in single vs bilateral lung transplant recipients using either all features or only pre-transplant features as specified in Table S1. B. SHAP values for 1 year mortality prediction single lung transplant (left) vs bilateral lung transplant (right) recipients using only pre-transplant features.




Figure S6: Stratification of patients by prolonged ischemic time (>10h) reveals a higher proportion of 1 year mortality, ECMO at 72 hours after transplant, and death during the index stay. Stacked proportional bar plots demonstrating the differences in proportions of 1 year mortality, ECMO at 72 hours after transplant, and death during the index stay (rows) between different stratifications of the patients (columns). Green indicates a positive flag for the binary outcome of interest whereas blue indicates a negative flag. Stratification by EVLP in comparison to matched controls with <10h of lung ischemic time (middle column) revealed some mitigation of poor outcomes. On the other hand, stratification by EVLP in comparison to those with >10h of lung ischemic time (last column) revealed greater mitigation of poor outcomes. Numbers of patients in each grouping are indicated on the graphs.

## **Supplemental Table**

	I	1		1				I	
Feature Name	STAR Data Dictionary Description DONOR-RECIPIENT ABO MATCH LEVEL	When collected	1	-	-		2015-Present Model	-	-
ABO_MAT	RECIPIENT AGE (YRS)	At time of transplant	Yes	Yes		Yes			Yes
AGE DOW	DONOR AGE (YRS)	At time of transplant At time of transplant	Yes	Yes		Yes			Yes
AGE_DON ALCOHOL HEAVY DON	Heavy Alcohol Use (heavy=2+ drinks/day)	At time of transplant	Yes			Yes No			Yes No
AMIS	A LOCUS MISMATCH LEVEL	At time of transplant	Yes			Yes	Yes		Yes
BLOOD_INF_DON	DECEASED DONOR-BLOOD AS INFECTION SOURCE	At time of transplant	Yes	100		Yes			Yes
BMI_DON_CALC	Donor BMI - Pre/At Donation Calculated	At time of transplant	Yes			Yes			Yes
BMIS	B LOCUS MISMATCH LEVEL	At time of transplant	Yes			Yes			Yes
BW4	Candidate Most Recent/at Removal BW4 Antigen From Waiting List	At time of transplant	Yes			Yes			Yes
BW6	Candidate Most Recent/at Removal BW6 Antigen From Waiting List	At time of transplant	Yes			Yes			Yes
CALC LAS LISTDATE	Candidate Final Calculated Lung Allocation Score on Date of Listing	At time of transplant	Yes						No
CARDARREST NEURO	DECEASED DONOR-CARDIAC ARREST POST BRAIN DEATH	At time of transplant	Yes			Yes			Yes
CIG GRT 10 OLD	HISTORY OF CIGARETTE USE >10 PACK YEARS @ REGISTRATION	At time of transplant	Yes			No	No	No	No
CIG_USE	HISTORY OF CIGARETTE USE	At time of transplant	Yes	No	No	No	No	No	No
CMV_DON	DONOR SEROLOGY ANTI CMV (FOR LIVING DONOR, PRE UNET DATA ONLY)	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
CMV_IGG	RECIPIENT-CMV BY IGG TEST RESULT @ TRANSPLANT	At time of transplant	Yes	No	No	No	No	No	No
CMV_IGM	RECIPIENT-CMV BY IGM TEST RESULT @ TRANSPLANT	At time of transplant	Yes						No
COMPOSITE_DEATH_DATE	Composite Patient Death Date from OPTN or Verified from External Sources	At time of transplant	Yes	No	No	No	No	No	No
CONTIN_ALCOHOL_OLD_DON	DECEASED DONOR-HISTORY OF ALCOHOL DEPENDENCY+ RECENT 6MO USE	At time of transplant	Yes			-			No
CONTIN_CIG_DON	DECEASED DONOR-HISTORY OF CIGARETTES IN PAST@ >20PACK YRS+RECENT 6MO USE CIGARETTE USE > 10 PACK YRS AND CONINUED USE DURING LAST SIX MONTHS	At time of transplant	Yes			1.50			No
CONTIN_CIG_OLD	DECEASED DONOR-HISTORY OF COCAINE USE+RECENT 6MO USE	At time of transplant At time of transplant	Yes			137			No
CONTIN_COCAINE_DON CONTIN_IV_DRUG_OLD_DON	DECEASED DONOR-HISTORY OF IV DRUG USE+RECENT 6MO USE	At time of transplant	Yes						No
CONTIN IV DRUG OLD DON	DECEASED DONOR-HISTORY OF OTHER DRUGS IN PAST+RECENT 6MO USE	At time of transplant	Yes						No
CPRA	Recipient Most Recent CPRA	At time of transplant	Yes						No No
CPRA_PEAK	RecipientPeak CPRA	At time of transplant	Yes						No
CREAT_TRR	RECIPIENT SERUM CREATININE AT TIME OF TX	At time of transplant	Yes				0.000		Yes
DAYSWAIT CHRON	TOTAL DAYS ON WAITING LIST	At time of transplant	Yes			Yes			Yes
DIAL AFTER LIST	DIALYSIS OCCURRING BETWEEN LISTING AND TRANSPLANT	At time of transplant	Yes						No
DIAL_PRIOR_TX	Calculated: Ever Dialysis Prior Tx?	At time of transplant	Yes						No
DISTANCE	DISTANCE FROM DONOR HOSP TO TX CENTER (Nautical Miles)	At time of transplant	Yes						Yes
ECMO_72HOURS	Recipient ECMO at 72 Hours	At time of transplant	Yes	No	No	No	Yes	No	No
ECMO_TCR	PATIENT ON LIFE SUPPORT - ECMO @ REGISTRATION	At time of transplant	Yes			Yes			Yes
ECMO_TRR	PATIENT ON LIFE SUPPORT - ECMO @ TRANSPLANT	At time of transplant	Yes			Yes			Yes
END_BLU_FLG	LUNG PREFERENCE AT REMOVAL/CURRENT TIME/ TCR - BOTH (1=Y)	At time of transplant	Yes			100			No
END_BMI_CALC	Calculated Candidate BMI at Removal/Current Time REMOVAL/CURRENT CALCULATED LUNG ALLOCATION SCORE	At time of transplant	Yes			Yes			Yes
END_CALC_LAS	REMOVAL/CURRENT CALCULATED LUNG ALLOCATION SCORE  Serum Creatinine at TRR/Offer/Removal/Current Time (HL. LU only)	At time of transplant At time of transplant	Yes						No
END_CREAT	LUNG PREFERENCE AT REMOVAL/CURRENT TIME/TCR - LEFT (1=Y)	At time of transplant	Yes						No
END_LLU_FLG	REMOVAL/CURRENT LUNG ALLOCATION SCORE AT MATCH TIME	At time of transplant	Yes						No
END_MATCH_LAS	O2 Requirement at Rest at TRR/Offer/Removal/Current Time	At time of transplant	Yes						No
END_O2	LUNG PREFERENCE AT REMOVAL/CURRENT TIME/ TCR - RIGHT (1=Y)	At time of transplant	Yes			Yes			No
END_RLU_FLG ETHNICITY	RECIPIENT ETHNICITY (HISPANIC VS. NON-HISPANIC)	At time of transplant	Yes			AND THE RESERVE OF THE PERSON NAMED IN COLUMN TWO IN COLUM	0.000		No Yes
EXTRACRANIAL CANCER DON	DECEASED DONOR-EXTRACANIAL CANCER AT PROCUREMENT	At time of transplant	Yes						No
FEV1_TRR	PULMONARY STATUS: FEV1 % PREDICTED @ TRANSPLANT	At time of transplant	Yes			Yes			Yes
FIO2_72HOURS	Recipient FiO2 at 72 Hours	At time of transplant	Yes			No			No
FUNC_STAT_TCR	RECIPIENT FUNCTIONAL STATUS @ REGISTRATION	At time of transplant	Yes			Yes			Yes
FUNC_STAT_TRF	TRF FUNCTIONAL STATUS @ TRR/FOL	At time of transplant	Yes						No
FUNC_STAT_TRR	RECIPIENT FUNCTIONAL STATUS @TRANSPLANT	At time of transplant	Yes						Yes
FVC_TRR	PULMONARY STATUS: FVC % PREDICTED @ TRANSPLANT	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
GENDER	RECIPIENT GENDER	At time of transplant	Yes						Yes
GENDER_DON	DONOR GENDER	At time of transplant	Yes						Yes
GRF STAT	GRAFT STATUS	At time of transplant	Yes						No
GSTATUS	GRAFT FAILED (1=YES)	At time of transplant	Yes	Yes	No	No	No	No	No
GTIME	GRAFT LIFESPAN-Days From Transplant to Failure/Death/Last Follow-Up	At time of transplant	Yes		No	No	No	No	No
HEMO_CO_TRR	MOST RECENT HEMODYNAMICS CO LIMIN @ TRANSPLANT	At time of transplant	Yes	No	Yes	Yes	Yes	Yes	Yes
HEMO_PA_DIA_TRR	MOST RECENT HEMODYNAMICS PA (DIA) MM/HG @ TRANSPLANT	At time of transplant	Yes		Yes	Yes	Yes	Yes	Yes
HEMO_PA_MN_TRR	MOST RECENT HEMODYNAMICS PA (MEAN) MM/HG @ TRANSPLANT	At time of transplant	Yes						Yes
HEMO_PCW_TRR	MOST RECENT HEMODYNAMICS PCW (MEAN) MM/HG @ TRANSPLANT	At time of transplant	Yes						Yes
HEMO_SYS_TRR	MOST RECENT HEMODYNAMICS PA (SYS) MM/HG @ TRANSPLANT	At time of transplant	Yes						Yes
HIST_ALCOHOL_OLD_DON	DECEASED DONOR-HISTORY OF ALCOHOL DEPENDENCY DECEASED DONOR-HISTORY OF CIGARETTES IN PAST @ >20PACK YRS	At time of transplant At time of transplant	Yes	110					No
HIST_CIG_DON	DECEASED DONOR-HISTORY OF COCAINE USE IN PAST	At time of transplant	Yes						Yes
HIST_COCAINE_DON HIST_OTH_DRUG_DON	DECEASED DONOR-HISTORY OF COCAME USE IN PAST	At time of transplant	Yes			Yes Yes			Yes Yes
HISTRY_CIG_OLD	CIGARETTE USE > 20 PACK YRS (PRE-10/25/99)	At time of transplant	Yes			Yes No			Yes No
HLAMIS	HLA MISMATCH LEVEL	At time of transplant	Yes						Yes
INFECT_IV_DRUG_TRR	INFECTION REQUIRING IV DRUG THERAPY (WITHIN 2 WEEKS PRIOR TO TRANSPLANT)	At time of transplant	Yes						Yes
INHALED_NO_TCR	TCR Patient on Life Support://Inhaled NO	At time of transplant	Yes						Yes
INHALED_NO_TRR	TRR Patient on Life Support://Inhaled NO	At time of transplant	Yes						No
INHALEDNO_72HOURS	Recipient Inhaled NO at 72 Hours	At time of transplant	Yes			No			No
INTUBATED_72HOURS	Recipient Intubated at 72 Hours	At time of transplant	Yes	No	No	No			No
ISCHTIME	ISCHEMIC TIME IN HOURS	At time of transplant	Yes			Yes	Yes		Yes
LIFE_SUP_TRR	CANDIDATE LIFE SUPPORT @ REGISTRATION	At time of transplant	Yes			Yes			Yes
LOS	RECIPIENT LENGTH OF STAY POST TX	At time of transplant	Yes			Yes			No
LV_EJECT	DECEASED DONOR LV EJECTION FRACTION %	At time of transplant	Yes						No
MOST_RCNT_CREAT	PATIENT MOST RECENT ABSOLUTE CREATININE AT LISTING	At time of transplant	Yes			No			No
NUM_PREV_TX	THE NUMBER OF PREVIOUS TRANSPLANTS  OTHER MECHANISM OF LIFE Y/N, 1=Y @ TRANSPLANT	At time of transplant At time of transplant	Yes			Yes		-	Yes
OTH_LIFE_SUP_TRR	DECEASED DONOR INFECTION OTHER SOURCE-CONFIRMED	At time of transplant	Yes			Yes		1000	No
OTHER_INF_DON	Recipient Pa02 at 72 Hours	At time of transplant	Yes			Yes			Yes
PAO2_72HOURS PCO2_DON	DDR pCO2:	At time of transplant	Yes			No			No
PCO2_DON PCO2_TRR	PULMONARY STATUS. PCO2 MM/HG @ TRANSPLANT	At time of transplant	Yes			No Yes			No Yes
PERFUSED_PRIOR	TRR LUNG(S) PERFUSED PRIOR TO TRANSPLANT?	At time of transplant	Yes						No
PGE_TRR	PATIENT ON LIFE SUPPORT: PGE @ TRANSPLANT	At time of transplant	Yes						Yes
PNEUMORED_OLD	CANDIDATE PNEUMOREDUCTION PRIOR TO LISTING	At time of transplant	Yes						No
	CANDIDATE PNEUMOTHORAX PRIOR TO LISTING	At time of transplant	Yes						No
PNEUMOTHORAX OLD	DECEASED DONOR PO2 ON 100%	At time of transplant	Yes						Yes
		At time of transplant	Yes			Yes			Yes
PO2	DDR:Lung pO2 on Fio2 //If Yes, Lung pO2 on FiO2 of:		Yes						No
PO2 PO2_FIO2_DON	RECIPIENT MOST RECENT PRA% @ TRANSPLANT	At time of transplant	162	140					No
PO2_FIO2_DON PRAMR	RECIPIENT MOST RECENT PRAY @ TRANSPLANT RECIPIENT MOST RECENT PRAY CLASS I @ TRANSPLANT	At time of transplant At time of transplant	Yes				No	No	THU
PO2_PO2_DON PO2_FIO2_DON PRAMR_PRAMR_CL1	RECIPIENT MOST RECENT PRAS & TRANSPLANT RECIPIENT MOST RECENT PRAS, CLASS I & TRANSPLANT RECIPIENT MOST RECENT PRAS, CLASS II & TRANSPLANT	At time of transplant At time of transplant At time of transplant		No	No	No			No
PO2 PO2 FIO2 DON PRAMR PRAMR GL1 PRAMR GL2 PRAPK	RECIPIENT MOST RECEIT PRAS, @ TRANSPLANT RECIPIENT MOST RECEIT PRAS, CLASS I, @ TRANSPLANT RECIPIENT MOST RECEIT PRAS, CLASS II, @ TRANSPLANT RECIPIENT PEAK PRAS, @ TRANSPLANT	At time of transplant At time of transplant At time of transplant At time of transplant	Yes	No No	No No	No No	No	No	
PNEUMOTHORAX OLD PO2 PO2 FIO2 DON PRAMR PRAMR CL1 PRAMR CL2 PRAPK PRAPK CL1	RECIPIENT MOST RECEIT PRAS & TRANSPLANT RECIPIENT MOST RECEIT PRAS (LASS I) ® TRANSPLANT RECIPIENT MOST RECEIT PRAS (LASS I) ® TRANSPLANT RECIPIENT PEAK PRAS & TRANSPLANT RECIPIENT PEAK PRAS & TRANSPLANT RECIPIENT PEAK PRAS (LASS I) ® TRANSPLANT	At time of transplant	Yes Yes	No No No No	No No No No	No No No No	No No No	No No	No No No
PO2 FIO2 DON PRAMR PRAMR GL1 PRAMR CL2 PRAPK PRAPK CL1 PRAPK CL1 PRAPK CL2	RECIPIENT MOST RECEIT PRAS. Q TRAISPLANT RECIPIENT MOST RECEIT PRAS. CLASS I Q TRAISPLANT RECIPIENT MOST RECEIT PRAS. CLASS I Q TRAISPLANT RECIPIENT PEAK PRAS. Q TRAISPLANT RECIPIENT PEAK PRAS. CLASS I Q TRAISPLANT RECIPIENT PEAK PRAS. CLASS I Q TRAISPLANT	At time of transplant	Yes Yes Yes Yes Yes	No No No No No	No No No No No	No No No No No	No No No	No No No	No No No No
PO2 PO2, FIO2, DON PRAMIR PRAMIR GL1 PRAMIR GL2 PRAPIX PRAPIX CL2 PRAPX CL1 PRAPX CL1 PRAPX L2 PRAPX L3 PRAPX L	RECIPIENT MOST RECEIT FRANS @ TRANSPLANT RECIPIENT MOST RECEIT FRANS CLASS II @ TRANSPLANT RECIPIENT MOST RECEIT FRANS CLASS II @ TRANSPLANT RECIPIENT PEAK FRANS CLASS II @ TRANSPLANT CALCULATED PROMOUNT TRANSPLANT OF ANY ORDER CALCULATED PROMOUNT TRANSPLANT OF ANY ORDER CALCULATED PROMOUNT TRANSPLANT OF ANY ORDER TO THE PEAK FRANS CLASS II @ TRANSPLANT	At time of transplant	Yes Yes Yes Yes Yes Yes	No No No No No Yes	No No No No No Yes	No No No No No Yes	No No No No Yes	No No No No Yes	No No No No Yes
PO2 PO2 FIO2 DON PRAMR PRAMR CL1 PRAMR CL2 PRAPK PRAPK	RECIPIENT MOST RECEIT PRAS. Q TRAISPLANT RECIPIENT MOST RECEIT PRAS. CLASS I Q TRAISPLANT RECIPIENT MOST RECEIT PRAS. CLASS I Q TRAISPLANT RECIPIENT PEAK PRAS. Q TRAISPLANT RECIPIENT PEAK PRAS. CLASS I Q TRAISPLANT RECIPIENT PEAK PRAS. CLASS I Q TRAISPLANT	At time of transplant	Yes Yes Yes Yes Yes Yes Yes	No No No No No Yes	No No No No No Yes	No No No No No Yes	No No No No Yes	No No No No Yes	No No No No

PROS INFUS TRR	TRR RECIPIENT PROSTACYCLIN INFUSION	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
PROSTACYCLIN TRR	TRR RECIPIENT PROSTACYCLIN INHALATION	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
PST AIRWAY	EVENTS PRIOR TO DISCHARGE: AIRWAY DEHISCENCE	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
PST_DIAL	EVENTS PRIOR TO DISCHARGE: DIALYSIS	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
PST_PACEMAKER	EVENTS PRIOR TO DISCHARGE: PERMANENT PACEMAKER	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
PST_STROKE	EVENTS PRIOR TO DISCHARGE: STROKE	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
PSTATUS	Boolean Most Recent Patient Status (based on composite death date) (1=Dead, 0=Alive)	At time of transplant	Yes	Yes	No	No	No	No	No
PTIME	Patient Survival Time in days (based on composite death date)	At time of transplant	Yes	Yes	No	No	No	No	No
PULM_INF_DON	DECEASED DONOR-INFECTION PULMONARY SOURCE	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
RECOV_OUT_US	ORGAN RECOVERED OUTSIDE U.S. RECIPIENT REINTUBATED POST TRANSPLANT	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REINTUBATED	PAN-RESISTANT BACTERIAL INFECTION @ REGISTRATION	At time of transplant At time of transplant	Yes	No	No	Yes	Yes	No	No
RESIST INF	EVENTS OCCURRING BETWEEN LISTING AND TRANSPLANT: STERNOTOMY	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
STERNOTOMY_TRR		At time of transplant	Yes	No	No	No	No	No	No
STEROID ADSTAIN	DURATION OF ABSTINENCE FOR CIGARETTE USE	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DUR_ABSTAIN	CANDIDATE THORACOTOMY LEFT AT LISTING	At time of transplant	Yes	No	No	No	No	No	No
THORACOT_LT_OLD THORACOT_RT_OLD	CANDIDATE THORACOTOMY RIGHT AT LISTING	At time of transplant	Yes	No	No	No	No	No	No
TOTAL_PERFUSION_TIME	TOTAL TIME (MINUTES) LUNG(S) ON PERFUSION	At time of transplant	Yes	No No	No No	No No	No.	No No	No No
TRACHEOSTOMY TRR	TRR TRACHEOSTOMY	At time of transplant	Yes	No	No	Yes	Yes	No	No
TRTREJIY	TREATED FOR REJECTION WITHIN 1 YEAR	At time of transplant	Yes	No	No	No	No	No	No
TX_YEAR	TRANSPLANT YEAR	At time of transplant	Yes	Yes	No	No	No	No	No
TXED	CANDIDATE RECEIVED DECEASED DONOR TRANSPLANT? 1=YES	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
VENT_SUPPORT_AFTER_LIST	EVENTS OCCURRING BETWEEN LISTING AND TRANSPLANT: EPISODE OF VENTILATORY SUPPOR	At time of transplant	Yes	No	Yes	Yes	Yes	Yes	Yes
VENT_SUPPORT_TRR	TRR EPISODE OF VENTILATORY SUPPORT	At time of transplant	Yes	No	Yes	Yes	Yes	Yes	No
VENT_TIMEFRAME_TRR	TRR MOST RECENT VENT SUPPORT TIMEFRAME	At time of transplant	Yes	No	No	Yes	Yes	No	No
VENTILATOR_TRR	PATIENT ON LIFE SUPPORT - VENTILATOR @ TRANSPLANT	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
VENTILATOR_TCR	PATIENT ON LIFE SUPPORT - VENTILATOR @ REGISTRATION	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
WORK_INCOME_TRR	RECIPIENT WORK FOR INCOME AT TRANSPLANT?	At time of transplant	Yes	No	No	No	No	No	No
ATGAM DAYS	ATGAM # OF DAYS INDUCTION (ANTI-LYMPHOCYTE RECEPTOR ANTIBODY)	At time of transplant	Yes	No	No	No	No	No	No
ATGAM_IND		At time of transplant	Yes	No	No	No	No	No	No
ATGAM_MAINT	ATGAM MAINTENANCE AT TIME OF TX (ANTI-LYMPHOCYTE RECEPTOR ANTIBODY)	At time of transplant	Yes	No	No	No	No	No	No
CAMPATH_ANTIREJ	CAMPATH ANTIREJECTION	At time of transplant	Yes	No	No	No	No	No	No
CAMPATH_DAYS	CAMPATH # OF DAYS INDUCTION	At time of transplant	Yes	No	No	No	No	No	No
CAMPATH_IND	CAMPATH INDUCTION AT TIME OF TX	At time of transplant	Yes	No	No	No	No	No	No
CAMPATH MAINT	CAMPATH MAINTENANCE AT TIME OF TX	At time of transplant	Yes	No	No	No	No	No	No
CELLCEPT_ANTIREJ	CELLCEPT ANTIREJECTION (T-CELL ACTIVATION INHIBITOR)	At time of transplant	Yes	No	No	No	No	No	No
CELLCEPT_DAYS	CELLCEPT # OF DAYS INDUCTION (T-CELL ACTIVATION INHIBITOR)	At time of transplant	Yes	No	No	No	No	No	No
CELLCEPT_IND	CELLCEPT INDUCTION AT TIME OF TX (T-CELL ACTIVATION INHIBITOR)	At time of transplant	Yes	No	No	No	No	No	No
CELLCEPT_MAINT	CELLCEPT MAINTENANCE AT TIME OF TX (T-CELL ACTIVATION INHIBITOR)	At time of transplant	Yes	No	No	No	No	No	No
CYCLOSPORIN_ANTIREJ	CYCLOSPORIN ANTIREJECTION (T-CELL ACTIVATION INHIBITOR)	At time of transplant	Yes	No	No	No	No	No	No
CYCLOSPORIN_IND	CYCLOSPORIN INDUCTION AT TIME OF TX (T-CELL ACTIVATION INHIBITOR)	At time of transplant	Yes	No	No	No	No	No	No
CYCLOSPORIN_MAINT	CYCLOSPORIN MAINTENANCE AT TIME OF TX (T-CELL ACTIVATION INHIBITOR)	At time of transplant	Yes	No	No	No	No	No	No
GENERICMMF_MAINT	GENERICMMF MAINTENANCE AT TIME OF TX	At time of transplant	Yes	No	No	No	No	No	No
GENERICTACROLIMUS_MAINT	GENERICTACROLIMUS MAINTENANCE AT TIME OF TX	At time of transplant	Yes	No	No	No	No	No	No
IMURAN_ANTIREJ	IMURAN ANTREJECTION (ANTIMETABOLITE)	At time of transplant	Yes	No	No	No	No	No	No
IMURAN_DAYS		At time of transplant	Yes	No	No	No	No	No	No
IMURAN_IND	IMURAN INDUCTION AT TIME OF TX (ANTIMETABOLITE)	At time of transplant	Yes	No	No	No	No	No	No
IMURAN_MAINT	IMURAN MAINTENANCE AT TIME OF TX (ANTIMETABOLITE)	At time of transplant	Yes	No	No	No	No	No	No
SIMULECT_ANTIREJ	SIMULECT ANTIREJECTION (ANTI-LYMPHOCYTE RECEPTOR ANTIBODY)	At time of transplant	Yes	No	No	No	No	No	No.
SIMULECT_DAYS	SIMULECT # OF DAYS INDUCTION (ANTI-LYMPHOCYTE RECEPTOR ANTIBODY)	At time of transplant	Yes	No	No	No	No	No	No
SIMULECT_IND	SIMULECT INDUCTION AT TIME OF TX (ANTI-LYMPHOCYTE RECEPTOR ANTIBODY)	At time of transplant	Yes	No	No	No	No	No	No .
SIMULECT_MAINT	SIMULECT MAINTENANCE AT TIME OF TX (ANTI-LYMPHOCYTE RECEPTOR ANTIBODY)	At time of transplant	Yes	No	No	No	No	No	No
	STEROIDS ANTIREJECTION	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
STEROIDS_ANTIREJ				81-		22.5			
STEROIDS_ANTIREJ STEROIDS_DAYS	STEROIDS # OF DAYS INDUCTION	At time of transplant	Yes	No	No	No	No	No	No
	STEROIDS # OF DAYS INDUCTION STEROIDS INDUCTION AT TIME OF TX	At time of transplant	Yes Yes	Yes	No Yes	No Yes	No Yes	No Yes	No No
STEROIDS_DAYS	STERGIOS # OF DAYS RIDUCTION STERGIOS RIDUCTION AT TIME OF TX STERGIOS MAINTENANCE AT TIME OF TX	At time of transplant At time of transplant	1						
STEROIDS DAYS STEROIDS IND STEROIDS MAINT B. CELL DONE XMAT AHG	STEROIDS # OF DAYS INDUCTION STEROIDS INDUCTION AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX INF PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT	At time of transplant At time of transplant At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
STEROIDS DAYS STEROIDS IND STEROIDS MAINT B_CELL_DONE_XMAT_AHG B_CELL_DONE_XMAT_FLOW_CYT	STEROIDS # OF DAYS BRUCTION STEROIDS REQUESTED ## THE OF TX STEROIDS REQUESTED ## THE OF TX STEROIDS MAINTENANCE AT TIME OF TX FOR PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE	At time of transplant At time of transplant At time of transplant At time of transplant	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No
STEROIDS DAYS STEROIDS IND STEROIDS MAINT B_CELL_DONE_XMAT_AHG B_CELL_DONE_XMAT_FLOW_CYT	STEROIDS # OF DAYS IRQUICTION STEROIDS INDUCTION AT TIME OF TX STEROIDS INDUCTION AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX RN PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RN PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE RN PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT	At time of transplant	Yes Yes Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No No No	Yes Yes No No	No No
STEROIDS DAYS STEROIDS IND STEROIDS MAINT B_CELL_DONE_XMAT_AHG B_CELL_DONE_XMAT_FLOW_CYT	STEROIDS # OF DAYS INDUCTION STEROIDS ROUCTION AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX RH PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AHR TEST RESULT RH PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE RH PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AHR TEST RESULT PRA (%) MOST RECENT CLASS!	At time of transplant	Yes Yes Yes Yes	Yes Yes No No	Yes Yes No No	Yes Yes No No	Yes Yes No No No	Yes Yes No No	No No No
STEROIDS DAYS STEROIDS IND STEROIDS MAINT B_CELL_DONE_XMAT_AHG B_CELL_DONE_XMAT_FLOW_CYT B_CELL_DONE_XMAT_NO_AHG PRA1	STEROIDS # OF DAYS BRUCTION STEROIDS BRUCTION AT TIME OF TX STEROIDS BRUCTION AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX FRI PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AHD TEST RESULT FRI PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE: FRI PHYSICAL CROSSMATCH - B CELL CROSSMATCH CYTOTOXICITY NO AHG TEST RESULT FRA (%) MOST RECENT CLASS I FRA (%) MOST RECENT CLASS I	At time of transplant	Yes Yes Yes Yes Yes Yes Yes	Yes Yes No No No No No	Yes Yes No No No No No No No	Yes Yes No No No No No No	Yes Yes No No No	Yes Yes No No No No No No	No No No No No No No
STERCIOS DAYS STERCIOS MOD STERCIOS MAINT B. CELL DONE, XMAT, AHG B. CELL DONE, XMAT, AHG B. CELL DONE, XMAT, NO, AHG PRA1 PRA2 T. CELL DONE, XMAT, NO, AHG TRA1 T. CELL DONE, XMAT, AHG	STEROIDS # OF DAYS INDUCTION STEROIDS INDUCTION AT THE COF TX STEROIDS INDUCTION AT THE COF TX STEROIDS MAINTENANCE AT TIME OF TX RR PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AHO TEST RESULT RR PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE: RR PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AHO TEST RESULT PRA (%) MOST RECENT CLASS II RR (%) MOST RECENT CLASS II RR PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AHO TEST RESULT	At time of transplant	Yes Yes Yes Yes Yes Yes Yes Yes	Yes Yes No No No No No No	Yes Yes No	Yes Yes No	Yes Yes No No No No No	Yes Yes No	No No No No No No No No No
STEROIDS DAYS STEROIDS IND STEROIDS MIND B. CELL DONE MANT AHG B. CELL DONE MAT FLOW CYT B. CELL DONE MAT NO AHG PRA1 FRA2 T. CELL DONE MAT AHG T. CELL DONE MAT FLOW CYT	STEROIDS # OF DAYS BRUCTION  STEROIDS BRUCTION AT TIME OF TX  STEROIDS BRUCTION AT TIME OF TX  STEROIDS BRUCTION AT TIME OF TX  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AHD TEST RESULT  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AHD TEST RESULT  PRA (%) MOST RECENT CLASS I  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AHD TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AHD TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RES	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No No No No No No No No No
STERCIOS DAYS STERCIOS MIND STERCIOS MIND B CELL DONE MANT AHG B CELL DONE MAT FLOW CYT B CELL DONE MAT NO AHG PRA1 T CELL DONE MAT HO T CELL DONE MAT HOW CYT T CELL DONE MAT HOW CYT T CELL DONE MAT NO AHG	STEROIDS # OF DAYS BRUCTION STEROIDS BRUCTION AT TIME OF TX STEROIDS BRUCTION AT TIME OF TX STEROIDS BRUCTION AT TIME OF TX RI PHYSICAL GROSSMATCH - B-DELL GROSSMATCH CYTOTOXICITY AND TEST RESULT RIP HYSICAL GROSSMATCH - B-DELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE RIP HYSICAL CROSSMATCH - B-DELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I RIP HYSICAL GROSSMATCH - T-DELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP HYSICAL GROSSMATCH - T-DELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE! RIP HYSICAL GROSSMATCH - T-DELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE! RIP HYSICAL CROSSMATCH - T-DELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE! RIP HYSICAL CROSSMATCH - T-DELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE! RIP HYSICAL CROSSMATCH - T-DELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE! RIP HYSICAL CROSSMATCH - T-DELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE!	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No No No No No No No No No No No No No N
STERCIOS DAYS STERCIOS IND STERCIOS MAINT B CELL DONE ZMAT AHG B CELL DONE ZMAT FLOW CYT B CELL DONE ZMAT NO AHG PRA2 T CELL DONE ZMAT AHG T CELL DONE ZMAT NO AHG CTR CODE	STEROIDS # OF DAYS BRUCHTON  STEROIDS BRUCHTON  STEROIDS BRUCHTON AT TIME OF TX  STEROIDS SMANTENANCE AT TIME OF TX  STEROIDS SMANTENANCE AT TIME OF TX  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS    PRA (%) MOST RECENT CLASS    RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOME TRY TEST RES  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STERCIOS DAYS STERCIOS MIND STERCIOS MAINT B CELL DONE MAINT AHG B CELL DONE MAINT FLOW CYT B CELL DONE MAIT FLOW CYT B CELL DONE MAIT NO AHG PRA1 T CELL DONE MAIT FLOW CYT T CELL DONE MIAT FLOW CYT T CODE MIT OPO CIT CODE	STEROIDS # OF DAYS BRUCTION STEROIDS BRUCTION AT TIME OF TX FIR PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT FIR PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRA (%) MOST RECENT CLASS I FIR PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT FIRA (%) MOST RECENT CLASS I FIR PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT FIR PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RES FIR PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT FIRE PHYSICAL CROSSMATCH CYTOTOXICITY	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes  Yes  No	Yes Yes No	Yes Yes No	No N
STERCIOS DAYS STERCIOS IND STERCIOS MAINT 9 CELL DONE XMAT AHG 8 CELL DONE XMAT FLOW CYT 8 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT AHG 1 CELL DONE XMAT AHG 1 CELL DONE XMAT NO AHG IT CODE INT OPO CIT CODE END OPO CIT CODE	STEROIDS & OF DAYS BRUCKTON  STEROIDS ROUTCON AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOWCITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOWCITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  PRA (%) MOST RECENT CLASS I  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOWCITY AND TEST RESULT  OF HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOWCITY FLOW CYTOMETRY TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOWCITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOWCITY AND TEST RESULT  ENCRYPTED TRANSPLAIT CENTER CODE  ENCRYPTED NITIAL, OPEN MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED NITIAL, OPEN MAPPED FROM USTING CENTER AND BEGINNING DATE	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes Yes No	No N
STERCIOS DAYS STERCIOS MID STERCIOS MID STERCIOS MAINT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT NO AHG PRA2 T. CELL DONE MAT AHG T. CELL DONE MAT FLOW CYT T. CELL DONE MAT FLOW CYT T. CELL DONE MAT NO AHG CITE. CODE MIT OPO CITE. CODE END OPO CITE. CODE END OPO CITE. CODE END OPO CITE. CODE	STEROIDS & OF DAYS BRUCTION  STEROIDS BRUCTION AT TIME OF TX  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST REF  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS II  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED RIMINAL OPO MAPPED FROM LISTING CENTER AND BEGINNING DATE  ENCRYPTED RIMINAL OPO MAPPED FROM LISTING CENTER AND BEGINNING DATE  ENCRYPTED REMOVALCURRENT OPO MAPPED FROM LISTING CENTER AND EBCONYSEY TRANSPORTED  ENCRYPTED REMOVALCURRENT OPO MAPPED FROM LISTING CENTER AND EBCONYSEY TRANSPORTED  ENCRYPTED OF CENTER CODE (GPOO OF THE EOCCUPENY FROM DOR FORM	At time of transplant	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STEROIDS DAYS STEROIDS IND STEROIDS MAINT 9 CELL DONE XMAT AHG 9 CELL DONE XMAT AHG 8 CELL DONE XMAT NO AHG PRA1 T CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG CTR CODE INT OPD CTR CODE END OPD CTR CODE END OPD CTR CODE USTING CTR CODE USTING CTR CODE	STEROODS # OF DAYS BRUICTION  STEROODS MUCHENAISE AT TIME OF TX  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY HO AND TEST RESULT  PRA (N) MOST RECENT CLASS I  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY ON AND TEST RESULT  ENCRYPTED TRANSPLANT CENTER CODE  ENCRYPTED TRANSPLANT CENTER CODE  ENCRYPTED RIPMAL OPO MAPPED FROM LISTING CENTER AND BEGINNING DATE  ENCRYPTED BRIDDAL OPO MAPPED FROM LISTING CENTER AND BEGINNING DATE  ENCRYPTED DEBMOVALCURRENT OPO MAPPED FROM LISTING CENTER AND ENDING DATE  ENCRYPTED DEBMOVALCURRENT OPO MAPPED FROM LISTING CENTER AND ENDING DATE  ENCRYPTED DEBMOVALCURRENT OPO MAPPED FROM LISTING CENTER AND ENDING DATE  ENCRYPTED DEBMOVALCURRENT OPO MAPPED FROM LISTING CENTER AND ENDING DATE  ENCRYPTED VIEW LISTING CENTER CODE  ENCRYPTED VIEW LISTING CENTER OF THE DECREASED DONOR RECOVERY FROM DOR FORM  ENCRYPTED VIEW LISTING CENTER CODE  ENCRYPTED VIEW LISTING CENTER CODE  ENCRYPTED VIEW LISTING CENTER OF THE DECREASED DONOR RECOVERY FROM DOR FORM  ENCRYPTED VIEW LISTING CENTER CODE  ENCRYPTED VIEW LI	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STEROIDS DAYS STEROIDS MIND STEROIDS MIND STEROIDS MIND B CELL DONE MANT FLOW CYT B CELL DONE MANT FLOW CYT B CELL DONE MANT NO AHG PRA2 T CELL DONE MANT AHG T CELL DONE MANT AHG T CELL DONE MANT NO AHG OTT CODE MIT OPO CTR CODE LISTING CTR CODE MATCH LOS INDISI	STEROIDS # OF DAYS BRUCKTON  STEROIDS BRUCKTON  STEROIDS SINCICTION AT TIME OF TX  STEROIDS SINCICTION AT TIME OF TX  STEROIDS SINCICTION AT TIME OF TX  STEROIDS SINCICH SECRET SINCICH SECRET SINCIPLE  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (N) MOST RECENT CLASS    RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND BEGINNISD DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NORWALLCUSRENT OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED OPD CENTER CODE (OPD OF THE DECEASED DONOR RECOVERY FROM DOR FORM  ENCRYPTED WILL USTING CENTER	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STEROIDS DAYS STEROIDS MIND STEROIDS MIND B CELL DONE MAT FLOW CYT B CELL DONE MAT FLOW CYT B CELL DONE MAT FLOW CYT B CELL DONE MAT NO AHG PRA1 PRA2 T CELL DONE MAT FLOW CYT T CELL DONE MAT FLOW	STEROIDS & OF DAYS BRUCTION  STEROIDS BRUCTION AT TIME OF TX  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIF PHYSICAL CROSSMATCH - TCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED TRANSPLANT CENTER CODE  ENCRYPTED TRANSPLANT CENTER CODE  ENCRYPTED BINDAL OPO MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED BINDAL OPO CAMPED OFFO THE DECEASED DONOR RECOVERY FROM DDR FORM  ENCRYPTED WILLSTING CENTER  MARCH LAS at start of waitist  Waitist Utigency Measure at start of waitist  Waitist Utigency Measure at start of waitist	At time of transplant	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No Yes Yes Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STERCIOS DAYS STERCIOS IND STERCIOS MAINT B CELL DONE XMAT AHG B CELL DONE XMAT FLOW CYT B CELL DONE XMAT NO AHG PRA2 T CELL DONE XMAT AHG T CELL DONE XMAT NO AHG GTR CODE INT OPO CTR CODE END OPO CTR CODE END OPO CTR CODE LISTING CTR CODE LISTING CTR CODE LISTING CTR CODE MATCH LAS intosi WL MEASURE intosi MM intidial	STEROIDS # OF DAYS BRUCKTON  STEROIDS BRUCKTON  STEROIDS SINCICTION AT TIME OF TX  STEROIDS SINCICTION AT TIME OF TX  STEROIDS SINCICTION AT TIME OF TX  STEROIDS SINCICH SECRET SINCICH SECRET SINCIPLE  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (N) MOST RECENT CLASS    RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND BEGINNISD DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NORWALLCUSRENT OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED OPD CENTER CODE (OPD OF THE DECEASED DONOR RECOVERY FROM DOR FORM  ENCRYPTED WILL USTING CENTER	At time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STEROIDS DAYS STEROIDS MIND STEROIDS MIND B. CELL DONE MANT AHG B. CELL DONE MANT FLOW CYT B. CELL DONE MANT NO AHG PRA1 PRA2 T. CELL DONE MAT FLOW CYT T. CELL DONE MAT NO AHG CTR. CODE INT OPO CTR. CODE END. OPO CTR. CODE END. OPO CTR. CODE USTING CTR. CODE USTING CTR. CODE USTING CTR. CODE MIT OPO CTR. CODE MIT OPI CODE MIT OPI CODE MIT OPI CODE MIT OPI CODE MIT MEASURE Initial MIT INITIAL MIT MEASURE Initial MIT INITIAL MIT MEASURE	STEROIDS # OF DAYS BRUCTION  STEROIDS BRUCTION AT TIME OF TX  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS II  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED BITMAL OPD MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED BITMAL OPD MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED OPD CENTER CODE (OPD OF THE DECEASED DONOR RECOVERY FROM DOR FORM  MAIGHLAS I start of wardist  Waitinst Uppercy Measure at start of wardist  BM at start of wardist  Cordec ledes (10) at start of wardist	As time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STERCIOS DAYS STERCIOS IND STERCIOS MAINT 9 CELL DONE XMAT AHG 8 CELL DONE XMAT FLOW CYT B CELL DONE XMAT NO AHG PRA2 T. CELL DONE XMAT NO AHG T. CELL DONE XMAT AHG T. CELL DONE XMAT AHG T. CELL DONE XMAT FLOW CYT T. CELL DONE XMAT FLOW	STEROIDS # OF DAYS BRUCKTON STEROIDS BRUCKTON STEROIDS BRUCKTON STEROIDS STEROIDS AT TIME OF TX STEROIDS STEROIDS AT TIME OF TX STEROIDS S	Al time of transplant	Yes	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	Yes Yes No	No N
STERCIOS DAYS STERCIOS MOD STERCIOS MIND STERCIOS MAINT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT NO AHG PRA2 T. CELL DONE MAT NO AHG T. CELL DONE MAT NO AHG CTR. CODE BIT OPO CTR. CODE END OPO CTR. CODE END OPO CTR. CODE LISTING CTR. CODE LISTING CTR. CODE MATCH LOS MATCH	STEROIDS # OF DAYS BRUCHTON STEROIDS BRUCHTON STEROIDS SHOUTCH AT TIME OF TX STEROIDS SMARTERIARICE AT TIME OF TX STEROIDS SMARTERIARICE AT TIME OF TX RIP HYSICAL CROSSMARTCH - B-CELL CROSSMARTCH CYTOTOXICITY AND TEST RESULT RIP HYSICAL CROSSMARTCH - B-CELL CROSSMARTCH CYTOTOXICITY FLOW CYTOMETRY TEST RE- RIP HYSICAL CROSSMARTCH - B-CELL CROSSMARTCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I PRA (%) MOST RECENT CLASS I RIP HYSICAL CROSSMARTCH - T-CELL CROSSMARTCH CYTOTOXICITY AND TEST RESULT PRH PHYSICAL CROSSMARTCH - T-CELL CROSSMARTCH CYTOTOXICITY AND TEST RESULT RIP HYSICAL CROSSMARTCH - T-CELL CROSSMARTCH CYTOTOXICITY FLOW CYTOMETRY TEST RE- RIP HYSICAL CROSSMARTCH - T-CELL CROSSMARTCH CYTOTOXICITY NO AND TEST RESULT ENCRYPTED NITIAL, OPD MAPPED FROM USTING CENTER AND BEGINNING DATE ENCRYPTED WINDAY, AND TEST RESULT CROSSMARTCH CYTOTOXICITY IN CASE THE MADE PROMINED BETT ENCRYPTED OF THE LISTING CENTER. MAICH LAS at start of waitist Waitist Utgency Measure at start of waitist Users to Most to Markets Cardion books (C) at start of waitist Cardion books (C) at start of waitist Cardion books (C) at start of waitist	As time of transplant Wallist Wallist Wallist Wallist Wallist	Yes	Yes Yes No	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes Yes No	No N
STERCIOS DAYS STERCIOS MAINT 9 CELL DONE XMAT AHG 9 CELL DONE XMAT AHG 8 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG OTR CODE NIT OPO CTR CODE END OPO CTR CODE END OPO CTR CODE USTNMG CTR CODE MATCH LAS initial WI, MEASURE initial GREATNINE initial FEV POST ACT initial FEV POST ACT initial	STEROIDS # OF DAYS BRUCTION  STEROIDS BRUCTION AT TIME OF TX  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST REF  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS #  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED REMOVAL/CURRENT OPO MAPPED FROM LISTING CENTER AND ENDING DATE  ENCRYPTED OPD CENTER CODE (OPO OF THE DECEASED DONOR RECOVERY FROM DOR FORM  Waltist Utgercy Measure at start of waitist  BMI at start of waitist  BMI at start of waitist  Chatairne at start of waitist  Chatairne at start of waitist  Chatairne at start of waitist	As time of transplant Washist Washist Washist Washist Washist	Yes	Yes Yes No	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes  Yes  No  No  No  No  No  No  No  No  No  N	No N
STERCIOS DAYS STERCIOS MO STERCIOS MO STERCIOS MAINT 8 CELL DONE XMAT AHG 8 CELL DONE XMAT FLOW CYT 8 CELL DONE XMAT NO AHG PRA2 1 CELL DONE XMAT NO AHG T CELL DONE XMAT AHG T CELL DONE XMAT NO AHG GTR CODE INIT. OPO_CTR CODE END OPO_CTR CODE END OPO_CTR CODE LISTING CTR CODE LISTING CTR CODE MIT. OPO_CTR CODE LISTING CTR CODE MIT. OPO_CTR CODE CODE LISTING CTR CODE MIT. OPO_CTR CODE LISTING CTR CODE LISTING CTR CODE MIT. OPO_CTR CODE CODE CODE CODE CODE CODE CODE CODE	STEROIDS # OF DAYS BRUCKTON STEROIDS BUDICTION STEROIDS MAINTENANCE AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE- RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT ENCRYPTED TROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT ENCRYPTED TROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT ENCRYPTED BRITIAL OPD MAPPED FROM USTRON CENTER AND BEGINNING DATE ENCRYPTED WINDAW ON MAPPED FROM USTRON CENTER AND BEGINNING DATE ENCRYPTED OF DEMPER CODE (OPO OF THE DECEASED DONOR RECOVERY FROM DDR FORM ENCRYPTED AND LISTING CENTER CODE ENCRYPTED WINDAWS AND STANDAY OF THE DECEASED DONOR RECOVERY FROM DDR FORM MIGHL AS I stant of waisinst Ustrainst Undersor Measure at stant of waitinst  DMI at stant of waitinst Cardion of doutinst Actual Post BionchoolisistoffeV at stant of waitinst Paccent Post PisonchoolistoffeV at stant of waitinst	Al time of transplant Waelfist Waelfist Waelfist Waelfist Waelfist Waelfist Waelfist	Yes	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes   100	Yes 1 Yes 1 No 1 No 1 No N	Yes   Yes	No N
STERCIOS DAYS STERCIOS MAINT 9 CELL DONE XMAT AHG 9 CELL DONE XMAT AHG 8 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG OTR CODE NIT OPO CTR CODE END OPO CTR CODE END OPO CTR CODE USTNMG CTR CODE MATCH LAS initial WI, MEASURE initial GREATNINE initial FEV POST ACT initial FEV POST ACT initial	STEROIDS # OF DAYS BRUCKTON  STEROIDS BRUCKTON  STEROIDS SHOUCTON AT TIME OF TX  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (N) MOST RECENT CLASS    PRA (N) MOST RECENT CLASS    RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED STORM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED STORM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED STORM USTING CENTER AND ENDING DATE  CROSSMATCH WASHIST  CARRIED MARKET  CARRIED AND MARKET  CARRIED MARKET  CARRIED MARKET  ENCRYPTED NITIAL OPD MAPPED STORM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED STORM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED STORM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED STORM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED STORM OPD MARKET  CARRIED MARKET  ENCRYPTED NITIAL OPD MAPPED STORM OPD MARKET  ENCRYPTED NITIAL OPD MAPPED STORM OPD MARKET  ENCRYPTED NITIAL OPD MAPPED STORM OPD MARKET  ENCRYPTED NITIAL OPD MARKET  ENCRYPTED NITIAL OPD MARKET  ENCRYPTED NITIAL OPD MARKET  ENCRYPTED NITIAL	As time of transplant Washist Washist Washist Washist Washist Washist Washist	Yes	Yes Yes No	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes  Yes  No  No  No  No  No  No  No  No  No  N	No N
STERCIOS DAYS STERCIOS MO STERCIOS MO STERCIOS MAINT B CELL DONE XMAT AHG B CELL DONE XMAT FLOW CYT B CELL DONE XMAT NO AHG PRA2 T. CELL DONE XMAT AHG T. CELL DONE XMAT FLOW CYT T. CELL DONE XMAT AHG T. CELL DONE XMAT ANG STERCION COLO BINT C	STEROIDS # OF DAYS BRUCKTON STEROIDS BUDGETON STEROIDS MAINTENANCE AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX H PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT first PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE- RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY ON AND TEST RESULT ENCRYPTED TRANSPLANT CENTER CODE ENCRYPTED BRITAL OPEN DAMPED FROM USTRION CENTER AND BEGINNING DATE ENCRYPTED WINDLAND COMPRED FROM USTRION CENTER AND BEGINNING DATE ENCRYPTED OF CENTER CODE (OPO OF THE DECEASED DONOR RECOVERY FROM DOR FORM ENCRYPTED AND LISTING CENTER CODE ENCRYPTED AND LISTING CENTER AND ENDOME  MISTING SENTER  MISTING SENTER	As time of transplant	Yes	Yes Yes No	Yes  Yes  No  No  No  No  No  No  No  No  No  N	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Ne N
STERCIOS DAYS STERCIOS MOD STERCIOS MIND STERCIOS MAINT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT FLOW CYT B. CELL DONE MAT NO AHG PRA2 T. CELL DONE MAT NO AHG T. CELL DONE MAT THOW CYT T. CELL DONE MAT THOW MIT COP CTR. CODE UST THO CODE LISTING CTR. CODE MATCH LOS JUSTIC MATCH MAT	STEROIDS # OF DAYS BRUCKTON STEROIDS BRUCKTON STEROIDS SHOUTCH AT TIME OF TX STEROIDS SHOUTCH AT TIME OF TX STEROIDS SHOUTCH AT TIME OF TX STEROIDS SMARTENARICE AT TIME OF TX RIP PHYSICAL CROSSMARTCH - B-CELL CROSSMARTCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMARTCH - B-CELL CROSSMARTCH CYTOTOXICITY FLOW CYTOMETRY TEST RESULT PRA (B) MOST RECENT CLASS I PRA (B) MOST RECENT CLASS I PRA (B) MOST RECENT CLASS I RIP PHYSICAL CROSSMARTCH - T-CELL CROSSMARTCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMARTCH - T-CELL CROSSMARTCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMARTCH - T-CELL CROSSMARTCH CYTOTOXICITY AND TEST RESULT ENCRYPTED MINIA, OPD MAPPED FROM USTING CENTER AND BEGINNING DATE ENCRYPTED MINIA, OPD MAPPED FROM USTING CENTER AND ENDING DATE ENCRYPTED MINIA, OPD MAPPED FROM USTING CENTER AND ENDING DATE ENCRYPTED DATE CODE (OPD OF THE DECEASED DONOR RECOVERY FROM DOR FORM MAIGHT AND	As time of transplant Walling Walling Washist	Yes	Yes Yes No	Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	No N
STEROIDS DAYS STEROIDS IND STEROIDS MAINT B CELL DONE YMAT AHG B CELL DONE YMAT FLOW CYT B CELL DONE YMAT NO AHG PRA2 T. CELL DONE YMAT NO AHG T. CELL DONE YMAT FLOW CYT T. CELL DONE YMAT FLOW CYT T. CELL DONE YMAT FLOW CYT T. CELL DONE YMAT HO AHG CTR. CODE INT OPO_CTR. CODE END OPO_CTR. CODE END OPO_CTR. CODE END OPO_CTR. CODE MATCH LAS initial WL_MEASURE initial ML_MEASURE initial GL_initial CL_initial FEV_POST_ACT_initial FEV_POST_ACT_initial FEV_POST_ACT_initial FEV_PRE_PCT_initial FEV_PRE_PCT_initial FEV_PRE_PCT_initial	STEROIDS & OF DAYS BRUCTION  STEROIDS BRUCTION AT TIME OF TX  RIP HYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIP HYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS II  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED BITTAL OP DIAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED BITTAL OP DIAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED OPP CENTER CODE (OPFO OF THE DECEASED DONOR RECOVERY FROM DOR FORM  WAITIST USERS OF THE WAITING CENTER AND THE STATE OF THE DECEASED DONOR RECOVERY FROM DOR FORM  WAITIST USERS OF THE WAITING CENTER AND THE STATE OF THE DECEASED DONOR RECOVERY FROM DOR FORM  WAITIST USERS OF THE WAITING CENTER AND THE STATE OF THE DECEASED DONOR RECOVERY FROM DOR FORM  WAITIST USERS OF THE WAITING CENTER AND THE STATE OF THE DECEASED DONOR RECOVERY FROM DOR FORM  WAITIST USERS OF THE WAITING CENTER AND THE STATE OF THE S	As time of transplant	Yes	Yes Yes No	Yes  Yes  No  No  No  No  No  No  No  No  No  N	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Ne N
STEROIDS DAYS STEROIDS MIND STEROIDS MIND STEROIDS MIND B CELL DONE ZMAT AHG B CELL DONE ZMAT FLOW CYT B CELL DONE ZMAT NO AHG PRA2 I CELL DONE ZMAT NO AHG T CELL DONE ZMAT NO AHG IT CELL DONE ZMAT NO AHG IT CELL DONE ZMAT NO AHG IT CODE MIT OPO CTR CODE DOPO CTR CODE USTING CTR CODE USTING CTR CODE MIT OPO CTR CODE USTING CTR CODE MIT OPO CTR CODE USTING CTR CODE FUN CODE TO CODE MIT OPO CTR CODE USTING CTR CODE USTING CTR CODE FUN CODE  F	STEROODS # OF DAYS BRUCKTON STEROODS MOLICITON AT TIME OF TX STEROODS MOLICITON AT TIME OF TX STEROODS MAINTENANCE AT TIME OF TX STEROODS MAINTENANCE AT TIME OF TX RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I PRA (%) MOST RECENT CLASS I PRA (%) MOST RECENT CLASS I RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT PRA (%) MOST RECENT CLASS I RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT ENCRYPTED TRANSPLANT CENTER CODE ENCRYPTED NITIAL, OPD MAPPED FROM USTING CENTER AND BEGINNING DATE ENCRYPTED NITIAL, OPD MAPPED FROM USTING CENTER AND ENDING DATE ENCRYPTED AND ENCOMPLICATION OPD MAPPED FROM USTING CENTER AND ENDING DATE ENCRYPTED OF CENTER CODE (OPD OF THE DECEASED DONOR RECOVERY FROM DDR FORM ENCRYPTED WAS USTING CENTER. Match LAS at start of waitist Waitist Utgency Measure at start of waitist Cardon books (C) at start of waitist Cardon books (C) at start of waitist Actual Predicted Pre Brenchodidator FEV at start of waitist Percent Predicted Pre Brenchodidator FEV at start of waitist Fructional Status at start of waitist	As time of transplant Wallist	Yes	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes   Yes	Yes Yes No	Yes   No   No   No   No   No   No   No   N	No N
STERCIOS DAYS STERCIOS MO STERCIOS MAINT 9 CELL DONE XMAT AHG 8 CELL DONE XMAT AHG 8 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG CITCODE INT OPO CTR CODE INT OPO CTR CODE US OF COD	STEROIDS # OF DAYS BRUCTION  STEROIDS BRUCTION AT TIME OF TX  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  PRA (%) MOST RECENT CLASS I  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED WITH A CHARLES OF THE DECEASED DONOR RECOVERY FROM DOR FORM  MARCH LAS AT SEND OF THE DECEASED DONOR RECOVERY FROM DOR FORM  Waitist Upgency Measure at start of waitist  Cardioc Indox (C) at start of waitist  Cardioc Indox (C) at start of waitist  Cardioc Indox (C) at start of waitist  Paccent Post From Bronchodistor FEV at start of waitist  Paccent Post From Bronchodistor FEV at start of waitist  Paccent Predicted Pre Bronchodistor FEV at start of waitist  Actual Fresteder Pre Bronchodistor FEV at start of waitist  Actual Forested Pre Bronchodistor FEV at start of waitist  Actual Forested Pre Bronchodistor FEV at start of waitist  Actual Forested Pre Bronchodistor FEV at start of waitist  Actual Forested Pre Bronchodistor FEV at start of waitist  Actual Forested Pre Bronchodistor FEV at start of waitist  Actual Forested Pre Bronchodistor Act of waitist  Actual Forested Pre Bronchodistor FEV at start of waitist  Actual Forested Pre Bronchodistor Act of waitist  Actual Forested Pre Bronchodistor Act of waitist  Actual Forested Pre Bronchodistor Act of waitist	As time of transplant User time User transplant As time of transplant As time of transplant As time of transplant User time User transplant User time User transplant User trans	Yes	Yes Yes No	Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	No N
STEROIDS DAYS STEROIDS MID STEROIDS MID STEROIDS MID STEROIDS MAINT B CELL DONE ZMAT AHG B CELL DONE ZMAT FLOW CYT B CELL DONE ZMAT NO AHG PRA2 T. CELL DONE ZMAT NO AHG T. CELL DONE ZMAT NO AHG T. CELL DONE ZMAT NO AHG CTR CODE INT. OPO. CTR CODE OPO. CTR CODE OPO. CTR CODE USTING CTR CODE USTING CTR CODE USTING CTR CODE MIT. OPO. CTR CODE USTING CTR CODE FUND POT POT Initial FEV PRE PCT Initial FEV PRE PCT Initial FVC PRE PCT Initial FVC PRE Initial	STEROODS # OF DAYS BRUCKTON  STEROODS MICHON AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOWCITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOWCITY FLOW CYTOMETRY TEST RE-  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOWCITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOWCITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOWCITY AND TEST RESULT  ENCRYPTED AND THE OWNER OF THE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOWCITY NO AND TEST RESULT  ENCRYPTED NITIAL ORD MAPPED PROM USTING CENTER AND BEGINNING DATE  ENCRYPTED NITIAL ORD MAPPED PROM USTING CENTER AND BEGINNING DATE  ENCRYPTED ORD LISTING CENTER CODE  ENCRYPTED ORD LISTING CENTER CODE  ENCRYPTED ORD CENTER CODE (OPO OF THE DECEASED DONOR RECOVERY FROM DOR FORM  MAIGH LAS at start of waitist  Maich LAS at start of waitist  Date of the Code of	As time of transplant Wallist	Yes	Yes   Yes	Yes   Yes   No   No   No   No   No   No   No   N	Yes   Yes	Yes Yes No	Yes   No   No   No   No   No   No   No   N	No N
STERCIOS DAYS STERCIOS MO STERCIOS MO STERCIOS MAINT 8 CELL DONE MAINT AHG 8 CELL DONE MAINT FLOW CYT 8 CELL DONE MAINT FLOW CYT 9 CELL DONE MAINT NO AHG PRA2 1 CELL DONE MAINT AHG 1 CELL DONE MAINT AHG 1 CELL DONE MAINT AHG 1 CELL DONE MAINT NO AHG CITR CODE INIT OPO CITR CODE END OPO CITR CODE END OPO CITR CODE LISTING CITR CODE LISTING CITR CODE MILITING CITR CODE MILITING CITR CODE COPO CITR CODE LISTING CITR CODE MILITING CITR CODE LISTING CITR CODE MILITING CITR CODE LISTING CITR CODE MILITING FLOW POST ACT Initial FEV POST ACT Initial FEV PRE PCT INITIA	STEROIDS # OF DAYS BRUCKTON  STEROIDS BRUCKTON  STEROIDS SHOULTON AT TIME OF TX  RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (N) MOST RECENT CLASS I  PRA (N) MOST RECENT CLASS I  PRA (N) MOST RECENT CLASS I  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND BEGINNED DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED NITIAL OPD MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED WILL USTING CENTER  MAIGHLAS I SEND MAPPED FROM USTING CENTER AND ENDING DATE  ENCRYPTED WILL USTING CENTER  Wallist Uppercy Measure at start of waitist  Wallist Uppercy Measure at start of waitist  Carden best (C) at start of waitist  Carden best (C) at start of waitist  Actual Prosted Per Bronchoditator FEV at start of waitist  Purcent Post Post Bronchoditator FEV at start of waitist  Purcent Predicted Pre Bronchoditator FEV at start of waitist  New York Heart Assoc Class at start of waitist  New York Heart Assoc Class at start of waitist  New York Heart Assoc Class at start of waitist  New York Heart Assoc Class at start of waitist  New York Heart Assoc Class at start of waitist  New York Heart Assoc Class at start of waitist  New York Heart Assoc Class at start of waitist	As time of transplant Washist	Yes	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes   Yes	Yes Yes No	Yes   No   No   No   No   No   No   No   N	No N
STERCIOS DAYS STERCIOS MO STERCIOS MAINT 9 CELL DONE XMAT AHG 8 CELL DONE XMAT AHG 8 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG PRAY 1 CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG NO CONTROL ON AMAT NO AHG T CELL DONE XMAT NO AHG CITR CODE NIT OPO CTR CODE END OPO CTR CODE END OPO CTR CODE USTNMG CTR CODE MATCH LAS initial FEV POST ACT initial FUN CS INITIAL FUN C	STEROODS # OF DAYS BRUCKTON STEROODS MOLICITON AT TIME OF TX STEROODS MANTENANCE AT TIME OF TX STEROODS MANTENANCE AT TIME OF TX STEROODS MANTENANCE AT TIME OF TX RR PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RR PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE- RR PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I RR PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT ENCRYPTED TROOSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT ENCRYPTED BRITING ON MAPPED FROM USTRON CENTER AND BEGINNING DATE ENCRYPTED BRITING ON MAPPED FROM USTRON CENTER AND BEGINNING DATE ENCRYPTED ON LISTEN CENTER CODE ENCRYPTED WITH A STERMAN CONTROL OF THE DECEASED DONOR RECOVERY FROM DDR FORM ENCRYPTED AND LISTENG CENTER CODE ENCRYPTED OF CENTER CODE (OPO OF THE DECEASED DONOR RECOVERY FROM DDR FORM MAIGH LAS at start of warbist Curdion didno; (c) at start of warbist  March LAS at start of warbist  Actual Protect Other Decondance FEV at start of warbist  Packet Post Bronchoditator FEV at start of warbist  Predicted PVC Pre Bronchoditator FEV at start of warbist  Functional Status at start of warbist  Functional Status at start of warbist  Predicted PVC Pre Bronchoditator FEV at start of warbist  Functional Status at start of warbist  Predicted PVC Pre Bronchoditator FEV at start of warbist  Functional Status at start of warbist  Predicted PVC Pre Bronchoditator FEV at start of warbist  Predicted PVC Pre Bronchoditator at start of warbist  Predicted	As time of transplant Wallist	Yes	Yes   Yes   No   Yes   No   No   No   No   No   No   No   N	Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	No N
STEROIDS DAYS STEROIDS IND STEROIDS MAINT B CELL DONE XMAT AHG B CELL DONE XMAT FLOW CYT B CELL DONE XMAT NO AHG PRA1 T. CELL DONE XMAT NO AHG T. CELL DONE XMAT FLOW CYT T. CELL DONE XMAT HO AHG CTR. CODE INTO OPO. CTR. CODE END OPO. CTR. CODE ENTRY CODE MATCH LAS instal TEV. POST ACT Instal FEV. POST ACT Instal FV. PAS Instal NYHA, Initial PA. Instal PA. MEAN Instal PAP. MEAN Instal	STEROIDS # OF DAYS BRUCHTON STEROIDS BRUCHTON STEROIDS SHOULTON AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX STEROIDS MAINTENANCE AT TIME OF TX RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE- RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I PRA (%) MOST RECENT CLASS I RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT ENCRYPTED THANSPLANT CENTER CODE BLOCKYPTED NITHAL POR MAPPED FROM USTING CENTER AND BEGINNING DATE ENCRYPTED NITHAL POR MAPPED FROM USTING CENTER AND BEGINNING DATE ENCRYPTED WINNAL POR MAPPED FROM USTING CENTER AND ENDING DATE ENCRYPTED OF USTANDER CODE (GPO OF THE DECEASED DONOR RECOVERY FROM DDR FORM ENCRYPTED WIN LISTING CENTER Match LAS at start of waitist Waitist Uppercy Measure at start of waitist Cardon flocky (C) at start of waitist  Match LAS at start of waitist Cardon flocky (C) at start of waitist  Parcent Pact Planchodistor FEV at start of waitist  Actual Prodicted Phe Brenchodistor FEV at start of waitist  Parcent Pact Brenchodistor FEV at start of waitist  Parcent Pact Planchodistor FEV at start of waitist  Parcent Pact Planchodistor PEV at start of waitist  Parcent	As time of transplant Wallist Washist	Yes	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes   Yes	Yes Yes No	Yes   No   No   No   No   No   No   No   N	No N
STEROIDS DAYS STEROIDS IND STEROIDS MAINT  8 CELL DONE XMAT AHG  9 CELL DONE XMAT AHG  9 CELL DONE XMAT NO AHG  PRAY  1 CELL DONE XMAT NO AHG  PRAY  1 CELL DONE XMAT NO AHG  T. CELL DONE XMAT NO AHG  T. CELL DONE XMAT NO AHG  CTR. CODE  INT OPO CTR. CODE  END OPO CTR. CODE  END OPO CTR. CODE  USTING CTR. CODE  MATCH, LAS, initial  CREATNINE initial  CREATNINE initial  FEV. POST ACT initial  FEV. POST ACT initial  FEV. PRE Initial  FUC. ASS initial  PVC. ASS initial  PVC. ASS initial  PAL AND	STEROODS # OF DAYS BRUCKTON  STEROODS MOLICITON AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  RH PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RH PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  PRA (%) MOST RECENT CLASS I  RH PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RH PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND THE TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  FINE PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND THE TEST RESULT  FINE PHYSICAL CROSSMATCH CONTROL TO THE TEST RESULT  FINE PHYSICAL CROSSMATCH CONTROL T	As time of transplant	Yes	Vesi Yes No	Yes Yes No	Yes   Yes	Yes Yes No	Yes   No   No   No   No   No   No   No   N	Ne N
STEROIDS DAYS STEROIDS MAINT 9 CELL DONE XMAT AHG 8 CELL DONE XMAT AHG 8 CELL DONE XMAT FLOW CYT 8 CELL DONE XMAT NO AHG PRA1 T CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG T CELL DONE XMAT NO AHG T CELL DONE XMAT AHG T CELL DONE XMAT FLOW CYT T CELL	STEROODS # OF DAYS BRUCKTON STEROODS BRUCKTON STEROODS MAINTENANCE AT TIME OF TX STEROODS MAINTENANCE AT TIME OF TX STEROODS MAINTENANCE AT TIME OF TX RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE- RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT PRA (%) MOST RECENT CLASS I RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT ENCRYPTED TRANSPLAIT CENTER CODE ENCRYPTED NITIAL, OPEN DAPPED FROM USTING CENTER AND BEGINNING DATE ENCRYPTED WINDLA CROSSMATCH - TO POMAPPED FROM USTING CENTER AND ENDING DATE ENCRYPTED OF DEATHER CODE (OPO OF THE DECEASED DONOR RECOVERY FROM DOR FORM ENCRYPTED OF USTING CENTER CODE ENCRYPTED OF DEATHER MAIGH LAS AT SHAT OF WARRIST  MAIGH LAS AT SHAT OF WARRIST ENCRYPTED OF DEATHER ENCRYPTED OF D	As time of transplant Washist	Yes	Yes Yes No	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes	No N
STEROIDS DAYS STEROIDS MIND STEROIDS MIND STEROIDS MIND B CELL DONE JAMAT AHG B CELL DONE JAMAT FLOW CYT B CELL DONE JAMAT NO AHG PRA2 T. CELL DONE JAMAT NO AHG T. CELL DONE JAMAT NO AHG ROWNER JAMAT NO AHG T. CELL DONE JAMAT NO AHG CITR CODE INT. OPO. CITR CODE OPO. CITR CODE USTNO COTR CODE USTNO COTR CODE USTNO COTR CODE USTNO CITR CODE USTNO CITR CODE USTNO CITR CODE USTNO COTR CODE USTNO CITR CODE USTNO CI	STEROIDS # OF DAYS BRUCKTON  STEROIDS BRUCKTON  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS #  PRA (%) MOST RECENT CLASS #  PRA (%) MOST RECENT CLASS #  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  RIP CROCKYPTED NITAD, PAR DEATH CROCE  ENCRYPTED OP CENTER CODE (OPO OF THE DECEASED DONOR RECOVERY FROM DOR FORM  MAIGH LAS at start of wartist  Cardeo Robex (C) at start of wartist  Wallist Uppercy Measure at start of wartist  Cardeo Robex (C) at start of wartist  Actual Producted Pie Bronchoditator FEV at start of wartist  Actual Producted Pie Bronchoditator FEV at start of wartist  Percent Predicted Pie Bronchoditator FEV at start of wartist  Rev York Heart Assoc Class at start of wartist  Supplemental Oxygen Amount at start of wartist  Performancy Artery Distotic Pressure at start of wartist  Demo Criteria - Mixerium Acceptable Donner Age (months) at start of wartist  Donner Criteria - Mixerium Acceptable Donner Age (months) at start of wartist  Donner Criteria - Mixerium Acceptable Donner Age (months) at start of wartist  Donner Criteria - Mixerium Acceptable Donner Age (months) at start of wartist  Donner Criteria - Mixerium Acceptable Donner Age (months) at start of wartist  Donner Criteria - Mixerium Acceptable Donner Age (months) at start of wartist	As time of transplant	Yes	Vesi Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes   Yes	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	No N
STERCIOS DAYS STERCIOS STERCIOS IND STERCIOS MAINT B CELL DONE XMAT AHG B CELL DONE XMAT AHG B CELL DONE XMAT NO AHG PRAY TO CHARLES AND AHG B CELL DONE XMAT NO AHG PRAY TO CELL DONE XMAT NO AHG TO COT CODE BATCH CODE BATCH CODE BATCH LAS Initial WILLIAM STERCION MATCH LAS Initial BM INITIAL GENT CODE BATCH LAS INITIAL BEY POST ACT INITIAL FEV PRE A	STEROODS # OF DAYS BRUCKTON  STEROODS MICHOLOTON AT TIME OF TX  STEROODS MANTENANCE AT TIME OF TX  STEROODS MANTENANCE AT TIME OF TX  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIP PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  ENCRYPTED NITRAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED NITRAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  ENCRYPTED NITRAL ON MAPPED PROFILE ONE  ENCRYPTED NITRAL ON MAPPED PROFILE ONE  ENCRYPTED NITRAL ONE MAPPED PROFILE ONE  ENCRYPTED ON THE STER CODE  ENCRYPTED ON THE STER COD	As time of transplant Wealthst	Yes	Yes Yes No	Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	Ne N
STERCIOS DAYS STERCIOS DAYS STERCIOS IND STERCIOS MAINT B CELL DONE MAINT AHG B CELL DONE MAINT FLOW CYT B CELL DONE MAINT FLOW CYT B CELL DONE MAINT NO AHG PRA2 T. CELL DONE MAINT AHG T. CELL DONE MAINT NO AHG CITR CODE INT OPO_CITR CODE END OPO_CITR CODE END OPO_CITR CODE END OPO_CITR CODE LISTING CTR CODE LISTING CTR CODE LISTING TOR CODE LISTING LIS	STEROIDS # OF DAYS BRUCKTON  STEROIDS BRUCKTON  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  RIP HYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO ANS TEST RESULT  PRA (B) MOST RECENT CLASS I  PRA (B) MOST RECENT CLASS I  PRA (B) MOST RECENT CLASS I  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  PRA (B) MOST RECENT CLASS I  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP HYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  ENCRYPTED NAMENDE, ANT CENTER CODE  ENCRYPTED OP DE CENTER CODE (DPO OF THE DECEASED DONOR RECOVERY FROM DOR FORM  MAICH LAS at start of wardist  Cardon clocks (C) at start of wardist  Cardon clocks (C) at start of wardist  Cardon clocks (C) at start of wardist  Actual Predicted Pre Brenchoditator FEV at start of wardist  Actual Predicted Pre Brenchoditator FEV at start of wardist  Parcent Part Brenchodistor FEV at start of wardist  Parcent Part Brenchodistor FEV at start of wardist  Parcent Predicted Pre Brenchoditator FEV at start of wardist  Parcent Predicted Pre Brenchoditator FEV at start of wardist  Parcent Predicted Pre Brenchoditator FEV at start of wardist  Parcent Part Predicted Pre Brenchoditator FEV at start of wardist  Part Predicted Pre Brenchoditator FEV at start of wardist  Parcent Part Predicted Pre Brenchoditator FEV at start of wardist  Part Predicted Pre Brenchoditator FEV at start of wardist  Part Predicted Pre Brenchoditator FEV at start of wardist  Part Predicted Predic	As time of transplant Washist	Yes	Yes   Yes	Yes   Yes   No   No   No   No   No   No   No   N	Yes   Yes	Yes Yes No	Yes   No   No   No   No   No   No   No   N	No N
STERCIOS DAYS STERCIOS MAINT 9 CELL DONE SMAINT 9 CELL DONE SMAT AHG 8 CELL DONE SMAT AHG 8 CELL DONE SMAT NO AHG PRAY 1 CELL DONE SMAT NO AHG PRAY 1 CELL DONE SMAT NO AHG T CELL DONE SMAT NO AHG CITR CODE NIT OPO CTR CODE END OPO CTR CODE END OPO CTR CODE USTNO CTR CODE USTNO CTR CODE MATCH LAS initial FEV POST ACT Initial FEV PRE ACT Initial FVC PTE Initial FVC PTE Initial FVC PTE Initial FVC ABS Initial FVC PTE Initial FVC PTE Initial FVC PTE Initial FVC ABS Initial FVC PTE Initial FVC PTE Initial FVC PTE Initial FVC ABS Initial FVC PTE Initial	STEROIDS # OF DAYS BRUCKTON  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  RIF PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIF PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  ENCRYPTED TRANSPLANT CENTER CODE  ENCRYPTED BRITINAL OPO DAMPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED BRITIAL OPO DAMPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED WINDLA CONTROL OF THE DECEASED DONOR RECOVERY FROM DDR FORM  ENCRYPTED AND LISTING CENTER CODE  ENCRYPTED WE LISTING CENTER  Match LAS at start of wastist  Cardioc and start of wastist  Actual Prote Of the Bronchoditator FEV at start of wastist  Actual Prote Of the Bronchoditator FEV at start of wastist  Functional Status at start of wastist  Function	As time of transplant	Yes	Vesi Yes No	Yes Yes No	Yes   Yes	Yes Yes No	Yes   Yes	No N
STERCIOS DAYS STERCIOS MO STERCIOS MO STERCIOS MAINT B CELL DONE MAINT AHG B CELL DONE MAT FLOW CYT B CELL DONE MAT FLOW CYT B CELL DONE MAT NO AHG PRA2 T. CELL DONE MAT AHG T. CELL DONE MAT AHG T. CELL DONE MAT AHG T. CELL DONE MAT THO AHG GTR. CODE MIT OPO CTR. CODE END OPO CTR. CODE END OPO CTR. CODE MATCH LAS initial WL MEASURE initial MI mittel GL initial FEV POST ACT initial FEV PRE PCT initial FEV PST ACT initial FOUNCE THAN INITIAL DOWN CRIT INITIAL DOWN CRIT INITIAL DOWN CRIT MAX HGT initial	STEROODS # OF DAYS BRUCKTON  STEROODS MICHOTON AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  STEROODS MAINTENANCE AT TIME OF TX  RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIP PHYSICAL CROSSMATCH - BCELL CROSSMATCH CYTOTOXICITY NO ANS TEST RESULT  PRA (%) MOST RECENT CLASS I  PRA (%) MOST RECENT CLASS I  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIP PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  ENCRYPTED TRANSPLAIT CENTER CODE  BLOCKYPTED NITIAL, OPD MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED WINDLA (POR MAPPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED ON LISTING CENTER  Match LAS at start of wallist  Cardeo Check (C) at start of wallist  Actual Foreithed Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Percent Predicted Phe Brenchodidator FEV at start of wallist  Democritics - Minimum Acceptable Donor Hought (Pin) at start of wallist  Democritics - Minimum Acceptable Donor Megity (Pin) at start of wallist  Donor Citeria - Minimum Acc	As time of transplant Washist	Yes	Yes   Yes	Yes   Yes   No   No   No   No   No   No   No   N	Yes   Yes	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	No N
STERCIOS DAYS STERCIOS MAINT 9 CELL DONE SMAINT 9 CELL DONE SMAT AHG 8 CELL DONE SMAT AHG 8 CELL DONE SMAT NO AHG PRAY 1 CELL DONE SMAT NO AHG PRAY 1 CELL DONE SMAT NO AHG T CELL DONE SMAT NO AHG CITR CODE NIT OPO CTR CODE END OPO CTR CODE END OPO CTR CODE USTNO CTR CODE USTNO CTR CODE MATCH LAS initial FEV POST ACT Initial FEV PRE ACT Initial FVC PTE Initial FVC PTE Initial FVC PTE Initial FVC ABS Initial FVC PTE Initial FVC PTE Initial FVC PTE Initial FVC ABS Initial FVC PTE Initial FVC PTE Initial FVC PTE Initial FVC ABS Initial FVC PTE Initial	STEROIDS # OF DAYS BRUCKTON  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  STEROIDS MAINTENANCE AT TIME OF TX  RIF PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY FLOW CYTOMETRY TEST RE-  RIF PHYSICAL CROSSMATCH - B-CELL CROSSMATCH CYTOTOXICITY NO AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  PRA (%) MOST RECENT CLASS I  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND TEST RESULT  RIF PHYSICAL CROSSMATCH - T-CELL CROSSMATCH CYTOTOXICITY AND AND TEST RESULT  ENCRYPTED TRANSPLANT CENTER CODE  ENCRYPTED BRITINAL OPO DAMPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED BRITIAL OPO DAMPED FROM USTING CENTER AND BEGINNING DATE  ENCRYPTED WINDLA CONTROL OF THE DECEASED DONOR RECOVERY FROM DDR FORM  ENCRYPTED AND LISTING CENTER CODE  ENCRYPTED WE LISTING CENTER  Match LAS at start of wastist  Cardioc and start of wastist  Actual Prote Of the Bronchoditator FEV at start of wastist  Actual Prote Of the Bronchoditator FEV at start of wastist  Functional Status at start of wastist  Function	As time of transplant	Yes	Vesi Yes No	Yes Yes No	Yes   Yes	Yes Yes No	Yes   Yes   No   No   No   No   No   No   No   N	No N

BMI end	BMI at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
Cl end	Cardiac Index (CI) at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
CREATININE end	Creatinine at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
FEV POST ACT end	Actual Post Bronchodilator FEV at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
FEV POST PCT end	Percent Post Post BronchodilatorFEV at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
FEV PRE ACT end	Actual Predicted Pre Bronchodilator FEV at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
FEV PRE PCT end	Percent Predicted Pre Bronchodilator FEV at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
FUNC STAT end	Functional Status at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
FVC ABS end	Actual Forced Vital Capacity (FVC) at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
FVC PRE end	Predicted FVC Pre Bronchodilator at end of waitlist	Wattist	Yes	No	No	No	No	No	No
NYHA end	New York Heart Assoc Class at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
O2 end	Supplemental Oxygen Amount at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
PA end	Pulmonary Artery Systolic Pressure at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
PADIAST INIT end	Pulmonary Artery Diastolic Pressure at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
PAP MEAN end	Pulmonary artery Pressure Mean at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
PCW end	Pulmonary Capillary Wedge Mean at end of waitist	Waitlist	Yes	No	No	No	No	No	No
SIX MIN WALK end	Six Minute Walk Distance at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
DONCRIT ACPT DCD end	Donor Criteria - Accept DCD donor at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
DONCRIT MAX AGE end	Donor Criteria - Maximum Acceptable Donor Age (months) at end of waitist	Waitlist	Yes	Yes	No	No	No	No	No
DONCRIT MAX HGT end	Donor Criteria - Maximum Acceptable Donor Height (cm) at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	Yes
DONCRIT MAX WGT end	Donor Criteria - Maximum Acceptable Donor Weight (kg) at end of waitlist	Waitlist	Yes	No	No	No	No	No	No
DONCRIT MIN AGE end	Donor Criteria - Minimum Acceptable Donor Age (months) at end of waitlist	Waitlist	Yes	Yes	No	No	No	No	No
DONCRIT MIN HGT end	Donor Criteria - Minimum Acceptable Donor Height (cm) at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	Yes
DONCRIT MIN WGT end	Donor Criteria - Minimum Acceptable Donor Weight (kg) at end of waitlist	Waitlist	Yes	No.	No	No	No.	No	No
TIME ON WL	Time on watlist (days)	Waitlist	Yes	No	No	No	No	No	No
DAYS ON WL	Time on wattist (days)	Waitlist	Yes	No	No	No	No	No	No
BMI year 1	Recipient BMI at year 1	Follow-up	Yes	No	No	No	No	No	No
BRONC OBLIT year 1	Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 1	Follow-up	Yes	No	No.	No	No	No.	No.
BRONG STRIC year 1	Lung Graft Status Bronchial Stricture since Last Follow-up at year 1	the leading to the le	Yes	No	No	No	No	No	-
CHRONIC DIAL year 1	Post Transplant Events since Last Follow-up If Renal Dysfunction, Chronic Dialysis? at year 1	Follow-up	Yes	No	No	No	No	No	No No
	Most Recent Serum Creatinine at year 1	Follow-up	-	1100	No	No	No	100	-
CREAT_year_1	Current Supplemental O2 Requirements at Rest and/or Exercise at year 1	Follow-up	Yes	No No	No	No.	No.	No No	No No
	Graft Status at Time of Follow-Up (Y=Functioning, N=Failed) at year 1	Follow-up	1.00		No	No	1.00	1.00	11.0
GRF_STAT_year_1	Hospitalizations during Follow-Up Period at year 1	Follow-up	Yes	No	No.		No	No	No
HOSP_year_1	Hospitalized for Infection during Follow-up Period at year 1	Follow-up	Yes	No		No	No	No	No
HOSP_INF_year_1	Hospitalized for Rejection during Follow-up Period at year 1	Follow-up	Yes	No	No No	No No	No.	No	No
HOSP_REJ_year_1	Any Medications Given during follow-up for Maintenance or Anti-Rejection? at year 1	Follow-up	Yes	No		1111	No	No	No
IMMUNO_MAINT_MED_year_1	Lung Graft Status — Oxygen Requirement (L/min) at rest at the time of Follow-up at year 1	Follow-up	Yes	No	No	No	No	No	No
O2_REQ_year_1	Post Transplant Events since Last Follow-up — If Renal Dysfunction, Renal Transplant since Thoracic Tran	Follow-up	Yes	No	No	No	No	No	No
RENAL_TX_year_1	Patient Treated for Rejection (Y/N/U) during Follow-Up Period at year 1		Yes	No	No	No	No	No	No
TRT_REJ_year_1	RECIPIENT WORK FOR INCOME? at year 1	Follow-up	Yes	No	No	No	No	No	No
WORK_INCOME_year_1	CELLCEPT ANTIREJECTION (T-CELL ACTIVATION INHIBITOR) at year 1	Follow-up	Yes	No	No	No	No	No	No
CELLCEPT_ANTIREJ_year_1	CELLCEPT ANTIKEJECTION (T-CELL ACTIVATION INHIBITOR) at year 1 CELLCEPT CURRENT MAINTENANCE AT TIME OF FOLLOWUP (T-CELL ACTIVATION INHIBITOR) at ye	Follow-up	Yes	No	No	No	No	No	No
CELLCEPT_MAINT_CUR_year_1	CELLCEPT CURRENT MAINTENANCE AT TIME OF FOLLOWUP (T-CELL ACTIVATION INHIBITOR) AT YE CELLCEPT MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVATION	Follow-up	Yes	No	No	No	No	No	No
CELLCEPT_MAINT_PREV_year_1			Yes	No	No	No	No	No	No
CYCLOSPORIN_MAINT_PREV_year	CYCLOSPORIN MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVA		Yes	No	No	No	No	No	No
GENERICMMF_MAINT_CUR_year_1	GENERICMMF CURRENT MAINTENANCE AT TIME OF FOLLOWUP at year 1	Follow-up	Yes	No	No	No	No	No	No
GENERICMMF_MAINT_PREV_year_	GENERICMMF MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 1	Follow-up	Yes	No	No	No	No	No	No
GENERICTACROLIMUS_MAINT_CU	GENERICTACROLIMUS CURRENT MAINTENANCE AT TIME OF FOLLOWUP at year 1	Follow-up	Yes	No	No	No	No	No	No

	GENERICTACROLIMUS MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 1	Follow-up	Yes	No	No	No	No	No	No
IMURAN_ANTIREJ_year_1	IMURAN ANTIREJECTION (ANTIMETABOLITE) at year 1	Follow-up	Yes	No	No	No	No	No	No
IMURAN_MAINT_CUR_year_1	IMURAN CURRENT MAINTENANCE AT TIME OF FOLLOWUP (ANTIMETABOLITE) at year 1	Followup	Yes	No.	No	No	No	No	No
IMURAN MAINT PREV year 1	IMURAN MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (ANTIMETABOLITE) at y	Eallowine	Yes	No	No				No
NEORAL_ANTIREJ_year_1	NEONAL ANTIRESECTION (FOLLS ACTIVATION INDIBITOR) at year 1	Follow-up	Yes	No	No				No
NEORAL_MAINT_CUR_year_1	NEORAL CURRENT MAINTENANCE AT TIME OF FOLLOWUP (T-CELL ACTIVATION INHIBITOR) at year	Follow-up	Yes	No	No	No	No	No	No
NEORAL_MAINT_PREV_year_1	NEORAL MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVATION IN	Follow-up	Yes	No	No	No	No	No	No
PROGRAF_ANTIREJ_year_1	PROGRAF ANTIREJECTION (ANTIMETABOLITE) at year 1	Follow-up	Yes	No	No	No	No	No	No
PROGRAF_MAINT_CUR_year_1	PROGRAF CURRENT MAINTENANCE AT TIME OF FOLLOWUP (ANTIMETABOLITE) at year 1	Followum			No				No
	PROGRAF MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (ANTIMETABOLITE) at	Callance							
PROGRAF_MAINT_PREV_year_1	RAPAMUNE ANTIREJECTION (T-CELL ACTIVATION INHIBITOR) at year 1			No	No				No
RAPAMUNE_ANTIREJ_year_1		Follow-up	Yes		No				No
RAPAMUNE_MAINT_CUR_year_1	RAPAMUNE CURRENT MAINTENANCE AT TIME OF FOLLOWUP (T-CELL ACTIVATION INHIBITOR) at y	Follow-up	Yes	No	No	No	No	No	No
RAPAMUNE MAINT_PREV_year_1	RAPAMUNE MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVATION	Follow-up	Yes	No	No	No	No	No	No
STEROIDS_ANTIREJ_year_1	STEROIDS ANTIREJECTION at year 1	Follow-up	Yes	No	No	No	No	No	No
STEROIDS MAINT_CUR_year_1	STEROIDS CURRENT MAINTENANCE AT TIME OF FOLLOWUP at year 1	Follow-up	Yes		No	No			No
	STEROIDS MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 1								
STEROIDS_MAINT_PREV_year_1		Follow-up	Yes		No				No
BLADDER_year_1	DeNovo Solid Tumor - Bladder at year 1	Follow-up	Yes		No				No
COLORECTAL_year_1	DeNovo Solid Tumor - Colo-rectal at year 1	Follow-up	Yes	No	No	No	No	No	No
DX_DATE10_year_1	Date of Diagnosis: Squamous Cell at year 1	Follow-up	Yes	No	No	No	No	No	No
DX_DATE101_year_1	Date of Diagnosis. Ovanan at year 1	Follow-up	Yes		No				No
ESOPHAGUS_year_1	DeNovo Solid Tumor - Esophagus at year 1	Follow-up	Yes	No	No			W-10-	No
KAPOSI_CUTANEOUS_year_1		Follow-up	Yes	No	No				No
KAPOSI_VISCERAL_year_1	DeNovo Solid Tumor - Kaposis's Sarcoma: Visceral at year 1	Follow-up	Yes		No	No	No	No	No
KAPOSI VISCERAL DONOR year	Donor Related Tumor - Kaposis's Sarcoma: Visceral at year 1	Follow-up	Yes	No	No	No	No	No	No
LARYNX_year_1	DeNovo Solid Tumor - Larynx at year 1	Follow-up	Yes	No	No	No	No	No	No
LEUK_year_1	DeNovo Solid Tumor - Leukemia at year 1	Follow-up			No				No
	Donor Related Tumor - Leukemia at year 1	Follow-up		No	No				No
LEUK DONOR year 1	DeNovo Solid Tumor - Lung at year 1	r oromop.	-	1000		10000	The state of the s	P(16)0000	-
LUNG_year_1	Donor Related Tumor - Lung at year 1	Follow-up		No	No	No			No
LUNG_DONOR_year_1		Follow-up	Yes	No	No	No			No
MALIG_year_1	Post Transplant Malignancy at year 1	Follow-up	Yes	No	No	No	No	No	No
MALIG DENOVO LYMPH year 1	Post Transplant Lymphoproliferative Disease (PTLD) at year 1	Follow-up	Yes		No				No
MALIG DENOVO TUMOR year 1	Post Transplant DeNovo Solid Tumor (excluding Skin Squamous/Basal Cancers) at year 1	Follow-up	Yes		No				No
HE DE GENTO TO TOMOST JOB. 1					No				
		Follow-up	Yes						No
		Follow-up	Yes		No				No
OTH_CANCER_year_1	DeNovo Solid Tumor - Other Cancers at year 1	Follow-up	Yes		No			No	No
OVARIAN_year_1	DeNovo Solid Tumor - Ovarian at year 1	Follow-up	Yes	No	No	No	No	No	No
PANCREAS year 1	DeNovo Solid Tumor - Pancreas at year 1	Follow-up	Yes	No	No	No	No	No	No
PRIM HEPATIC year 1	DeNovo Solid Tumor - Primary Hepatic Tumor at year 1	Follow-up	Yes	No	No				No
	DeNovo Solid Tumor - Primary Unknown at year 1								
PRIM_UNK_year_1	DeNovo Solid Tumor - Prostate at year 1	Follow-up	Yes	No	No				No
PROSTATE_year_1		Follow-up	Yes	No	No	No	No	No	No
RENAL_CAR_year_1	DeNovo Solid Tumor - Renal Carcinoma at year 1	Follow-up	Yes	No	No	No	No	No	No
SARCOMA year 1	DeNovo Solid Tumor - Sarcomas (excluding Kaposi's) at year 1	Follow-up	Yes	No	No	No	No	No	No
SKIN_BASAL_year_1	Skin Cancer Type - Basal Cell at year 1	Follow-up			No	No	No	No	No
SKIN MELANOMA year 1	DeNovo Solid Tumor - Skin Melanoma at year 1		-	1000	No	-	170		No
	Skin Cancer Type - Squamous Cell at year 1	Follow-up							77
SKIN_SQUAMOUS_year_1		Follow-up	Yes	No	No				No
									No
SM_INTEST_year_1	DeNovo Solid Tumor - Small Intestine at year 1	Follow-up	Yes	No	No	No	No	No	140
SM_INTEST_year_1 STOMACH_year_1	DeNovo Solid Tumor - Stomach at year 1	Follow-up Follow-up		No No	No No	No No		No	No
STOMACH_year_1		Follow-up Follow-up	Yes Yes	No	No	No	No	No	No
STOMACH_year_1 TESTICULAR_year_1	DeNovo Solid Tumor - Stomach at year 1 DeNovo Solid Tumor - Testicular at year 1	Follow-up Follow-up	Yes Yes Yes	No No	No No	No No	No No	No No	No No
STOMACH_year_1 TESTICULAR_year_1 THYROID_year_1	DeNovo Solid Tumor - Stomach at year 1 DeNovo Solid Tumor - Testicular at year 1 DeNovo Solid Tumor - Thyroid at year 1	Follow-up Follow-up Follow-up	Yes Yes Yes Yes	No No No	No No No	No No No	No No No	No No No	No No No
STOMACH_year_1 TESTICULAR_year_1 THYROID_year_1 TONGUE_THROAT_year_1	Defloro Solid Tumor - Stomach at year 1 Defloro Solid Tumor - Testricular at year 1 Defloro Solid Tumor - Testricular at year 1 Defloro Solid Tumor - Tongoud. Throat at year 1	Follow-up Follow-up Follow-up Follow-up	Yes Yes Yes Yes Yes	No No No	No No No	No No No	No No No	No No No	No No No No
STOMACH_year_1 TESTICULAR_year_1 THYROID_year_1 TONGUE_THROAT_year_1 UTERUS_CAR_year_1	Defloro Solid Tumor - Stomach at year 1 Defloro Solid Tumor - Testicular at year 1 Defloro Solid Tumor - Tryprid at year 1 Defloro Solid Tumor - Tongue, Throat at year 1 Defloro Solid Tumor - Carcinoma of the Utenus at year 1	Follow-up Follow-up Follow-up Follow-up Follow-up	Yes Yes Yes Yes	No No No No No	No No No No	No No No No	No No No No No	No No No No	No No No No No
STOMACH_year_1 TESTICULAR_year_1 THYROID_year_1 TONGUE_THROAT_year_1 UTERUS_CAR_year_1	Deltono Solid Tumor - Stomach at year 1 Deltono Solid Tumor - Testscular at year 1 Deltono Solid Tumor - Testscular at year 1 Deltono Solid Tumor - Tengotal styee 1 Deltono Solid Tumor - Tengotal styee 1 Deltono Solid Tumor - Carcinoma of the Litenus at year 1 Deltono Solid Tumor - Carcinoma of Vivia, Penneum or Penis, Scrotum at year 1	Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up	Yes Yes Yes Yes Yes	No No No No No	No No No No No	No No No No	No No No No No	No No No No	No No No No
STOMACH_year_1 TESTICULAR_year_1 THYROID_year_1 TONGUE_THROAT_year_1 UTERUS_CAR_year_1	Deltono Solid Tumor - Stomach at year 1 Deltono Solid Tumor - Testscular at year 1 Deltono Solid Tumor - Testscular at year 1 Deltono Solid Tumor - Thyroid at year 1 Deltono Solid Tumor - Tongous, Throat at year 1 Deltono Solid Tumor - Carcinnon of the Lhenus at year 1 Deltono Solid Tumor - Carcinnon and Yulna, Perneum or Penis, Scrotum at year 1	Follow-up Follow-up Follow-up Follow-up Follow-up	Yes Yes Yes Yes Yes Yes Yes Yes	No No No No No	No No No No	No N	No No No No No No No	No No No No No	No No No No No
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONGUE THROAT year 1 UTERUS CAR year 1 VUL PER PENIS SCROT CARCINI BM year 3	DeNovo Solid Tumor - Stomach at year 1 DeNovo Solid Tumor - Testricular at year 1 DeNovo Solid Tumor - Testricular at year 1 DeNovo Solid Tumor - Tongou at year 1 DeNovo Solid Tumor - Tongou at Throat at year 1 DeNovo Solid Tumor - Carcinoma of the Uhenus at year 1 DeNovo Solid Tumor - Carcinoma of Vulka. Penneum or Penis. Scrotum at year 1 Recipient BMI at year 3	Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up	Yes	No No No No No	No No No No No No No	No No No No No No No	No N	No No No No No No No	No No No No No No
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONOUE THROAT year 1 UUL PER PENIS SCROT CARCIN BM year 3 BRONC OBLIT year 3	Delivon Solid Tumor - Stemach at year 1 Delivon Solid Tumor - Testicular at year 1 Delivon Solid Tumor - Testicular at year 1 Delivon Solid Tumor - Trygotid at year 1 Delivon Solid Tumor - Trygotid at year 1 Delivon Solid Tumor - Carcinnon for the Lhenis at year 1 Delivon Solid Tumor - Carcinnon for Vulva, Penneum or Pensis, Scrotium at year 1 Recipient Bill at year 3 Lung Graft Status — Brenchiolitis Obliterans since Last Follow-up at year 3	Follow-up	Yes	No No No No No No No	No No No No No No No No	No No No No No No No No No	No N	No No No No No No No No No	No No No No No No No No
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONGUE THROAT year 1 UTERUS CAR year 1 UTERUS CAR year 1 WUL PER PENIS SOROT CARCINI BMI year 3 BRONC_OBLIT_year 3 BRONC_OBLIT_year 3 BRONC_STRIC_year 3	Defloro Solid Tumor - Stomach at year 1 Defloro Solid Tumor - Testicular at year 1 Defloro Solid Tumor - Testicular at year 1 Defloro Solid Tumor - Tongous , Throat at year 1 Defloro Solid Tumor - Tongous , Throat at year 1 Defloro Solid Tumor - Carcinoma of the Uterus at year 1 Defloro Solid Tumor - Carcinoma of Vulva, Penneum or Penis, Scrotum at year 1 Recipient BMI at year 3 Lung Graft Status — Bronchiolat Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolat Stricture since Last Follow-up at year 3	Follow-up	Yes	No	No No No No No No No No No	No No No No No No No No No	No N	No No No No No No No No No No	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TORIQUE THROAT year 1 ULERUS CAR year 1 VUL. PER PENIS SCROT CARCINI BMI, year 3 BRONC_OBUT_year 3 BRONC_STRIC_year 3 GRONC_ORION_STRIC_year 3 GRONC_ORION_COMMA_year 3	Delevos Solid Tumor - Stenecha at year 1 Delevos Solid Tumor - Testeccha at year 1 Delevos Solid Tumor - Trytorid at year 1 Delevos Solid Tumor - Trytorid at year 1 Delevos Solid Tumor - Tongous, Throat at year 1 Delevos Solid Tumor - Carcinoma of the Lienus at year 1 Delevos Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Recipient BMI at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of the Solid Tumor of Status — Bronchiolitis Obliterans of Status —	Follow-up	Yes	No N	No No No No No No No No No No No	No N	No N	No No No No No No No No No No No	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TOMOUE THROAT year 1 UILERUS CAR year 1 UILERUS CAR year 1 VILERUS CAR year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CHRONIC DULL year 3 CHRONIC DULL year 3	Defloro Solid Tumor - Stomach at year 1 Defloro Solid Tumor - Testicular at year 1 Defloro Solid Tumor - Testicular at year 1 Defloro Solid Tumor - Tenyoti at year 1 Defloro Solid Tumor - Carcinoma of the Uterus at year 1 Defloro Solid Tumor - Carcinoma of the Uterus at year 1 Defloro Solid Tumor - Carcinoma of Vivia, Pereneum or Penis, Scrotum at year 1 Recipient BMI at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchial Stricture since Last Follow-up at year 3 Post Transplant Events since Last Follow-up at Year 3 Post Transplant Events since Last Follow-up at Year 3 Post Transplant Events since Last Follow-up at Year 3 Post Transplant Events since Last Follow-up at Year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TOMOUE THROAT year 1 UILERUS CAR year 1 UILERUS CAR year 1 VILERUS CAR year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CHRONIC DULL year 3 CHRONIC DULL year 3	Deletion Solid Turner - Stemach at year 1 Deletion Solid Turner - Testecular year 1 Deletion Solid Turner - Carcinoma of the Lierus at year 1 Deletion Solid Turner - Carcinoma of the Lierus at year 1 Deletion Solid Turner - Carcinoma of Vulvia, Pernesium or Penes, Scrotum at year 1 Recipient Bild at year 3 Lung Card Status — Bronchiolitis Colliterans since Last Follow-up at year 3 Lung Card Status — Bronchiolitis Colliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3	Follow-up	Yes	No N	No No No No No No No No No No No	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROID year 1 TONGUE THROAT year 1 ULFRUIS CAR year 1 ULFRUIS CAR Year 1 ULFRUIS CARCON CARCIN BM, year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CHROMC DIAL year 3 CREAT year 3	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testectiar at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of Vulvia, Perneum or Penis, Scrotum at year 1 Recipient Bild sit year 3 Lung Carl Status — Bronchiolists Obliterans since Last Follow-up at year 3 Lung Carl Status — Bronchiolists Centra since Last Follow-up at year 3 Pest Timoslant Centra since Last Follow-up at year 3 Most Recent Serum Creations at year 3 Most Recent Serum Creations at year 3 Most Recent Serum Creations at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TOMOUE THROAT year 1 ULFERUS CARY year 1 ULFERUS CARY year 1 VUL PER PENIS SCROT CARCIN BM year 3 BRONC OBIT year 3 BRONC STRIC year 3 CREAT year 3	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testectiar at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of Vulvia, Perneum or Penis, Scrotum at year 1 Recipient Bild sit year 3 Lung Carl Status — Bronchiolists Obliterans since Last Follow-up at year 3 Lung Carl Status — Bronchiolists Centra since Last Follow-up at year 3 Pest Timoslant Centra since Last Follow-up at year 3 Most Recent Serum Creations at year 3 Most Recent Serum Creations at year 3 Most Recent Serum Creations at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 UL PER PENIS SCROT CARCIN BM year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CHROING DIAL year 3 CREAT year 3 CREAT year 3 GREAT year 3 GREAT year 3 HOSP year 3	Deleton Solid Tumor - Stemach at year 1 Deleton Solid Tumor - Testecidar at year 1 Deleton Solid Tumor - Carcinoma of the thems at year 1 Deleton Solid Tumor - Carcinoma of the thems at year 1 Deleton Solid Tumor - Carcinoma of Vulue, Pernesum or Pensis, Scrotum at year 1 Recipient Bild sit year 3 Lung Carl Status - Bronchiolists Obliterans since Last Follow-up at year 3 Lung Carl Status - Bronchiolists Colliterans ince Last Follow-up at year 3 Pest Timosplant Deveto since Last Follow-up - If Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Creatinine at year 3 Most Recent Serum Creatinine at year 3 Graft Status at Timor of Follow-Up Pri-Functioning, Ni-Faled) at year 3 Graft Status at Timor of Follow-Up Pri-Functioning, Ni-Faled) at year 3 Hospitalizations during Follow-Up Priod at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR Year 1 UL, PER PENIS SCROT CARCIN BMI, year 3 BRONC, BUIT year 3 BRONC, SITIC year 3 CREAT year 3 CREAT year 3 CREAT year 3 CREAT year 3 HOSP year 3 HOSP year 3 HOSP year 3	Deletion Solid Tumor - Stemach at year 1 Delforo Solid Tumor - Stemach at year 1 Delforo Solid Tumor - Tryyold ut year 1 Delforo Solid Tumor - Tryyold ut year 1 Delforo Solid Tumor - Tryyold ut year 1 Delforo Solid Tumor - Carcinnor and the Lienus at year 1 Delforo Solid Tumor - Carcinnor and the Lienus at year 1 Delforo Solid Tumor - Carcinnor and the Lienus at year 1 Recipient SMI at year 3 Lung Graft Status — Brenchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Brenchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Brenchiolitis Obliteran since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Most Recent Serum Creatinine at year 3 Graft Status at Time of Follow-Up (Y-Functioning, N-Faled) at year 3 Flospitalizations during Follow-Up Period at year 3 Flospitalizations during Follow-Up Period at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TOMOUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 VUL PER PENIS SCROT CARGIN BM year 3 BRONC STRIC year 3 BRONC STRIC year 3 CHRONIC DULL year 3 CHRONIC DULL year 3 CHRONIC PULL year 3 CHRONIC PULL year 3 TOMOUT YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEAR	Dellows Solid Tumor - Stemach at year 1 Dellows Solid Tumor - Testicular at year 1 Dellows Solid Tumor - Testicular at year 1 Dellows Solid Tumor - Testicular at year 1 Dellows Solid Tumor - Torgoid at year 1 Dellows Solid Tumor - Carcinoma of the Unexus at year 1 Dellows Solid Tumor - Carcinoma of the Unexus at year 1 Dellows Solid Tumor - Carcinoma of the Unexus at year 1 Dellows Solid Tumor - Carcinoma of the Unexus at year 1 Dellows Solid Tumor - Carcinoma of the Unexus at year 1 Dellows Solid Tumor - Carcinoma of thus Penneum or Penis, Scrotum at year 1 Recipient Bull at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Most Recent Status — Bronchiolitis Obliterans and Year Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Creatinine at year 3 Current Supplemental OZ Requirements at Rest and/or Exercise at year 3 Most Restand Serum Creatinine at year 3 Hospitalization for Infection during Follow-up Peniod at year 3 Nospitalization for Infection during Follow-up Peniod at year 3 Nospitalization for Infection during Follow-up Peniod at year 3	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TORIQUE THROAT year 1 TUREUS CAR year 1 UUL PER PENIS SCROT CARCINI BMI, year 3 BRONC OBUT year 3 BRONC OBUT year 3 GRONC DIAL, year 3 CREAT year 3 CREAT year 3 HOSP NEW Year 3 HOSP PREJ year 3 HOSP INF year 3 HOSP PREJ year 3 BRONC PENIS SCROT CARCINI BMILLION STRIC YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEAR	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testecular at year 1 Deletion Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Deletion Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Deletion Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Most Recent Serum Creatinine at year 3 Correct Supplemental OZ Requirements at Reat and/or Exercise at year 3 Most Recent Serum Creatinine at year 3 Most R	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 ULL PER PENIS SCROT CARCIN BMI year 3 BRONC SITIC year 3 BRONC STRIC year 3 CREAT year 3 CREAT year 3 CURRENTOZREGUIREMENTSYN y BROSP New 1 HOSP INF year 3 HOSP year 3 HOSP REJ year 3 MMUNO JANNI MED year 3 0 Z REQ year 3	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testectiar at year 1 Deletion Solid Tumor - Carcinnor at Other Lemia at year 1 Deletion Solid Tumor - Carcinnor at Other Lemia at year 1 Deletion Solid Tumor - Carcinnor at Other Lemia at year 1 Deletion Solid Tumor - Carcinnor at Other Lemia at year 1 Deletion Solid Tumor - Carcinnor at Other Lemia at year 3 Lung Graft Status - Effectionate of Solid Solid Tumor - Solid Tumor - Solid Solid Tumor - Solid Solid Tumor - Solid Tumor - Solid Solid Tumor - Solid Tumor	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TORIQUE THROAT year 1 ULFRUS CARY year 1 UUL PER PENIS SCROT CARCINI BMI, year 3 BRONC OBLIT, year 3 BRONC STRIC, year 3 GREAT year 3 CREAT year 3 CREAT year 3 HOSP New 13 HOSP PENIS Year 3 HOSP NEW 3 HOSP WAY 3 HOSP WAY 3 HOSP NEW 3 HOSP WAY 3 HOSP WAY 3 HOSP NEW 3 HOSP WAY	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testecular at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of Unitia, Perensum or Pensis, Scrotum at year 1 Long Graft Status - Bronchiolitis Colliterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Colliterans since Last Follow-up at year 3 Teste Graft Status - Bronchiolitis Colliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Most Recent Serum Creatinine at year 3 Graft Status at Time of Follow-up Follow-up Fellod at year 3 Testeptatizations found profilow-up Pensod at year 3 Testeptatizations found profilow-up Pensod at year 3 Any Medications Green during follow-up Pensod at year 3 Any Medications Green during Bollow-up Pensod at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICUAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 ULL PER PENIS SCROT CARCIN BMI year 3 BRONC SITIC year 3 BRONC SITIC year 3 GRONG STRIC year 3 CREAT year 3 CREAT year 3 HOSP year 3 HOSP year 3 HOSP REI year 3 HOSP REI year 3 ROSP REI year 3 ROSP REI year 3 ROSP REI year 3 REMAL TX year 3 TEREAL TX year 3 TEREAL TX year 3	Dellow Solid Tumor - Stemach at year 1 Dellow Solid Tumor - Stemach at year 1 Dellow Solid Tumor - Tryond ut year 1 Dellow Solid Tumor - Tryond ut year 1 Dellow Solid Tumor - Tryond ut year 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Graft Stemach 1 Dellow Solid Tumor - Carcinnom the United Stemach 1 Dellow Graft Stemach - Delnochial Stemach 1 Dellow Graft Stemach - Delnochial Stemach 1 Dellow Tryon Tryon Stemach 1 Dellow Stemach 1 Dello	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR Year 1 ULERUS CAR Year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CREAT year 3 CREAT year 3 CREAT year 3 CREAT year 3 HOSP year 3 HOSP Year 3 HOSP REJ year 3 HOSP REJ year 3 ROSP REJ year 3 ROSP REJ year 3 REMAL TX year 3 TERMIN MINUMON MANT MED year 3 OZ REG year 3 REMAL TX year 3 TERT REJ year 3	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testecular at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of Unitia, Perensum or Pensis, Scrotum at year 1 Long Graft Status - Bronchiolitis Colliterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Colliterans since Last Follow-up at year 3 Teste Graft Status - Bronchiolitis Colliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Most Recent Serum Creatinine at year 3 Graft Status at Time of Follow-up Follow-up Fellod at year 3 Testeptatizations found profilow-up Pensod at year 3 Testeptatizations found profilow-up Pensod at year 3 Any Medications Green during follow-up Pensod at year 3 Any Medications Green during Bollow-up Pensod at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Deletion Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 TURRUS CAR year 1 UUL PER PENIS SCROT CARCIN BM, year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 BRONC STRUC Year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC PENIS Year 3 HOSP INF year 3 HOSP INF year 3 MAUNO MANIT MED year 3 TIRT REL year 3	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testectian at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 1 Deletion Solid Tumor - Carcinoma of the Lienus at year 3 Lung Gard Status - Bronchiol Stoches and East Follow-up at year 3 Lung Gard Status - Bronchiol Stoches and East Follow-up at year 3 Post Transplant Events since Last Follow-up — if Renal Dysfunction. Chronic Dialysis? at year 3 Most Recent Serum Coudinine at year 3 Cornet Supplemental OZ Requirements at Rest and/or Exercise at year 3 Graft Status at Time of Follow-up Prefor at year 3 Testeptatizations founge Follow-up Prefor at year 3 Testeptatized for Infection duming Follow-up Prefor at year 3 Any Medications Given duming follow-up Feriod at year 3 Any Medications Given duming follow-up Feriod at year 3 Post Transplant Events since Last Follow-up — if Renal Dysfunction, Renal Transplant since Thoracic Transplant Events since Last Follow-up — if Renal Dysfunction, Renal Transplant since Thoracic Tran Patient Treated for Rejection (YMU) duming Follow-Up Period at year 3 Pott Transplant Events since Last Follow-up — if Renal Dysfunction, Renal Transplant since Thoracic Tran Patient Treated for Rejection (YMU) duming Follow-Up Period at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 UUL PER PENIS SCROT CARCIN BIM year 3 BRONC OBLIT year 3 BRONC STRIC year 3 GRONC STRIC year 3 CREAT year 3 CREAT year 3 CREAT year 3 HOSP year 3 HOSP year 3 HOSP year 3 HOSP REJ year 3 HOSP REJ year 3 TRIT REJ YEAR 3 CELLCEPT ANTIREJ YEAR 3	Dellow Solid Tumor - Stemach at year 1 Dellow Solid Tumor - Stemach at year 1 Dellow Solid Tumor - Trylorid at year 1 Dellow Solid Tumor - Trylorid at year 1 Dellow Solid Tumor - Trylorid at year 1 Dellow Solid Tumor - Carcinnom for the Lenu at year 1 Dellow Solid Tumor - Carcinnom for the Lenu at year 1 Dellow Solid Tumor - Carcinnom for the Lenu at year 1 Dellow Solid Tumor - Carcinnom for the Lenu at year 1 Dellow Solid Tumor - Carcinnom for the Lenu at year 1 Recipient BMI at year 3 Lung Graft Status — Bronchiolits Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchial Stricture since Last Follow-up at year 3 Lung Graft Status — Bronchial Stricture since Last Follow-up at year 3 Dellow Status — Bronchial Stricture since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Carlett Supplemental QC Requirements at Rest and/or Exercise at year 3 Hospitalization striction during Follow-up Pendod at year 3 Hospitalizations during Follow-up Pendod at year 3 Hospitalization furtherion during Follow-up Pendod at year 3 Hospitalization for Grow during Follow-up Pendod at year 3 Lung Craft Status — Oxygen Requirement (Lmin) at rest at the time of Follow-up at year 3 Lung Craft Status — Oxygen Requirement (Lmin) at rest at the time of Follow-up at year 3 RECIPIENT WORK FOR INDOME? at year 3 RECIPIENT WORK FOR REQUIREMENT ACTIVATION Nevellation() at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR year 3 BRONC STRIC year 3 BRONC STRIC Year 3 GREAT year 3 CHRONC DULL year 3 TONG THE YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEA	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testecular at year 1 Delivoo Solid Tumor - Carcinnona of twide, Pernesum or Pensis, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Pennesum or Pensis, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Pennesum or Pensis, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Pennesum or Pensis, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Pennesum or Pensis, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Pennesum of Pensis, Scrotum at year 1 Lung Gard Status - Bronchial Statuse anoce Last Follow-up at year 3 Post Transplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Cleatinine at year 3 Corat Status at Time of Follow-up Person at year 3 Testeptatace for Infection during Follow-up Penson at year 3 Testeptatace for Infection during Follow-up Penson at year 3 Any Medications Ginen during follow-up Penson at year 3 Lung Cust Status — Oxypen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Cust Status — Oxypen Requirement (Limin) at rest at the time of Follow-up at year 3 Patent Treated for Rejection (YNU) duming Follow-Up Person day year 3 CELLICET FURSHERSECTION (FOLL) ACTIVATION NetBEDTOR) at year 3 CELLICET FURSHERSECTION (FOLL) ACTIVATION NetBEDTOR) at year 3	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 WULPER PENIS SCROT CARCIN BMI, year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CREAT year 3 CREAT year 3 HOSP year 3 HOSP year 3 HOSP New year 3 HOSP NEW year 3 US NEW YEAR 3 HOSP NEW YEAR 3 TRIT REJ year 3 UNDER NOT MENULY YEAR 3 CELLCEPT MANTE CUR YEAR 3 CELLCEPT MANTE YEAR YEAR 3	Deletion Solid Tumor - Stemach at year 1 Deletion Solid Tumor - Testectular at year 1 Deletion Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Deletion Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Deletion Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Occurrett Supplementat Que Requirements at Rest and/or Exercise at year 3 Graft Status at Time of Follow-Up Peniod at year 3 Hospitalization during Follow-Up Peniod at year 3 Hospitalization during Follow-Up Peniod at year 3 Hospitalization during Follow-up Peniod at year 3 Hospitalization for Infection during Follow-up Peniod at year 3 Hospitalization for Infection during Follow-up Peniod at year 3 Lung Graft Status — Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Post Transplant Events since Last Follow-up - If Ream Infection Polytuniction, Renaul Transplant since Thoracic Tran Patient Treated for Rejection (YNUL) during Follow-Up Period at year 3 CELLCEPT ANTRELECTION (F-GELL ACTIVATION Re-REITOR) at year 3 CELLCEPT CURRENT MAINTENANCE & TIMES LAST FOLLOWAPP (F-CELL ACTIVATION)	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR Year 3 BRONC STRIC Year 3 BRONC STRIC Year 3 GREAT year 3 CHRONC DULL Year 3 HOSP NIF year 3 HOSP NIF year 3 HOSP NIF year 3 TRI REJ year 3 TRI REJ year 3 TRI REJ year 3 CELICEPT ANTIREJ Year 3 CELICEPT MANTI CUR year 3	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testectar at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoor Solid Tumor - Carcinoma of Solid Tumor - Carcinoma of Year 3 Delivoor Gard Status - Bronchial Stoneura since Last Follow-up at year 3 Post Transplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Coadinine at year 3 Graft Status at Timor of Follow-Up Perford at year 3 Testepatizacison founity of Solid Tumor of Year of Year Only Tested of Year 3 Testepatizacison founity of Solid Tumor of Year of Year 3 Testepatizacison founity of Solid Tumor year of Year 3 Testepatizacison founity of Solid Tumor year of Year 3 Testepatizacison founity of Solid Tumor year 3 Testepatizacison founity of Solid Tumor year of Year 3 Post Transplant Events since Last Follow-up Period at year 3 Post Transplant Events since Last Follow-up — if Renal Dysfunction, Renal Transplant since Thoracic Tran Patient Treated for Rejection (YAVU) dumor Follow-Up Period at year 3 CELLOEPET MORRO FOR NOOME? year 3 CELLOEPET ATTRELECTION (FOLL). ACTIVATION Refellettor (Year Year 3 CELLOEPET MORRO FOR NOOME? year 3	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 UUL PER PENIS SCROT CARCIN UTERUS CAR year 1 UUL PER PENIS SCROT CARCIN UTERUS CAR year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 GRONC DULT year 3 CREAT year 3 GRONC THE YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEA	Delivor Solid Tumor - Stenach at year 1 Delivor Solid Tumor - Testectular at year 1 Delivor Solid Tumor - Carcinnora del tuber at year 1 Delivor Solid Tumor - Carcinnora del tuber at year 1 Delivor Solid Tumor - Carcinnora del tuber at year 1 Delivor Solid Tumor - Carcinnora del tuber at year 1 Delivor Solid Tumor - Carcinnora del tuber at year 1 Delivor Solid Tumor - Carcinnora del tuber at year 3 Lung Graft Status - Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status - Broncholits Obliterans since Last Follow-up at year 3 Delivor Timospatra del territoris since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Delivor Timospatra del year since at year 3 Delivor timospatra del year 3 De	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR Year 3 BRONC STRUC Year 3 BRONC STRUC Year 3 BRONC STRUC Year 3 CHRONC DULL year 3 CHRONC DULL year 3 CHRONC DULL year 3 CHRONC DULL Year 3 CHRONC PORT YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEAR	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testecidar at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Lung Graft Status - Bronchial Storeur since Last Follow-up at year 3 Lung Graft Status - Bronchial Storeur since Last Follow-up at year 3 Post Tensplant Events since Last Follow-up — If Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Crustimina at year 3 Current Gupplemental OZ Requirements at Rest and/or Exercise at year 3 Graft Status at Time of Follow-Up Furctioning, Nir-Falled) at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Recent Serum Crustimina (Follow-up Period at year 3) Any Medications Green duming Follow-up for Mantenance or Anti-Rejection? at year 3 Recomment Current Server at the time of Follow-up at year 3 Recomment Current Server at the time of Follow-up at year 3 RECOMMENT CURRENT MAINTENANCE AT TIME OF FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELLICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR AT YEAR OF POLLOWUP FICELL ACTIVATION CENEROMAM PROJECT AT TIME OF FOLLOWUP FICELL ACTIVATION CENEROMAM PROJECT AT TIME OF FOLLOWUP FICELL ACTIVATION CENEROMAM PROJECT AT TIME OF FOLLOWUP FICELL ACTIVATION CENEROMAM P	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR Year 3 BRONC STRUC Year 3 BRONC STRUC Year 3 BRONC STRUC Year 3 CHRONC DULL year 3 CHRONC DULL year 3 CHRONC DULL year 3 CHRONC DULL Year 3 CHRONC PORT YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEAR	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testecidar at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peros, Scrotum at year 1 Lung Graft Status - Bronchial Storeur since Last Follow-up at year 3 Lung Graft Status - Bronchial Storeur since Last Follow-up at year 3 Post Tensplant Events since Last Follow-up — If Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Crustimina at year 3 Current Gupplemental OZ Requirements at Rest and/or Exercise at year 3 Graft Status at Time of Follow-Up Furctioning, Nir-Falled) at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Recent Serum Crustimina (Follow-up Period at year 3) Any Medications Green duming Follow-up for Mantenance or Anti-Rejection? at year 3 Recomment Current Server at the time of Follow-up at year 3 Recomment Current Server at the time of Follow-up at year 3 RECOMMENT CURRENT MAINTENANCE AT TIME OF FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELLICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR) at year 3 CELICEPT MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INHERITOR AT YEAR OF POLLOWUP FICELL ACTIVATION CENEROMAM PROJECT AT TIME OF FOLLOWUP FICELL ACTIVATION CENEROMAM PROJECT AT TIME OF FOLLOWUP FICELL ACTIVATION CENEROMAM PROJECT AT TIME OF FOLLOWUP FICELL ACTIVATION CENEROMAM P	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TORIQUE THROAT year 1 ULFRUS CARY year 1 ULFRUS CARY year 1 ULFRUS CARY year 3 BRONC OBLIT year 3 BRONC STRIC year 3 GRISCHOR DAL year 3 CREAT year 3 CREAT year 3 HOSP INF year 3 HOSP INF year 3 HOSP INF year 3 HOSP INF year 3 BAMINTO MANT MED year 3 OZ REQ year 3 TIRT REJ year 3 CELLCEPT MANT THEY year 3 CELLCEPT MANT TREY year 3 GENERICAME MANT CUR YEAR 3	Delivoo Solid Tumor - Stenoch at year 1 Delivoo Solid Tumor - Testecciar at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Pereneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Long Graft Status - Bronchiolitis Obtiterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Obtiterans since Last Follow-up at year 3 Post Transplant Events since Last Follow-up — If Penel Opstituction, Chornic Dalysis? at year 3 Most Recent Serum Creatinine at year 3 Craft Status at Time of Follow-up Period at year 3 Testeptatization founting Follow-up Pened at year 3 Testeptatization founting Follow-up Pened at year 3 Any Medications Criven during follow-up for Maintenance or Anth Rejection? at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Post Transplant elemts since Last Follow-up Pened at year 3 CELICEPT CINCREP SCR POSIN FORM EVA year 3 CELICEPT TURNER FORM NONE FOR INDOME 24 year 3 CELICEPT TURNER FORM FORM NONE 24 year 3 CELICEPT CINCREP FORM NONE FOR NONE 24 year 3 CELICEPT CINCREP FORM MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INVESTIGATION OF THIS FOLLOWUP FICELLIA ACTIVATION CELICEPT CINCREP FORM MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ICCELL ACTIVATION CELICEPT CINCREP MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ICCELL ACTIVATION CELICEPT CINCREP FORM MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ICCELL ACTIVATION CELICEPT CINCREP MAINTENANCE BETWEEN LAST FOLLOWUP	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR Year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 BRONC STRIC year 3 GRIONC THE YEAR 3 GRONC STRIC year 3 CREAT year 3 HOSP year 3 HOSP Year 3 HOSP NEW year 3 HOSP NEW year 3 TRI REJ year 3 WORK RICOME year 3 TRI REJ year 3 CELLOEPT MANT CUR year 3 CELLOEPT MANT CUR year 3 CYCLOSPORIN MANT PREV year 3 CELLOEPT MANT CUR Year 3 CYCLOSPORIN MANT PREV year 3 GENERICMIF MANT PREV YEAR 3 GENERICTACRORUMUS MANT PREV YEAR 3 GENERICTACRORUMUS MANT PREV YEAR 3 GENERICTACRORUMUS MANT PREV	Delivor Solid Tumor - Stemach at year 1 Delivor Solid Tumor - Testacular at year 1 Delivor Solid Tumor - Carcinnor and the Lierus at year 1 Delivor Solid Tumor - Carcinnor and the Lierus at year 1 Delivor Solid Tumor - Carcinnor and the Lierus at year 1 Delivor Solid Tumor - Carcinnor and Evulua. Perseneum or Penis. Scrotum at year 1 Recipient BMI at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Caraft Status at Time of Follow-Up ("Follow-up en Roman Dysfunction. Chronic Dialysis? at year 3 Most Recent Serum Creatinine at year 3 Caraft Status at Time of Follow-Up ("Follow-up en Roman Serum at year 3) Respirations during Follow-Up Period at year 3 Respirations during Follow-up Period at year 3 Respirations during Follow-up Period at year 3 Lung Graft Status — Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status — Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 RECIPIENT WORK FOR INCOME? at year 3 RECIPIENT WORK FOR INCOME? at year 3 CELLICEPT AURITHEAUS ES THUM Deliver Deliver Aurit And This Follow-up ("CELL ACTIVATION INHEBITOR) at year 3 CELLICEPT CURRENT MAINTENANCE AT TIME OF FOLLOWUP ("CELL ACTIVATION INHEBITOR) at year 3 GENERALIZATION MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ("CELL ACTIVATION CONNECTION ON PROPER INCOMINE CURRENT MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ("CELL ACTIVATION CONNECTION ON PROPER INCOMINE CURRENT MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ("CELL ACTIVATION CONNECTION ON PROPER INCOMINE AND THIS FOLLOWUP AT year 3 GENERALIZATION MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ("CELL ACTIVATION C	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR year 1 ULERUS CAR Year 3 BRONC STRIC Year 3 BRONC STRIC Year 3 BRONC STRIC Year 3 CHRONC DULL YEAR 3 HOSP NIF year 3 HOSP NIF year 3 MMURDO MANT MED Year 3 TRI REJ year 3 TRI REJ year 3 TRI REJ year 3 CELLCEPT ANTIREJ Year 3 CELLCEPT MANT PREV Year 3 CELLCEPT MANT PREV Year 3 GENERICANGROUND MANT PREMIONDRAN MANT PRIMURAN ANTIFELY YEAR 3	Delivoo Solid Tumor - Stenoch at year 1 Delivoo Solid Tumor - Testecciar at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Pereneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnon at Ortube, Peneneum or Penes, Scrotum at year 1 Long Graft Status - Bronchiolitis Obtiterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Obtiterans since Last Follow-up at year 3 Post Transplant Events since Last Follow-up — If Penel Opstituction, Chornic Dalysis? at year 3 Most Recent Serum Creatinine at year 3 Craft Status at Time of Follow-up Period at year 3 Testeptatization founting Follow-up Pened at year 3 Testeptatization founting Follow-up Pened at year 3 Any Medications Criven during follow-up for Maintenance or Anth Rejection? at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Post Transplant elemts since Last Follow-up Pened at year 3 CELICEPT CINCREP SCR POSIN FORM EVA year 3 CELICEPT TURNER FORM NONE FOR INDOME 24 year 3 CELICEPT TURNER FORM FORM NONE 24 year 3 CELICEPT CINCREP FORM NONE FOR NONE 24 year 3 CELICEPT CINCREP FORM MAINTENANCE BETWEEN LAST FOLLOWUP FICELL ACTIVATION INVESTIGATION OF THIS FOLLOWUP FICELLIA ACTIVATION CELICEPT CINCREP FORM MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ICCELL ACTIVATION CELICEPT CINCREP MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ICCELL ACTIVATION CELICEPT CINCREP FORM MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP ICCELL ACTIVATION CELICEPT CINCREP MAINTENANCE BETWEEN LAST FOLLOWUP	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TONGUE THROAT year 1 ULL PER PENIS SCROT CARCIN UTERUS CAR year 1 ULL PER PENIS SCROT CARCIN UTERUS CARL Year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CREAT year 3 GRONC DALL year 3 GRONC DALL year 3 GRONC DALL year 3 HOSP year 3 HOSP year 3 HOSP NEJ year 3 HOSP NEJ year 3 USER YEAR 3 CELLOEPT MANT MED year 3 CELLOEPT MANT CUR year 3 CYCLOSPORIS MANT PREV year 3 GENERICANE MANT PREV year 3 MURAN MANT CUR year 3	Delivor Solid Tumor - Stenach at year 1 Delivor Solid Tumor - Testacular at year 1 Delivor Solid Tumor - Carcinnora del Vulka Penneum or Penis. Scrotum at year 1 Delivor Solid Tumor - Carcinnora del Vulka Penneum or Penis. Scrotum at year 1 Delivor Solid Tumor - Carcinnora del Vulka Penneum or Penis. Scrotum at year 1 Long Graft Status - Etnochiolita Coliferana since Last Follow-up at year 3 Lung Graft Status - Etnochiolita Coliferana since Last Follow-up at year 3 Lung Graft Status - Etnochiolita Stocture since Last Follow-up at year 3 Lung Graft Status - Etnochiolita Stocture since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Corrent Supplementa Qu'Requirement at Reat and/or Exercise at year 3 Graft Status at Time of Follow-Up Period at year 3 Hospitalization during Follow-Up Period at year 3 Hospitalization for Infection during Follow-up Period at year 3 Hospitalization for Infection during Follow-up Period at year 3 Hospitalization for Infection during Follow-up Period at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 RECIPIEST WORK FOR INDOME? at year 3 CELLOEPT MIRITERACING IN FOLL ACTIVATION INHEBITOR) at year 3 CELLOEPT FOLIRERACING IN FOLL ACTIVATION INHEBITOR) at year 3 CELLOEPT FOLIRERACING IN FOLL ACTIVATION INHEBITOR) at year 3 CELLOEPT FOLIRERACING IN FOLL ACTIVATION INHEBITOR) at year 3 GENERICATION FOLIOWAP AND THIS FOLLOWAP (T-CELL ACTIVATION CYCLOSPORI MARTIENANCE BETWEEN LAST FOLLOWAP AND THIS FOLLOWAP (T-CELL ACTIVATION CYCLOSPORI MARTIENANCE BETWEEN LAST FOLLOWAP AND THIS FOLLOWAP (T-CELL ACTIVATION GENERICATION INHEBITOR) at year 3 GENERICATION COUNTS MARTIENANCE BETWEEN LAST FOLLOWAP AND THIS FOLLOWAP (T-CELL ACTIVATION M	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 UILYROD year 1 TONGUE THROAT year 1 UIL PER PENIS SCROT CARCIN UIL PER PENIS SCROT CARCIN UIL PER PENIS SCROT CARCIN UIL YEAR 3 BRONC STRIC Year 3 BRONC STRIC Year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 HOSP NIF year 3 HOSP NIF year 3 HOSP NIF year 3 TRI REJ year 3 TRI REJ year 3 TRI REJ year 3 CELLCEPT ANTIREJ year 3 CELLCEPT ANTIREJ year 3 CELLCEPT ANTIREJ year 3 CELLCEPT ANTIREJ Year 3 CELLCEPT MANT CUR year 3 CELLCEPT ANTIREJ Year 3 CELLCEPT MANT CUR year 3 CELLCEPT MANT CUR year 3 CELLCEPT MANT CUR year 3 CELLCEPT MANT PREV year 3 GENERICTARCRUMUS MANT PREV Year 3 GENERICTARCRUMUS MANT PREV Year 3 GENERICTARCRUMUS MANT PREV Year 3 MURAN MANT CUR YEAR 3 MURAN MANT PREV YEAR 3	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testecidar at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of twide, Pernesum or Peres, Scrotum at year 1 Long Gard Status - Bronchial Stoneure since Last Follow-up at year 3 Post Transplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Coadinine at year 3 Gard Status at Time of Follow-up Pered at year 3 Testepatization for sincing Follow-up Pered at year 3 Testepatization Garding Follow-up Pered at year 3 Testepatization Given Garing Follow-up Pered at year 3 Any Medications Given during Follow-up Pered at year 3 Post Transplant Events since Last Follow-up — if Renal Dysdunction, Renal Transplant since Thoracic Tran Patient Traveled for Rejection (YNIU) duming Follow-Up Period at year 3 CELLCEPT CURRENT FOR INCOME? year year 3 CELLCEPT CURRENT MARITERANCE AT TIME OF FOLLOWUP (TCELL ACTIVATION INTERTION) AT Year 3 CELLCEPT CURRENT MARITERANCE BETWEEN LAST FOLLOWUP (TCELL ACTIVATION INTERTION) At year 3 GENERATION CRITICAL ACTIVATION PER FOLLOWUP AT Year 3 GENERATION AND PERES PERES PERES PERES PERES PERES PERES PER SOLLOWUP AT YEAR 3 GENERATION AND PERES PERES	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TORIQUE THROAT year 1 UUL PER PENIS SCROT CARCIN UTERUS CAR year 1 UUL PER PENIS SCROT CARCIN UTERUS CAR year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 GRONC OBLIT year 3 GRONC DALL year 3 GRONC DALL year 3 GRONC DALL year 3 HOSP year 3 HOSP INF year 3 HOSP INF year 3 HOSP INF year 3 WORK BOLD YEAR 3 CELLCEPT ANTIREJ year 3 CELLCEPT ANTIREJ year 3 CELLCEPT MANT CUR year 3 CELLCEPT MANT CUR year 3 GELLCEPT MANT PREV Year 3 GENERICANT MANT PREV YEAR 3 MURAN MANT PREV YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT PREV YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT PREV YEAR 3 MURAN MANT FREV YEAR 3	Delivor Solid Tumor - Stenoch at year 1 Delivor Solid Tumor - Testectal at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Pens Transplant extent since Last Follow-up - If Renal Dysfunction, Chornic Dulaysis? at year 3 Most Recent Serum Creatinine at year 3 Cardt Status at Time of Follow-up Period at year 3 Graft Status at Time of Follow-up Period at year 3 Pensplatization during Follow-up Period at year 3 Pensplatization for Infection during Follow-up Period at year 3 Pensplatization for Marchine Status at Time of Follow-up Period at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Pensplatization form during Billow-up Period at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Peter Transplant Events since Last Follow-up Period at year 3 CELICEPT ANTRELECTION (FOLL ACTIVATION Re-IEDTOR) at year 3 CELICEPT CURRENT MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (FOELL ACTIVATION CYCLOSPORM MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (FOELL ACTIVATION CYCLOSPORM MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 3 GENEROCAMO FOR INCOMENT MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (AVITAMETABOLITE) at year 3 GENEROCAMO FOR SOLIDAR ALTON MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 3 GENEROCAMO FOLLOWUP (AVITAMETABOLITE) at year 3 MAURAN AURIEREDECTION (FOELL ACT	Follow up Follow	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TORIQUE THROAT year 1 ULERUS CAR year 1 ULERUS CAR Year 1 ULERUS CAR Year 1 ULERUS CAR Year 3 BRONC OBLIT year 3 BRONC STRIC Year 3 GRISCHOR DAL year 3 CREAT year 3 CREAT year 3 CREAT year 3 HOSP INF year 3 HOSP INF year 3 HOSP INF year 3 BAMINTO MANT MED year 3 OZ REQ year 3 TIRT REJ year 3 CELLCEPT MANT THEY YEAR 3 GENERICAME MANT CUR YEAR 3 GENERICATEROLBUS MANT PREV YEAR 3 BUIRAN MANT CUR YEAR 3 BUIRAN MANT CUR YEAR 3 BUIRAN MANT CUR YEAR 3 BUIRAN MANT PREV YEAR 3 BUIRAN MANT PREV YEAR 3 BUIRAN MANT CUR YEAR 3 BUIRAN MANT CUR YEAR 3 BUIRAN MANT PREV YEAR 3 BUIRAN MANT CUR YEAR 3	Delivor Solid Tumor - Stenoch at year 1 Delivor Solid Tumor - Testectal at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Pens Transplant extent since Last Follow-up - If Renal Dysfunction, Chornic Dulaysis? at year 3 Most Recent Serum Creatinine at year 3 Cardt Status at Time of Follow-up Period at year 3 Graft Status at Time of Follow-up Period at year 3 Pensplatization during Follow-up Period at year 3 Pensplatization for Infection during Follow-up Period at year 3 Pensplatization for Marchine Status at Time of Follow-up Period at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Pensplatization form during Billow-up Period at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Peter Transplant Events since Last Follow-up Period at year 3 CELICEPT ANTRELECTION (FOLL ACTIVATION Re-IEDTOR) at year 3 CELICEPT CURRENT MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (FOELL ACTIVATION CYCLOSPORM MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (FOELL ACTIVATION CYCLOSPORM MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 3 GENEROCAMO FOR INCOMENT MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (AVITAMETABOLITE) at year 3 GENEROCAMO FOR SOLIDAR ALTON MARITENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 3 GENEROCAMO FOLLOWUP (AVITAMETABOLITE) at year 3 MAURAN AURIEREDECTION (FOELL ACT	Follow up Follow	Yes	No N	No N	Ne	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 UILPRUS CAR year 1 UILPRUS CAR year 1 UILPRUS CAR Year 1 UILPRUS CAR YEAR YEAR 1 UILPRUS CARCINI YEAR YEAR 1 UILPRUS CARCINI YEAR 3 BRONC STRIC YEAR 3 BRONC STRIC YEAR 3 BRONC STRIC YEAR 3 CHRONC DUAL YEAR 3 CHRONC DUAL YEAR 3 CHRONC DUAL YEAR 3 CHRONC DUAL YEAR 3 HOSP NIF YEAR 3 HOSP NIF YEAR 3 HOSP NIF YEAR 3 HOSP NIF YEAR 3 BMURNO MANT MED YEAR 3 TRI REJ YEAR 3 RENAL TX YEAR 3 RENAL TX YEAR 3 RENAL TX YEAR 3 CELLCEPT ANTIREJ YEAR 3 CELLCEPT ANTIREJ YEAR 3 CELLCEPT MANT CUR YEAR 3 CELLCEPT MANT CUR YEAR 3 GENERICTACROLIMUS MANT PRE YEAR 3 GENERICTACROLIMUS MANT PRE YEAR 3 MURNA MANT CUR YEAR 3 MURNA MANT TOR YEAR 3 MURNA MANT TOR YEAR 3 MURNA MANT PREY YEAR 3 MEGRAL MATTREJ YEAR 3 MEGRAL MATTREJ YEAR 3 MEGRAL MATTREJ YEAR 3 MEGRAL MATT CUR YEAR 3 MEGRAL MATTREJ YEAR 3 MEGRAL MATT CUR YEAR 3	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testicular at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Pernesum or Peros, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Pernesum or Peros, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Pernesum or Peros, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Pernesum or Peros, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Pernesum or Peros, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Pernesum or Peros, Scrotum at year 1 Lung Gard Status - Bronchial Stoneura since Last Follow-up at year 3 Dest Tensplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Coadinina at year 3 Dest Tensplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dialysis? at year 3 Gard Status at Time of Follow-Up Perford at year 3 Tespatiazed for Infection duming Follow-up Period at year 3 Hospitazed for Infection duming Follow-up Period at year 3 Any Medicultions Green duming Follow-up Period at year 3 Any Medicultions Green duming Follow-up Period at year 3 Post Transplant Events since Last Follow-up — if Renal Dysfunction, Renal Transplant since Thoracic Tran Patient Treated for Rejection (YNIV) duming Follow-Up Period at year 3 CELICEPET MORE FOR NOOME? year year 3 CELICEPET ATTRELECTION (FORL), ACTIVATION Refellet Rejection? In year 3 CELICEPET ATTRELECTION (FORL), ACTIVATION Refellet Rejection Period year 3 GENEROCAME CURRENT MAINTENANCE AT TIME OF FOLLOWUP (FOELL ACTIVATION) INTERTITION OF RESPONDED AND AND AND THIS FOLLOWUP (FOELL ACTIVATION) GENEROCAME CURRENT MAINTENANCE AT TIME OF FOLLOWUP AND THIS FOLLOWUP (FOELL ACTIVATION) GENEROCAME MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (FOELL ACTIVATION) GENEROCAME CURRENT MAINTENANCE BETWEEN LAST FOLLOWUP	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 TONGUE THROAT year 1 TUREUS CAR year 1 UUL PER PENIS SCROT CARCIN UPER PENIS SCRO	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testecidar at year 1 Delivoo Solid Tumor - Carcinnona of twide, Pereneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Peneneum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of twide, Peneneum or Penes, Scrotum at year 1 Long Graft Status - Bronchiolists Obtiterans since Last Follow-up at year 3 Delivoor Transplant Events since Last Follow-up — If Penel Opstituction, Chronic Dalysis? at year 3 Most Recerd Serum Creatinine at year 3 Delivoor Transplant Events since Last Pollow-up — If Penel Opstituction, Chronic Dalysis? at year 3 Delivoor Transplant and Opstituction Penel At year 3 Delivoor Transplant and Grade Grade at year 3 Delivoor Transplant and Grade Grade at year 3 Delivoor Transplant and Follow-up Penel at year 3 Delivoor Transplant Servets since Last Follow-up Penel at year 3 Delivoor Transplant Servets since Last Follow-up Penel at year 3 Delivoor Transplant Servets since Last Follow-up Penel at year 3 Delivoor Transplant Servets since Last Follow-up Penel at year 3 Delivoor Transplant Servets since Last Follow-up Penel at year 3 Delivoor Transplant Servets since Last Follow-up Penel At year 3 Delivoor Transplant Servets since Last Follow-up Penel At year 3 Delivoor Transplant Servets since Last Follow-up Penel At year 3 Delivoor Transplant Servets since Last Follow-up Penel At year 3 Delivoor Transplant Servets since Last Follow-up Penel At year 3 Delivoor Transplant Servets since Last Follow-up Penel At year 3 Delivoor Transplant Servets Servets Servets Servets Servets Servets Servets Servets Se	Follow up Follow	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TOMOGE THROAT year 1 UILERUS CARY year 1 UILERUS CARY year 1 VIUL PER PENIS SOROT CARGIN BM year 3 BRONC STRIC year 3 BRONC STRIC year 3 CHRONIC DIAL year 3 CHRONIC PIER 3 MANUAL YEAR 3 MANUAL TOMOSP YEAR 3 WORK RICOME year 3 TET REL year 3 WORK RICOME Year 3 CELLCEPT MANTT PREV year 3 CELLCEPT MANTT CUR year 3 CELLCEPT MANTT CUR year 3 GENERICAME MANT PREV year 3 BAURAN MANT CUR year 3 BAURAN MANT CUR year 3 MURAN MANT PREV year 3 BAURAN MANT CUR YEAR 3 BAURAN MANT PREV YEAR 3 BAURAN MANT CUR YEAR 3 BAURAN MANT PREV YEAR 3	Delivor Solid Tumor - Stenach at year 1 Delivor Solid Tumor - Testacular at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Recipient Billi at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Desperting Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Certification Status — Broncholits Obliterans at Reat and/or Exercise at year 3 Graft Status at Time of Follow-Up Period at year 3 Testaptatized for Infection during Follow-up Period at year 3 Pospatatized for Infection during Follow-up Period at year 3 Despetatized for Rejection during Follow-up Period at year 3 Despetatized for Rejection during Follow-up Period at year 3 Despetatized for Rejection of those period at year 3 Despetatized for Rejection of Cell Lactivation (Pollow-up Period at year 3) Despetatized for Rejection of Cell Lactivation (Pollow-up Period at year 3) Despetatized for Rejection of Cell Lactivation (Pollow-up Period at year 3) Despetatized for Rejection of Cell Lactivation (Pollow-up Period at year 3) Despetative of the Rejection of Cell Lactivation (Pollow-up Period at year 3) Despetation of the Repetation (Pollow-up Period at year 3) Despetation of the Repetation (Pollow-up Period at year 3) Despetation of the Repetation (Pollow-up Period at year 3) Despetation of the Repetation (Pollow-up Period at year 3) Despetation of the Repetation (Pollow-up Period at year 3) Despetation of the Repetation (Pollow-up	Follow up Follow	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROID year 1 TONGUE THROAT year 1 TURRUS CAPE 1 TONGUE THROAT year 1 TULERUS CAR year 1 VUL PER PENIS SCROT CARCIN UPAR 2 BRONC STRUC YEAR 3 BRONC OBLIT year 3 BRONC STRUC YEAR 3 BRONC STRUC YEAR 3 GORGET YEAR 3 GORGET YEAR 3 GORGET YEAR 3 HOSP NIF year 3 HOSP NIF year 3 MAUNO MANT MED year 3 MAUNO MANT MED YEAR 3 TIRT REL YEAR 3 EVELOEPT ANTIFEL YEAR 3 CELLCEPT MANT CUR YEAR 3 GENERICMEN MANT PREV YEAR 3 BUIRAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 NEORAL MANT THEY YEAR 3	Delivior Solid Tumor - Stenich at year 1 Delivior Solid Tumor - Testecidar at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Ling Graft Status - Bronchiolistis Colitierans since Last Follow-up at year 3 Ling Graft Status - Bronchiolistis Colitierans since Last Follow-up at year 3 Delivior Status - Bronchiolistis Colitierans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Most Recent Serum Creatinine at year 3 Graft Status at Time of Follow-up Ferification (Recent Serum Creatinine at year 3) Despatiazation status and Graft Serum at year 3 Despatiazation status and Follow-up Ferification (Recent Serum Creatinine at year 3) Perspatiazation status and Follow-up Ferification at year 3 Despatiazation status for Follow-up Ferification at year 3 Despatiazation follow-up Ferif	Follow up Follow	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROID year 1 TONGUE THROAT year 1 TURRUS CAPE 1 TONGUE THROAT year 1 TULERUS CAR year 1 VUL PER PENIS SCROT CARCIN UPAR 2 BRONC STRUC YEAR 3 BRONC OBLIT year 3 BRONC STRUC YEAR 3 BRONC STRUC YEAR 3 GORGET YEAR 3 GORGET YEAR 3 GORGET YEAR 3 HOSP NIF year 3 HOSP NIF year 3 MAUNO MANT MED year 3 MAUNO MANT MED YEAR 3 TIRT REL YEAR 3 EVELOEPT ANTIFEL YEAR 3 CELLCEPT MANT CUR YEAR 3 GENERICMEN MANT PREV YEAR 3 BUIRAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 MURAN MANT CUR YEAR 3 NEORAL MANT THEY YEAR 3	Delivior Solid Tumor - Stenich at year 1 Delivior Solid Tumor - Testecidar at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Delivior Solid Tumor - Carcinoma of the Lienus at year 1 Ling Graft Status - Bronchiolistis Colitierans since Last Follow-up at year 3 Ling Graft Status - Bronchiolistis Colitierans since Last Follow-up at year 3 Delivior Status - Bronchiolistis Colitierans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Most Recent Serum Creatinine at year 3 Graft Status at Time of Follow-up Ferification (Recent Serum Creatinine at year 3) Despatiazation status and Graft Serum at year 3 Despatiazation status and Follow-up Ferification (Recent Serum Creatinine at year 3) Perspatiazation status and Follow-up Ferification at year 3 Despatiazation status for Follow-up Ferification at year 3 Despatiazation follow-up Ferif	Follow up Follow	Yes	No N	No N	Nee	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TORIQUE THROAT year 1 ULERUS CARY year 1 ULERUS CARY year 1 ULERUS CARY Year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 GREAT year 3 CREAT year 3 CREAT year 3 HOSP DIAL year 3 HOSP PREJ year 3 HOSP PREJ year 3 HOSP PREJ year 3 TRI REQ Year 3 TRI REL Year 3 CELLOEPT MANTI CUT Year 3 GENERICAMP MANTI FREY YEAR 3 BUJRAN MANTI FREY YEAR 3 NEORAL MANTI FREY YEAR 3 NEORAL MANTI FREY YEAR 3 NEORAL MANTI FREY YEAR 3 PROGRAF MANTI CUT YEAR 3 PROGRAF MANTI FREY YEAR 3	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testectian at year 1 Delivior Solid Tumor - Carcinoma of twide, Pereneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of twide, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of twide, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of twide, Peneneum or Penes, Scrotum at year 1 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Penes Transplant Events since Last Follow-up — If Penel Objection, Chronic Dalysis? at year 3 Most Recent Serum Creatinine at year 3 Coraft Status at Time of Follow-up Fellow at year 3 Testeptatazed for Infection during Follow-up Pened at year 3 Testeptatazed for Infection during Follow-up Pened at year 3 Any Medications Green during Brotow-up Pened at year 3 Long Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Long Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Peter Transplant dents since Last Follow-up - If Renal Dysfunction, Renal Transplant since Thoracic Transplant fermion for the Carcinoma at year 3 Peter Treated for Rejection (Y/NU) during Follow-up Period at year 3 CELLOSEPT MINDERS FOR INCOME 27 year 3 CELLOSEPT ATTIRES FOR FOR INCOME 27 year 3 CELLOSEPT ATTIRES FOR FOR INCOME 27 year 3 CELLOSEPT ATTIRES FOR FOR INCOME 27 year 3 CELLOSEPT MINDERS FOR INCOME 28 year 3	Follow up Follow	Yes	No N	No N	Ne N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 TURENS CAR year 1 VUL PER PENIS SCROT CARCIN BM year 3 BRONC STRIC year 3 BRONC STRIC year 3 BRONC STRIC Year 3 CHRONC DULL year 3 TO STRIC YEAR 3 HOSP INF year 3 HOSP INF year 3 HOSP INF year 3 REMAL TX year 3 REMAL TX year 3 REMAL TX year 3 REMAL TX year 3 CELLCEPT ANTIFEL year 3 CELLCEPT ANTIFEL year 3 CELLCEPT ANTIFEL Year 3 GENERICAME MANT CUR year 3 GENERICAME MANT CUR year 3 GENERICAME MANT YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEAR	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testectian at year 1 Delivior Solid Tumor - Carcinoma of twide, Pereneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of twide, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of twide, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of twide, Peneneum or Penes, Scrotum at year 1 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Penes Transplant Events since Last Follow-up — If Penel Objection, Chronic Dalysis? at year 3 Most Recent Serum Creatinine at year 3 Coraft Status at Time of Follow-up Fellow at year 3 Testeptatazed for Infection during Follow-up Pened at year 3 Testeptatazed for Infection during Follow-up Pened at year 3 Any Medications Green during Brotow-up Pened at year 3 Long Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Long Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Peter Transplant dents since Last Follow-up - If Renal Dysfunction, Renal Transplant since Thoracic Transplant fermion for the Carcinoma at year 3 Peter Treated for Rejection (Y/NU) during Follow-up Period at year 3 CELLOSEPT MINDERS FOR INCOME 27 year 3 CELLOSEPT ATTIRES FOR FOR INCOME 27 year 3 CELLOSEPT ATTIRES FOR FOR INCOME 27 year 3 CELLOSEPT ATTIRES FOR FOR INCOME 27 year 3 CELLOSEPT MINDERS FOR INCOME 28 year 3	Follow up Follow	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TORIGUE THROAT year 1 ULFRUS CARY year 1 ULFRUS CARY year 1 VUL PER PENIS SCROT CARCIN UN YEAR YEAR 1 SIRONC OBLIT year 3 BRONC STRIC YEAR 3 GRINCING DAL, year 3 CREAT year 3 GRINCING DAL, year 3 CREAT year 3 HOSP INF YEAR 3 ENDER YEAR 3 EVEL YEAR 3 EVEL YEAR 3 EVEL YEAR 3 EVEL YEAR 3 CELLCEPT ANTIREJ YEAR 3 CELLCEPT MANT CUR YEAR 3 CELLCEPT MANT CUR YEAR 3 CELLCEPT MANT CUR YEAR 3 GENERICANCH MANT CUR YEAR 3 MURAN MANT PREV YEAR 3 BUIRAN MANT PREV YEAR 3 NEORAL MANTE YEAR YEAR 3 NEORAL MANT CUR YEAR 3 PROGRAF MANT CUR YEAR 3	Delivor Solid Tumor - Stenach at year 1 Delivor Solid Tumor - Testacular at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Delivor Solid Tumor - Carcinoma of Vulna, Penneum or Penis, Scrotum at year 1 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Post Transplant extents since Last Follow-up - If Renal Dysfunction, Chronic Dulaysis? at year 3 Most Recent Serum Creatinine at year 3 Card Status at Time of Follow-Up Period at year 3 Testacular obliteration during Follow-up Period at year 3 Postpatization during Follow-up Period at year 3 Testacular obliteration during Follow-up Period at year 3 Postpatization during Follow-up Period at year 3 Testacular for Rejection during Follow-up Period at year 3 Despatization during Follow-up Period a	Follow up	Yes	No N	No N	Nee	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONGUE THROAT year 1 TURRUS CAR year 1 ULL PER PENIS SCROT CARGIN BM year 3 BRONC OBLIT year 3 BRONC STRUC Year 3 GRONC OBLIT year 3 GRONC OBLIT year 3 CHRONIC DUAL year 3 CHRONIC DUAL year 3 CHRONIC DUAL year 3 CHRONIC PORT YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEAR	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testacidar at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernenum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernenum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernenum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernenum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernenum or Peros, Scrotum at year 1 Long Graft Status - Bronchiel Storeur since Last Follow-up at year 3 Long Graft Status - Bronchiel Storeur since Last Follow-up at year 3 Post Tensplant Events since Last Follow-up — If Renal Dysfunction, Chronic Dialysis? at year 3 Most Recerk Serum Crustinine at year 3 Graft Status at Time of Follow Up (Y-Functioning, Nr-Faled) at year 3 Graft Status at Time of Follow Up Reprod at year 3 Repatitacidate for Infection duming Follow-up Period at year 3 Repatitacidate for Infection duming Follow-up Period at year 3 Repatitacidate for Infection duming Follow-up Period at year 3 Repatitacidate for Infection duming Follow-up Period at year 3 Repatitacidate for Period Period Status at Time of Follow-up at year 3 Repatitacidate for Period Status at Time of Follow-up Period at year 3 Repatitacidate for Period Status at Time Of Follow-up at year 3 Repatitacidate for Period Status at Time Of Follow-up at year 3 Repatitacidate for Period Status at Time Of Follow-up Period at year 3 Repatitacidate for Period Status at Time Of Follow-up Period at year 3 Received Time Period Status at Time Of Follow-up Period At year 3 Received Time Period Status at Time Of Follow-up Period Status at the Immediate Period Period Status at the Immediate Period Period Status at Time Of Follow-up Period S	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 TONGUE THROAT year 1 TUREUS CAR year 1 UUL PER PENIS SCROT CARCIN UPER PENIS SCRO	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testectular at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Perinsum of Perins, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Perinsum or Perins, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Perinsum or Perins, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Perinsum or Perins, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Perinsum or Perins, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Perinsum or Perins, Scrotum at year 3 Lung Graft Status - Bronchiol Stricture since Last Follow-up at year 3 Delivior Status - Bronchiol Stricture since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Graft Status at Time of Follow-up Ferinsum or Perinsum or Status at Time of Follow-up Ferinsum or Perinsum or Status at Time of Follow-up Ferinsum or Statu	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONGUE THROAT year 1 TURRUS CAP year 1 TURRUS CAP year 1 TURRUS CAP year 1 YUL PER PENIS SCROT CARCIN BM year 3 BRONC STRIC year 3 BRONC STRIC year 3 CHRONC COLL year 3 CHRONC COLL year 3 CREAT year 3 CHRONC COLL year 3 CREAT year 3 HOSP INF year 3 HOSP INF year 3 HOSP INF year 3 HOSP INF year 3 REHAL TX year 3 REHAL TX year 3 REHAL TX year 3 CELICEPT MATTER YEAR 3 CELICEPT MATTER YEAR 3 CELICEPT MATTER YEAR 3 CELICEPT MATT CHR YEAR 3 CELICEPT MATT CHR YEAR 3 CELICEPT MATT CHR YEAR 3 GENERICAME MANT YEAR YEAR YEAR YEAR SHANN TOUR YEAR 3 MURAN HANT CUR year 3 MURAN HANT CUR YEAR 3 MURAN HANT CUR YEAR 3 MURAN HANT YEAR YEAR 3 MURAN HANT CUR YEAR 3 MURAN HANT THEY YEAR 3 MURAN HANT THEY YEAR 3 NEORAL MANTE J YEAR 3 NEORAL MANTE J YEAR 3 NEORAL MANTE J YEAR 3 PROGRAF MANT PREV YEAR 3	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testacidar at year 1 Delivior Solid Tumor - Carcinoma of Vulue, Perseneum or Pereis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulue, Perseneum or Pereis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulue, Perseneum or Pereis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulue, Perseneum or Pereis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulue, Perseneum or Pereis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulue, Perseneum or Pereis, Scrotum at year 1 Lung Graft Status - Bronchiel Storeum since Last Follow-up at year 3 Destacidar Solid Tumor - Delivior at year 3 Destacidar Solid Tumor - Delivior at year 3 Most Recerc Serum Creations at year 3 Current Supplemental OZ Requirements at Rest and/or Exercise at year 3 Graft Status at Time of Follow Up Pir Functioning, NirFalled) at year 3 Delivior Solid Tumor - Solid Perseneum of Solid S	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 TONGUE THROAT year 1 UIL PER PENIS SCROT CARGIN BIM year 3 BRONC STRIC year 3 BRONC STRIC year 3 BRONC STRIC year 3 CHRONIC DUAL year 3 HOSP INF year 3 HOSP INF year 3 BMUNDO MANT MED year 3 OZ REQ year 3 REMAL TX year 3 TIX TREJ year 3 WORK RICCHE YEAR STRICK YEAR YEAR YEAR YEAR YEAR YEAR YEAR YEAR	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testacular at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Tumo Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Solid Status — Broncholits Obliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Cardt Status at Time of Follow-Up ("Functioning, Ni-Faled) at year 3 Testaction of Solid Status at Time of Follow-Up ("Functioning, Ni-Faled) at year 3 Testaction of the Solid Status at Time of Follow-Up ("Functioning, Ni-Faled) at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time Solid Status at the time of Follow-Up Penod at year 3 Testaction of the Solid Status at Time Solid Status at the Solid Status a	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROID year 1 TONGUE THROAT year 1 TURRUS CAPE 1 TONGUE THROAT year 1 TULERUS CAR year 1 VUL PER PENIS SCROT CARCIN UPON 1 BM, year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 BRONC STRUC Year 3 CHRONIC DIAL year 3 HOSP NIF year 3 HOSP NIF year 3 MAUNO MANIT MED year 3 MAUNO MANIT MED year 3 TIRT REL year 3 MAUNO MANIT MED Year 3 CELLOEPT MANIT CUR year 3 CELLOEPT MANIT PREV year 3 CELLOEPT MANIT CUR year 3 CELLOEPT MANIT CUR year 3 GEHERICMIF MANIT CUR year 3 GEHERICMIF MANIT CUR year 3 GEHERICMIF MANIT CUR year 3 MURAN MAINT CUR year 3 NEORAL MANIT PREV year 3 ROGRAF MANIT PREV year 3 ROGRAF MANIT PREV year 3 ROGRAF MANIT CUR year 3 ROGRAF MANIT CUR year 3 ROGRAF MANIT CUR year 3 ROGRAF MANIT PREV year 3 ROGRAF MANIT CUR year 3 ROGRAF MANIT CUR year 3 ROGRAF MANIT CUR year 3 ROGRAFMANIT CUR year 3 ROGRAFMANIT CUR year 3 ROGRAFMANIT CUR year 3 ROGRAFMANIT CUR YEAR 3 STEROIDS MANIT CUR YEAR 3 STEROIDS MANIT PREV year 3 STEROIDS MANIT PREV year 3	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testectian at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Pereneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Peneneum or Penes, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulva, Peneneum or Penes, Scrotum at year 1 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Long Graft Status - Bronchiolitis Obliterans since Last Follow-up at year 3 Post Transplant Events since Last Follow-up — if Penell Oysfunction, Chronic Dalysis? at year 3 Most Recent Serum Creatinine at year 3 Craft Status at Time of Follow-up Fired at year 3 Testestate of the Infection during Follow-up Pened at year 3 Testestate for Infection during Follow-up Pened at year 3 Testestate for Infection during Follow-up Pened at year 3 Any Medications Green during Follow-up Fired at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Lung Graft Status - Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Post Transplant elemts since Last Follow-up Pened at year 3 CELICEPT INTERES FOR INCOME 2 year 3 CELICEPT CHROPEN FOR INCOME 2 year 3 CELICEPT CHROPE	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TORIQUE THROAT year 1 ULERUS CARY year 1 ULERUS CARY year 1 ULERUS CARY Year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 GREAT year 3 GREAT year 3 HOSP INF year 3 TOR INF YEAR 3 HOSP INF YEAR 3 HOSP INF YEAR 3 HOSP INF YEAR 3 GELICEPT MAINT CUR YEAR 3 CELLCEPT AUTHREI YEAR 3 CELLCEPT MAINT CUR YEAR 3 CELLCEPT MAINT CUR YEAR 3 CELLCEPT MAINT CUR YEAR 3 GENERICANTE MAINT FREV YEAR 3 GENERICANTE MAINT FREV YEAR 3 GENERICANTE MAINT FREY YEAR 3 BUIRAN MAINT PREV YEAR 3 GENERICANTE MAINT CUR YEAR 3 BUIRAN MAINT PREV YEAR 3 BUIRAN MAINT PREV YEAR 3 REORAL MAINT CUR YEAR 3 FROGRAF MAINT CUR YEAR 3 FROGRAF MAINT CUR YEAR 3 FROGRAF MAINT PREV YEAR 3 REORAL MAINT PREV YEAR 3 REORAL MAINT PREV YEAR 3 FROGRAF MAINT PREV YEAR 3 STEROIDS MAINT PREV YEAR 3 STEROIDS MAINT CUR YEAR 3	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testacular at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Lung Graft Status — Broncholits Obliterans since Last Follow-up at year 3 Pen Status — Broncholits Obliterans since Last Follow-up at year 3 Most Recent Serum Creatinine at year 3 Cardt Status at Time of Follow-Up ("Functioning, Ni-Faled) at year 3 Most Recent Serum Creatinine at year 3 Destact Serum Serum Creatinine at year 3 Destact Serum Serum Creatinine at year 3 Destact Serum Seru	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 TURRUS CAP year 1 TURRUS CAP year 1 TURRUS CAP year 1 TULL PER PENIS SCROT CARCIN UNL PER PENIS SCROT CARCIN UNL PER PENIS SCROT CARCIN UNL YEAR YEAR 3 BRONC STRIC Year 3 BRONC STRIC Year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 HOSP NIF year 3 HOSP NIF year 3 HOSP NIF year 3 TOR THE YEAR 3 TOR THE YEAR 3 TOR THE YEAR 3 TOR THE YEAR 3 CELLOEPT ANTIRE J YEAR 3 GENERICTACROLINUS MANT PREV YEAR 3 GENERICTACROLINUS MANT PREV YEAR 3 BUIRAN MANT CUR YEAR 3 HURAN MANT CUR YEAR 3 HURAN MANT CUR YEAR 3 HURAN MANT PREV YEAR 3 HORAL ANTIRE J YEAR 3 HEORAL ANTIRE J YEAR 3 HEORAL MANT PREV YEAR 3 HEORAL MANT TOR YEAR 3 HEORAL MANT YEAR YEAR 3 HEORAL MANT YEAR YEAR 3 HEORAL WANT YEAR YEAR 3 HEORAL MANT YEAR YEAR 3 HEORAL MANT TOR YEAR 3 HEORAL MANT YEAR YEAR 3 HE	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testectair at year 1 Delivoo Solid Tumor - Carcinnona of Vulsa, Pernesum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of Vulsa, Pernesum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of Vulsa, Pernesum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of Vulsa, Penesum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of Vulsa, Penesum or Penes, Scrotum at year 1 Delivoo Solid Tumor - Carcinnona of Vulsa, Penesum or Penes, Scrotum at year 1 Long Gard Status — Bronchiol Stockure since Last Follow-up at year 3 Desit Transplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dalysis? at year 3 Most Recent Serum Cleatinine at year 3 Craft Status at Time of Follow-Up (YF-Functioning, NF-Faled) at year 3 Testepatacates for since Losd Penesum of Year at year 3 Testepatacates for since follow-Up (YF-Functioning, NF-Faled) at year 3 Testepatacates for since Losd Penesum Pened at year 3 Testepatacates for since Losd Penesum Pened at year 3 Testepatacates for since Losd Penesum Pened at year 3 Testepatacates for since Losd Penesum Pened at year 3 Testepatacates for Septem of temper Selection Penesum Penedum At year 3 Testepatacates for Sentens since Last Follow-up Pened at year 3 Testepatacates for Sentens since Last Follow-up Penedum At year 3 Testepatacates for Sentens since Last Follow-up Penedum At year 3 Testepatacates for Sentens since Last Follow-up Penedum At year 3 Testepatacates for Sentens since Last Follow-up Penedum At year 3 Testepatacates for Sentens since Last Follow-up Penedum At the since Tested for Rejection (Ynlu) duming Follow-up Penedum At the since Tested Sentens since Last Follow-up Penedum At the since Tested Sentens since Last Follow-up Penedum At the Sent Tested Sentens since Last Follow-up Penedum At	Follow up Follow	Yes	No N	No N	Noc	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 THYROID year 1 THYROID year 1 TORIQUE THROAT year 1 ULFRUS CARY year 1 ULFRUS CARY year 1 ULFRUS CARY year 3 BRONC OBLIT year 3 BRONC OBLIT year 3 BRONC STRIC year 3 CHEAT year 3 CHEAT year 3 CHEAT year 3 CHEAT year 3 HOSP INF year 3 BAMINTO MANT INED year 3 OZ REQ year 3 BAMINTO MANT INED year 3 CELLCEPT ANTIFEL year 3 CELLCEPT ANTIFEL year 3 CELLCEPT MANT CUR year 3 CELLCEPT MANT PREV year 3 CELLCEPT MANT CUR year 3 GENERICAME MANT CUR year 3 GENERICAME MANT CUR year 3 GENERICAME MANT CUR year 3 BAURAN MANT PREV year 3 BAURAN MANT PREV year 3 BAURAN MANT CUR year 3 BAURAN MANT CUR year 3 BAURAN MANT CUR year 3 REORAL MANT CUR year 3 ROCRAL MANT CUR year 3 ROCRAL MANT PREV year 3 ROCRAL MANTEL YEAR 3 ROCRAL MANT PREV year 3 ROCRAL MANTEL YEAR 3 ROCRAL MANT PREV year 3 STEROIDS MANT CUR year 3 STEROIDS MANT CUR year 3 STEROIDS MANT CUR YEAR 3 STEROIDS MANT PREV YEAR 3	Delivior Solid Tumor - Stenach at year 1 Delivior Solid Tumor - Testacular at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 1 Delivior Solid Tumor - Carcinoma of Vulka, Penneum or Penis, Scrotum at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 3 Penis Transplant extent since Last Follow-up — If Renall Polivior-tion, Chornic Dialysis? at year 3 Most Recent Serum Creatinine at year 3 Cardt Status at Time of Follow-Up ("Functioning, In-Faled) at year 3 Hospitalizade for Repection during Follow-up Period at year 3 Hospitalizade for Repection during Follow-up Period at year 3 Hospitalizade for Repection during Follow-up Period at year 3 Hospitalizade for Repection during Follow-up Period at year 3 Postpratizade for Repection (mung Follow-up Period at year 3 Lung Graft Status — Oxygen Requirement (Limin) at rest at the time of Follow-up at year 3 Post Transplant extent since Last Follow-up — If Renall Pollow-Up Period at year 3 CELLOSEPT ANTIREJECTION (T. CELL ACTIVATION Renallition) at year 3 CELLOSEPT ANTIREJECTION (T. CELL ACTIVATION Renallition) at year 3 CELLOSEPT CARREST ROSE RECOMES — If Renall Pollow-Up Period at year 3 CELLOSEPT CARREST ROSE RECOMES — If Renall Pollow-Up Period at year 3 CELLOSEPT ANTIREJECTION (T. CELL ACTIVATION Renallition) at year 3 CELLOSEPT CARREST ROSE RECOMES — If Renall Pollow-Up Period at year 3 CELLOSEPT CARREST ROSE RECOMES — If Renall Pollow-Up Period at year 3 CELLOSEPT ANTIREJECTION (T. CELL ACTIVATION RENBETTOR) at year 3 CELLO	Follow up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 TURING AN Year 1 TURING CARRY YEAR 1 TURING YEAR YEAR 3 BRONG STRIC YEAR 3 BRONG STRIC YEAR 3 BRONG STRIC YEAR 3 CHRONG COALL YEAR 3 CHRONG COALL YEAR 3 CHRONG COALL YEAR 3 CHRONG COALL YEAR 3 HOSP INF YEAR 3 HOSP INF YEAR 3 HOSP INF YEAR 3 TOSP REL YEAR 3 REMAL TX YEAR 3 REMAL TX YEAR 3 REMAL TX YEAR 3 CELLOEPT ANTIFEL YEAR 3 CELLOEPT ANTIFEL YEAR 3 CELLOEPT ANTIFEL YEAR 3 CELLOEPT ANTIFEL YEAR 3 GENERICAME MANT CUR YEAR 3 GENERICAME MANT CUR YEAR 3 MURAN ANTIFEL YEAR 3 MURAN HARTEL YEAR 3 MERGAL MANT PREV YEAR 3 PROGRAF MANT CUR YEAR 3 PROGRAF MANT PREV YEAR 3 STEROIDS MAINT PREV YEAR 3	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testacidar at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Lung Gard Status - Bronchield Storeur since Last Follow-up at year 3 Lung Gard Status - Bronchield Storeur since Last Follow-up at year 3 Post Tensplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Creatinine at year 3 Gard Status at Time of Follow Up (Y-Functioning, In-Faled) at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Any Medicationis Giron duming Follow-up Period at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Any Medicationis Giron duming Follow-up Period at year 3 Dest Transplant Events since Last Follow-up Period at year 3 Cellicoper Carcino Form Solidow-up Period At y	Follow-up	Yes	No N	No N	No N	No N	No N	No N
STOMACH year 1 TESTICULAR year 1 TINYROD year 1 TONGUE THROAT year 1 TURRUS CAP year 1 TURRUS CAP year 1 TURRUS CAP year 1 VUL PER PENIS SCROT CARCIN UNL PER PENIS SCROT CARCIN UNL PER PENIS SCROT CARCIN UNL YEAR YEAR 3 BRONC STRIC Year 3 BRONC STRIC Year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 CHRONC DIAL year 3 HOSP NIF year 3 HOSP NIF year 3 HOSP NIF year 3 TOR TELL YEAR 3 TRI REJ year 3 TRI REJ year 3 TRI REJ year 3 CELLCEPT ANTIREJ YEAR 3 GENERICTACROLINUS MANT PREV YEAR 3 GENERICTACROLINUS MANT PREV YEAR 3 GENERICTACROLINUS MANT PREV YEAR 3 MURAN MANT CUR YEAR 3 NEORAL ANTIREJ YEAR 3 NEORAL ANTIREJ YEAR 3 NEORAL ANTIREJ YEAR 3 NEORAL ANTIREJ YEAR 3 NEORAL MANT CUR YEAR 3 NEORAL MANT CUR YEAR 3 NEORAL MANT TORY YEAR 3 NEORAL MANT YEAR YEAR	Delivoo Solid Tumor - Stenach at year 1 Delivoo Solid Tumor - Testacidar at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Delivoo Solid Tumor - Carcinoma of Vulue, Pernesum or Peros, Scrotum at year 1 Lung Gard Status - Bronchield Storeur since Last Follow-up at year 3 Lung Gard Status - Bronchield Storeur since Last Follow-up at year 3 Post Tensplant Events since Last Follow-up — if Renal Dysfunction, Chronic Dialysis? at year 3 Most Recent Serum Creatinine at year 3 Gard Status at Time of Follow Up (Y-Functioning, In-Faled) at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Any Medicationis Giron duming Follow-up Period at year 3 Hospitalized for Infection duming Follow-up Period at year 3 Any Medicationis Giron duming Follow-up Period at year 3 Dest Transplant Events since Last Follow-up Period at year 3 Cellicoper Carcino Form Solidow-up Period At y	Follow up	Yes	No N	No N	No N	No N	No N	No N

	In., and the second sec			Les .	L. C.		L		
KAPOSI VISCERAL DONOR year	DeNovo Solid Tumor - Larynx at year 3	Follow-up			No	No	No	No	No
LARYNX_year_3	DeNovo Solid Tumor - Lerynx at year 3 DeNovo Solid Tumor - Leukernia at year 3	Follow-up	Yes	No	No	No	No	No	No
LEUK_year_3	Donor Related Tumor - Leukemia at year 3	Follow-up	Yes	No	No	No	No	No	No
LEUK_DONOR_year_3	DeNovo Solid Tumor - Lung at year 3	Follow-up	Yes	No No	No No	No No	No No	No.	No No
LUNG_year_3 LUNG_DONOR_year_3	Donor Related Tumor - Lung at year 3	Follow-up Follow-up	Yes			No	No	No No	No.
MALIG_year_3		Follow-up	Yes			No	No	No	No
	Post Transplant Lymphoproliferative Disease (PTLD) at year 3	Follow-up	Yes		No	No	No	No	No
		Follow-up	Yes		No	No	No	No	No
MALIG DON REL year 3	Post Transplant Donor Related Turnor at year 3	Follow-up	Yes	No	No	No	No	No	No
MET LIVER year 3	DeNovo Solid Tumor - Metastatic Liver Tumor at year 3	Follow-up	Yes	No	No	No	No	No	No
OTH CANCER year 3	DeNovo Solid Tumor - Other Cancers at year 3	Follow-up	Yes	No	No	No	No	No	No
OVARIAN year 3		Follow-up	Yes		No	No	No	No	No
PANCREAS year 3	DeNovo Solid Tumor - Pancreas at year 3	Follow-up	Yes		No	No		No	No
PRIM_HEPATIC_year_3	DeNovo Solid Tumor - Primary Hepatic Tumor at year 3	Follow-up	Yes						No
PRIM_UNK_year_3	DeNovo Solid Tumor - Primary Unknown at year 3	Follow-up	Yes	No	No	No	No	No	No
PROSTATE_year_3	DeNovo Solid Tumor - Prostate at year 3	Follow-up	Yes	No	No	No	No	No	No
RENAL_CAR_year_3	Dellovo Solid Tumor - Renal Carcinoma at year 3	Follow-up	Yes	No	No	No	No	No	No
SARCOMA_year_3	DeNovo Solid Tumor - Sarcomas (excluding Kaposi's) at year 3	Follow-up	Yes	No	No	No	No	No	No
SKIN BASAL year 3	Skin Cancer Type - Basal Cell at year 3	Follow-up	Yes	No	No	No	No	No	No
SKIN MELANOMA year 3	DeNovo Solid Tumor - Skin Melanoma at year 3	Follow-up	Yes	No	No	No	No	No	No
SKIN SQUAMOUS year_3	Skin Cancer Type - Squamous Cell at year 3	Follow-up	Yes	No	No	No	No	No	No
SM_INTEST_year_3	DeNovo Solid Tumor - Small Intestine at year 3	Follow-up	Yes	No	No	No	No	No	No
STOMACH year 3	DeNovo Solid Tumor - Stomach at year 3	Follow-up	Yes		No	No	No	No	No
TESTICULAR year 3	DeNovo Solid Tumor - Testicular at year 3	Follow-up	Yes	No	No	No	No	No	No
THYROID_year_3	DeNovo Solid Tumor - Thyroid at year 3	Follow-up	Yes	No	No	No	No	No	No
TONGUE_THROAT_year_3	DeNovo Solid Tumor - Tongue, Throat at year 3	Follow-up	Yes	No	No	No	No	No	No
LITERUS CAR year 3	DeNovo Solid Tumor - Carcinoma of the Uterus at year 3	Follow-up	Yes	No	No	No	No	No	No
VUL PER PENIS SCROT CARCIN	DeNovo Solid Tumor - Carcinoma of Vulva, Perineum or Penis, Scrotum at year 3	Follow-up	Yes		No	No		No	No
BMI_year_5	Recipient BMI at year 5	Follow-up	Yes		No	No	No	No	No
BRONC_OBLIT_year_5	Lung Graft Status — Bronchiolitis Obliterans since Last Follow-up at year 5	Follow-up	Yes	No	No	No	No	No	No
BRONG_STRIC_year_5	Lung Graft Status Bronchial Stricture since Last Follow-up at year 5	Follow-up	Yes	No	No	No	No	No	No
CHRONIC_DIAL_year_5	Post Transplant Events since Last Follow-up — If Renal Dysfunction, Chronic Dialysis? at year 5	Follow-up	Yes	No	No	No	No	No	No
CREAT year 5	Most Recent Serum Creatinine at year 5	Follow-up	Yes	No	No	No	No	No	No
CURRENTO2REQUIREMENTSYN y	Current Supplemental O2 Requirements at Rest and/or Exercise at year 5	Follow-up	Yes	No	No	No	No	No	No
HOSP_year_5	Hospitalizations during Follow-Up Period at year 5	Follow-up	Yes	No	No	No	No	No	No
HOSP_INF_year_5	Hospitalized for Infection during Follow-up Period at year 5	Follow-up	Yes	No	No	No	No	No	No:
HOSP_REJ_year_5	Hospitalized for Rejection during Follow-up Period at year 5	Follow-up	Yes	No	No	No	No	No	No
IMMUNO_MAINT_MED_year_5	Any Medications Given during follow-up for Maintenance or Anti-Rejection? at year 5	Follow-up	Yes	No	No	No	No	No	No
O2_REQ_year_5	Lung Graft Status Oxygen Requirement (L/min) at rest at the time of Follow-up at year 5	Followern	Yes	No	No	No	No	No	No
RENAL_TX_year_5	Post Transplant Events since Last Follow-up — If Renal Dysfunction, Renal Transplant since Thoracic Trans	Follow-up	Yes	No	No	No	No	No	No
TRT_REJ_year_5	Patient Treated for Rejection (Y/N/U) during Follow-Up Period at year 5	Follow-up	Yes	No	No	No	No	No	No
WORK INCOME_year_5	RECIPIENT WORK FOR INCOME? at year 5	Follow-up	Yes	No	No	No	No	No	No
CELLCEPT_ANTIREJ_year_5	CELLCEPT ANTIREJECTION (T-CELL ACTIVATION INHIBITOR) at year 5	Follow-up	Yes	No	No	No	No	No	No
CELLCEPT_MAINT_CUR_year_5	CELLCEPT CURRENT MAINTENANCE AT TIME OF FOLLOWUP (T-CELL ACTIVATION INHIBITOR) at year	Follow-up	Yes	No	No	No	No	No	No
CELLCEPT_MAINT_PREV_year_5	CELLCEPT MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVATION	Follow-up	Yes	No	No	No	No	No	No
CYCLOSPORIN_MAINT_PREV_year	CYCLOSPORIN MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVAT	Follow-up	Yes	No	No	No	No	No	No
GENERICMMF_MAINT_CUR_year_5	GENERICMMF CURRENT MAINTENANCE AT TIME OF FOLLOWUP at year 5	Follow-up	Yes	No	No	No	No	No	No
GENERICMME MAINT PREV year	deficient of the following of the following and the following at the	Follow-up	Yes	No	No	No	No	No	No
GENERICTACROLIMUS MAINT CUI	GENERICTACROLIMUS CURRENT MAINTENANCE AT TIME OF FOLLOWUP at year 5	Follow-up	Yes	No	No		No	No	No
GENERICTACROLIMUS MAINT PRI	GENERICTACROLIMUS MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 5	Follow-up	Yes		No		No	No	No
IMURAN_ANTIREJ_year_5	IMURAN ANTIREJECTION (ANTIMETABOLITE) at year 5	Follow-up	Yes		No			No	No
IMURAN MAINT CUR year 5	MURAN CURRENT MAINTENANCE AT TIME OF FOLLOWUP (ANTIMETABOLITE) at year 5	Follow-up	Yes		No			No	No
IMURAN_MAINT_PREV_year_5	IMURAN MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (ANTIMETABOLITE) at y	Follow-up			No	No	No	No	No
NEORAL_ANTIREJ_year_5	NEORAL ANTIREJECTION (T-CELL ACTIVATION INHIBITOR) at year 5	Follow-up	Yes	No	No	No	No	No	No
NEORAL_MAINT_CUR_year_5	NEORAL CURRENT MAINTENANCE AT TIME OF FOLLOWUP (T-CELL ACTIVATION INHIBITOR) at year	Follow-up	Yes	No	No	No	No	No	No
NEORAL_MAINT_PREV_year_5	NEORAL MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVATION IN	Follow-up	Yes	No	No	No	No	No	No
PROGRAF_ANTIREJ_year_5	PROGRAF ANTIREJECTION (ANTIMETABOLITE) at year 5	Follow-up	Yes	No	No	No	No	No	No
PROGRAF_MAINT_CUR_year_5	PROGRAF CURRENT MAINTENANCE AT TIME OF FOLLOWUP (ANTIMETABOLITE) at year 5	Follow-up	Yes	No	No	No	No	No	No
PROGRAF_MAINT_PREV_year_5	PROGRAF MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (ANTIMETABOLITE) of	Follow-up	Yes		No			No	No
RAPAMUNE_ANTIREJ_year_5	RAPAMUNE ANTIREJECTION (T-CELL ACTIVATION INHIBITOR) at year 5	Follow-up	Yes	No	No	No	No	No	No
RAPAMUNE_MAINT_CUR_year_5	RAPAMUNE CURRENT MAINTENANCE AT TIME OF FOLLOWUP (T-CELL ACTIVATION INHIBITOR) at ye	Follow-up	Yes	No	No	No	No	No	No
RAPAMUNE_MAINT_PREV_year_5	RAPAMUNE MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP (T-CELL ACTIVATION	Follow-up	Yes	No	No	No	No	No	No
STEROIDS_ANTIREJ_year_5	STEROIDS ANTIREJECTION at year 5	Follow-up	Yes	No	No	No	No	No	No
STEROIDS_MAINT_CUR_year_5	STEROIDS CURRENT MAINTENANCE AT TIME OF FOLLOWUP at year 5	Follow-up	Yes	No	No	No	No	No	No
STEROIDS_MAINT_PREV_year_5	STEROIDS MAINTENANCE BETWEEN LAST FOLLOWUP AND THIS FOLLOWUP at year 5	Follow-up			No			No	No
BLADDER_year_5	DeNovo Solid Turnor - Bladder at year 5	Follow-up	Yes		No			No	No
COLORECTAL_year_5	DeNovo Solid Turnor - Colo-rectal at year 5	Follow-up			No			No	No
ESOPHAGUS_year_5	DeNove Solid Tumor - Esophagus at year 5	Follow-up			No			No	No
KAPOSI_CUTANEOUS_year_5	DeNovo Solid Tumor - Kaposis's Sarcoma: Cutaneous at year 5	Follow-up			No			No	No
KAPOSI_VISCERAL_year_5	DeNovo Solid Tumor - Kaposis's Sarcoma: Visceral at year 5	Follow-up						No	No
KAPOSI VISCERAL DONOR year	Donor Related Tumor - Kaposis's Saccoma: Visceral at year 5 DeNovo Solid Tumor - Larynx at year 5	Follow-up						No	No
LARYNX_year_5		Follow-up						No	No
LEUK_year_5	Donor Related Tumor - Leukemia at year 5	Follow-up	Yes					No	No
LEUK_DONOR_year_5		Follow-up	Yes		No			No	No
LUNG_year_5		Follow-up	Yes		No		-	No	No
LUNG_DONOR_year_5		Follow-up						No	140
MALIG_year_5		Follow-up			No			No	No
MALIG DENOVO LYMPH year 5		Follow-up			No			No	No
MALIG DENOVO TUMOR year 5		Follow-up			No No			No	No
MALIG DON REL year 5	DeNovo Solid Tumor - Metastatic Liver Tumor at year 5	Follow-up							No
MET_LIVER_year_5		Follow-up							No
OTH CANCER year 5	DeNovo Solid Tumor - Orien Caricers at year 5	Follow-up							No
OVARIAN_year_5	DeNovo Solid Tumor - Ovanan at year 5  DeNovo Solid Tumor - Pancreas at year 5	Follow-up						No	No
PANCREAS_year_5	DeNovo Solid Tumor - Principus at year 5 DeNovo Solid Tumor - Primary Hepatic Tumor at year 5	Follow-up							No
PRIM_HEPATIC_year_5 PRIM_UNK_year_5	DeNovo Solid Tumor - Primary Inknown at year 5	Follow-up							No
PROSTATE_year_5	Deliovo Solid Tumor - Printary Unknown at year 5	Follow-up						No	No
	advisors tripper region in the participant report for instanciants.	Follow-up			No			No	No
RENAL_CAR_year_5		Follow-up			No			No	No
SARCOMA_year_5	Skin Cancer Type - Basal Cell at year 5	Follow-up			No			No	No
SKIN BASAL year 5		Follow-up			No			No	No
SKIN MELANOMA year 5		Follow-up			No			No	No.
SKIN_SQUAMOUS_year_5 SM_INTEST_year_5		Follow-up			No No		0.00	No No	No No
		Follow-up							_
STOMACH year 5	DeNovo Solid Tumor - Stomach at year 5	Followers	Yes					No	
STOMACH year 5 TESTICULAR year 5	DeNovo Solid Tumor - Stomach at year 5 DeNovo Solid Tumor - Testicular at year 5	Follow-up Follow-up							No No

THYROID_year_5	DeNovo Solid Tumor - Thyroid at year 5	Follow-up	Yes	No	No	No	No	No	No
TONGUE_THROAT_year_5	DeNovo Solid Tumor - Tongue, Throat at year 5	Follow-up	Yes	No	No	No	No	No	No
UTERUS_CAR_year_5	DeNovo Solid Tumor - Carcinoma of the Uterus at year 5	Follow-up	Yes	No	No	No	No		No
	DeNovo Solid Turnor - Carcinoma of Vulva, Perineum or Penis, Scrotum at year 5	Fellow-up	Yes	No	No	No	No	No	No
FEV_percent_year_1	Lung Graft Status Most Recent Value Available for Forced Expiratory Volume at one second (%) at year	Follow-up	Yes	No	No	No	No	No	No.
FEF25_year_1	Graft Function - FEF25-75 (L/sec) at year 1	Follow-up	Yes	No	No	No	No	No	No
FEV_year_1	Graft Function - FEV1 (L) at year 1	Follow-up	Yes	No	No	No	No	No	No
FVC_year_1	Graft Function - FVC (L) at year 1	Follow-up	Yes	No	No	No	No	No	No
FEV_percent_year_3	Lung Graft Status Most Recent Value Available for Forced Expiratory Volume at one second (%) at year		Yes	No	No	No	No	No	No
FEF25_year_3	Graft Function - FEF25-75 (L/sec) at year 3	Follow-up	Yes	No	No	No	No	No	No
FEV_year_3	Graft Function - FEV1 (L) at year 3	Follow-up	Yes	No	No	No	No	No	No
FVC_year_3	Graft Function - FVC (L) at year 3	Follow-up	Yes	No	No	No	No	No	No
FEV_percent_year_5	Lung Graft Status Most Recent Value Available for Forced Expiratory Volume at one second (%) at year		Yes	No	No	No	No	No	No
FEF25 year 5	Graft Function - FEF25-75 (L/sec) at year 5	Follow-up	Yes	No	No	No	No	No	No
FEV_year_5	Graft Function - FEV1 (L) at year 5	Follow-up	Yes	No	No	No	No	No	No
FVC_year_5	Graft Function - FVC (L) at year 5	Follow-up	Yes	No	No	No	No		No
CITIZENSHIP	RECIPIENT CITIZENSHIP @ REGISTRATION	At time of transplant	-	-				1	
	DONOR CITIZENSHIP	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
CITIZENSHIP_DON	RECIPIENT ANY KNOWN MALIGNANCIES SINCE LISTING @ TRANSPLANT	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
MALIG_TRR		and the second s	Yes	No	No	No	No	No	No
MALIG_TCR	ANY PREVIOUS MALIGNANCY (EXCLUDE NON-MELANOMA SKIN CANCER) @ REGISTRATION	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
GRADE 1 MIN BRONC OBLIT year	Lung Graft Status Bronchiolitis Obliterans grade at least B1 since Last Follow-up at year 1	Follow-up	Yes	No	No	No	No	No	No
GRADE_1_MIN_BRONC_OBLIT_year	Lung Graft Status Bronchiolitis Obliterans grade at least B1 since Last Follow-up at year 3	Follow-up	Yes	No	No	No	No	No	No
	Lung Graff Status — Bronchiolitis Obliterans grade at least B1 since Last Follow-up at year 5	Follow-up	Yes	No	No	No	No	No	No
MALIG SKMEL TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - SKIN, MELANOMA	At time of transplant	Yes	No	No	No	No		No
MALIG_SKMEL_TCR	TYPE OF PREVIOUS MALIGNANCY - SKIN, MELANOMA	At time of transplant	Yes	No	No	No	No	No	No
MALIG_THYR_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - THYROID	At time of transplant	Yes	No	No	No	No	No	No
MALIG_THYR_TCR	TYPE OF PREVIOUS MALIGNANCY - THYROID	At time of transplant	Yes	No	No	No	No	No	No
MALIG_BREAST_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - BREAST	At time of transplant	Yes	No	No	No	No	No	No
MALIG_BREAST_TCR	TYPE OF PREVIOUS MALIGNANCY - BREAST	At time of transplant	Yes	No	No	No	No	No	No
MALIG_OTH_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - OTHER	At time of transplant	Yes	No	No	No	No		No
MALIG OTH TCR	TYPE OF PREVIOUS MALIGNANCY - OTHER	At time of transplant	Yes	No	No	No			No
MALIG_TONGUE/THR/LAR_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - TONGUE, THROAT, LARYNX	At time of transplant	Yes						No
MALIG_TONGUE/THR/LAR_TCR	TYPE OF PREVIOUS MALIGNANCY - TONGUE, THROAT, LARYNX	At time of transplant	Yes	No	No	No	No	No.	No.
MALIG_GENURIN_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - GENITOURINARY	At time of transplant	Yes	No	No	No	No	No	No
MALIG GENURIN TCR	TYPE OF PREVIOUS MALIGNANCY - GENITOURINARY	At time of transplant	Yes	No	No	No	No	No	No
MALIG_UNK_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - UNKNOWN	At time of transplant	Yes	No	No	No.	No	No.	No.
MALIG UNK TCR	TYPE OF PREVIOUS MALIGNANCY - UNKNOWN	At time of transplant	Yes	No	No	No	No	No	No
	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - LIVER	At time of transplant	-	100			-	1	1
MALIG LI TRR	TYPE OF PREVIOUS MALIGNANCY - LIVER	At time of transplant At time of transplant	Yes	No	No	No	No	No	No
MALIG_LI_TCR		At time of transplant	Yes	No	No		No	No	No
MALIG_LU_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - LUNG		Yes	No	No	No	No	No	No
MALIG_LU_TCR	TYPE OF PREVIOUS MALIGNANCY - LUNG	At time of transplant	Yes	No	No	No	No	No	No
MALIG_CNS_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - CNS	At time of transplant	Yes	No	No	No	No	No	No
MALIG_CNS_TCR	TYPE OF PREVIOUS MALIGNANCY - CNS	At time of transplant	Yes	No	No	No	No	No	No
MALIG LEUK TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - LEUKEMIA	At time of transplant	Yes	No	No	No	No	No	No
MALIG LEUK TCR	TYPE OF PREVIOUS MALIGNANCY - LEUKEMIA	At time of transplant	Yes	No	No	No	No	No	No
MALIG_SKNON-MEL_TRR	TYPE OF MALIGNANCY BETWEEN LISTING AND TRANSPLANT - SKIN NON-MELANOMA	At time of transplant	Yes	No	No	No	No	No	No
MALIG SKNON-MEL TCR	TYPE OF PREVIOUS MALIGNANCY - SKIN NON-MELANOMA	At time of transplant	Yes	No	No	No	No	No	No
ACUTE REJ EPI No	ACUTE REJECTION EPISODE BETWEEN TRANSPLANT AND DISCHARGE? No	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	No
ACUTE RELEDI Ves Not Treated	ACUTE REJECTION EPISODE BETWEEN TRANSPLANT AND DISCHARGE? Yes Not Treated	At time of transplant	Yes	Yes	Yes	Yes	Yes		No
	ACUTE REJECTION EPISODE BETWEEN TRANSPLANT AND DISCHARGE? Yes Treated	At time of transplant		-					
ACUTE REJ EPI Yes Treated	RECIPIENT PRIMARY CAUSE OF DEATH CARDIOVASCULAR	At time of transplant	Yes	Yes	Yes		Yes		No
COD_CARDIOVASCULAR	RECIPIENT PRIMARY CAUSE OF DEATH CEREBROVASCULAR	At time of transplant	Yes	Yes	No	77.	No		No
COD_CEREBROVASCULAR			Yes	Yes			No		No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION-CHRONIC	At time of transplant	Yes	Yes			No	777	No
COD_MULTIORGAN	RECIPIENT PRIMARY CAUSE OF DEATH MULTIORGAN	At time of transplant	Yes	Yes	No	No	No	No	No
COD_PULM	RECIPIENT PRIMARY CAUSE OF DEATH PULMONARY	At time of transplant	Yes	No	No	No	No		No
COD_COVID_19	RECIPIENT PRIMARY CAUSE OF DEATH COVID-1	At time of transplant	Yes	Yes	No	No	No	No	No
COD_GRAFT FAILURE: GRAFT INFI		At time of transplant	Yes	Yes	No	No	No	No	No
COD_GRAFT FAILURE: NON-SPEC	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: NON_SPECIFIC	At time of transplant	Yes	Yes	No	No	No	No	No
COD GRAFT FAILURE: PRIMARY F.	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: PRIMARY FAILURE	At time of transplant	Yes	Yes	No	No	No	No	No
		At time of transplant	Yes		No	No	No		No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION-ACUTE	At time of transplant	Yes				No		No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION-HYPERACUTE	At time of transplant	Yes	Yes	No	No	No		No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE. TECHNICAL	At time of transplant	Yes	Yes	No	No	No	-	No
COD_HEMORRHAGE	RECIPIENT PRIMARY CAUSE OF DEATH HEMORRHAGE	At time of transplant	Yes	Yes	No	No	No	10000	No
COD IMMUNOSUPPRESSIVE	RECIPIENT PRIMARY CAUSE OF DEATH IMMUNOSUPPRESSIVE	At time of transplant	Yes	Yes	No	No	No		No
COD INFECTION	RECIPIENT PRIMARY CAUSE OF DEATH INFECTION	At time of transplant	Yes			No	No		No
COD MALIG	RECIPIENT PRIMARY CAUSE OF DEATH MALIGNANCY	At time of transplant							
COD OTHER	RECIPIENT PRIMARY CAUSE OF DEATH OTHER	At time of transplant	Yes						No
	RECIPIENT PRIMARY CAUSE OF DEATH SUICIDE	At time of transplant	-				No		No.
COD_SUICIDE	RECIPIENT ETHNICITY CATEGORY Amer Ind/Alaska Native, Non-Hispanic	At time of transplant	Yes	Yes		No	No		No
	RECIPIENT ETHNICITY CATEGORY Asian, Non-Hispanic		Yes	Yes		Yes	Yes		Yes
ETHCAT_Asian, Non-Hispanic	RECIPIENT ETHNICITY CATEGORY Asian, Non-Hispanic RECIPIENT ETHNICITY CATEGORY Black, Non-Hispanic	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ETHCAT_Black, Non-Hispanic	RECIPIENT ETHNICITY CATEGORY Black, Non-Hispanic RECIPIENT ETHNICITY CATEGORY Hispanic/Latino	At time of transplant At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ETHCAT_Hispanic/Latino			Yes	Yes	Yes	Yes	Yes	Yes	Yes
ETHCAT_Multiracial, Non-Hispanic	RECIPIENT ETHNICITY CATEGORY Multiracial, Non-Hispanic	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		At time of transplant	Yes	Yes		Yes	Yes		Yes
ETHCAT_White, Non-Hispanic		At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ETHCAT_DON_Amer Ind/Alaska Nati	DONOR ETHNICITY CATEGORY Amer Ind/Alaska Native, Non-Hispanic	At time of transplant	Yes	Yes	Yes		Yes		Yes
ETHCAT DON Asian Non-Hispanic	DONOR ETHNICITY CATEGORY Asian, Non-Hispanic	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ETHCAT DON Black, Non-Hispanic	DONOR ETHNICITY CATEGORY Black, Non-Hispanic	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
ETHICAT DOM Higgspiell stine	IDONOR ETHNICITY CATEGORY Hispanic/Latino	At time of transplant	Yes	Yes	Yes	Yes	Yes		Yes
ETHCAT DON Multiracial Non-Histo	DONOR ETHNICITY CATEGORY Multiracial, Non-Hispanic	At time of transplant	Yes	Yes	Yes		Yes		Yes
C. C		At time of transplant	Yes	Yes	Yes		Yes		Yes
ETHCAT DON Nation Mauraign lather	JDONOR ETHNICITY CATEGORY Native Hawaiian/other Pacific Islander, Non-Hispanic		Yes	Yes	Yes		Yes		Yes
ETHCAT DON White Non-Hispanic	DONOR ETHNICITY CATEGORY Native Hawaiian/other Pacific Islander, Non-Hispanic  DONOR ETHNICITY CATEGORY White, Non-Hispanic	At time of transplant		1100	140	140	1.00	1.00	
ETHCAT DON White Non-Hispanic	DONOR ETHNICITY CATEGORY Native Hawaiian/other Pacific Islander, Non-Hispanic  DONOR ETHNICITY CATEGORY White, Non-Hispanic	At time of transplant		Vac			2.2.	R.C.	
ETHCAT_DON_White, Non-Hispanic GRF_FAIL_CAUSE_Acute Rejection	DONOR ETHRICITY CATEGORY Matthe Hawasian/other Pacific Islander, Non-Hispanic DONOR ETHRICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FAILURE Acute Rejection	At time of transplant	Yes	Yes	No	No	No		No
ETHCAT DON White, Non-Hispanic GRF_FAIL_CAUSE_Acute Rejection GRF_FAIL_CAUSE_Chronic Rejection	UDONOR ETHNICITY CATEGORY Native Hawaran/other Pacific Islander, Non-Hispanic DONOR ETHNICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FAILURE Acute Rejection CAUSE OF GRAFT FAILURE Chronic Rejection/Alherosclerosis	At time of transplant At time of transplant	Yes Yes	Yes	No No	No No	No	No	No
ETHCAT_DON_White, Non-Hispanic GRF_FAIL_CAUSE_Acute Rejection GRF_FAIL_CAUSE_Chronic Rejectio GRF_FAIL_CAUSE_Other	UDNING ETHNICITY CATEGORY Native Hawasan/other Pacific Islander, Non-Hispanic DONGR ETHNICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FAULURE Acute Rejection CAUSE OF GRAFT FAULURE Channe Rejection/Atherosclerosis CAUSE OF GRAFT FAULURE Channe Rejection/Atherosclerosis	At time of transplant At time of transplant At time of transplant	Yes Yes Yes	Yes Yes	No No No	No No	No No	No No	No No
ETHCAT DON White, Non-Hispanic GRF FAIL CAUSE Acute Rejection GRF FAIL CAUSE Chronic Rejectio GRF FAIL CAUSE Other GRF FAIL CAUSE Primary Non-Fur	UDNING ETHNICITY CATEGORY Native Hawaran/other Pacific Islander, Non-Hispanic DONGR ETHNICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FALURE Lacute Rejection CAUSE OF GRAFT FALURE Chronic Rejection/Altherosclerosis CAUSE OF GRAFT FALURE Chronic Rejection/Altherosclerosis CAUSE OF GRAFT FALURE DEPTH CAUSE CHRONIC CAUSE OF GRAFT FALURE CHRONIC	At time of transplant At time of transplant At time of transplant At time of transplant	Yes Yes Yes Yes	Yes Yes Yes	No No No No	No No No No	No No	No No No	No No No
ETHCAT DON White, Non-Hispanic GRF FAIL CAUSE Acute Rejection GRF FAIL CAUSE Chronic Rejectio GRF FAIL CAUSE Other GRF FAIL CAUSE Primary Non-Fur GROUPING CF	LIDORIOR ETHNICITY CATEGORY Marke Hawasaviother Pacific Islander, Non-Hispanic DORIOR ETHNICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FALLURE CHARK Rejection CAUSE OF GRAFT FALLURE Chark CAUSE OF GRAFT FALLURE Chark CAUSE OF GRAFT FALLURE Primary Hon-Function CAUSE OF GRAFT FALLURE Primary Hon-Function LUME DIAGNOSIS GROUPING ON WIGON THORADIC_DGNTCR_TGNTRR_DGN) Cystic Fibrosis	At time of transplant At time of transplant At time of transplant At time of transplant At time of transplant	Yes Yes Yes	Yes Yes Yes Yes	No No No No No	No No No No	No No	No No No	No No
ETHCAT DON White, Non-Hispanic GRF FAIL CAUSE Acute Rejection GRF FAIL CAUSE Chronic Rejectio GRF FAIL CAUSE Other GRF FAIL CAUSE Primary Non-Fur	JONIOR ETHNICITY CATEGORY Marke Hawasan/other Pacific Islander, Non-Hispanic   DONOR ETHNICITY CATEGORY White, Non-Hispanic   CAUSE OF GRAFT FAILURE Acute Rejection   CAUSE OF GRAFT FAILURE Channe Rejection/Alterosclerosis   CAUSE OF GRAFT FAILURE Channe Rejection/Alterosclerosis   CAUSE OF GRAFT FAILURE Channe Rejection   CAUSE CHANNER FAILURE CHANNER PRIMARY Mon-Function   LUHL DIAGNOSIS GROUPING ON WIL(ON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis   LUHL DIAGNOSIS GROUPING ON WIL(ON THORACIC_DONTCR_TGNTRR_DGN) Obstructive	At time of transplant	Yes Yes Yes Yes	Yes Yes Yes Yes	No No No No No	No No No No	No No	No No No No	No No No
ETHCAT DON White, Non-Hispanic GRF FAIL CAUSE Acute Rejection GRF FAIL CAUSE Chronic Rejectio GRF FAIL CAUSE Other GRF FAIL CAUSE Primary Non-Fur GROUPING CF	JONIOR ETHNICITY CATEGORY Marke Hawasan/other Pacific Islander, Non-Hispanic   DONOR ETHNICITY CATEGORY White, Non-Hispanic   CAUSE OF GRAFT FAILURE Acute Rejection   CAUSE OF GRAFT FAILURE Channe Rejection/Alterosclerosis   CAUSE OF GRAFT FAILURE Channe Rejection/Alterosclerosis   CAUSE OF GRAFT FAILURE Channe Rejection   CAUSE CHANNER FAILURE CHANNER PRIMARY Mon-Function   LUHL DIAGNOSIS GROUPING ON WIL(ON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis   LUHL DIAGNOSIS GROUPING ON WIL(ON THORACIC_DONTCR_TGNTRR_DGN) Obstructive	At time of transplant	Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes	No No No No No No	No No No No No No	No No No	No No No No No	No No No No No
ETHCAT DON. White, Non-Hispanic GRF FAIL. CAUSE Acute Rejection GRF FAIL. CAUSE Otheric Rejectio GRF FAIL. CAUSE. Primary Non-Fur GROUPING CONCENTION OF CONTROL GROUPING Obstructive GROUPING Purmonary vascular GROUPING Personary vascular	JUDIOR ETHINICITY CATEGORY Valtev Howasan/other Pacific Islander, Non-Hispanic DONOR ETHINICITY CATEGORY White, Non-Hispanic DONOR ETHINICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FALURE Control Rejection/Alherosclerosis CAUSE OF GRAFT FALURE Control CAUSE OF GRAFT FALURE Primary Non-Function LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR, TGMTRR, DGNI Cystic Fibrosis LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR, TGMTRR, DGNI) Obstructive LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR, TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular	At time of transplant	Yes Yes Yes Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	No No No No No No No	No No No No No No	No No No No No	No No No No No No	No No No No No No
ETHCAT DON. White, Non-Hispanic GRF FAIL. CAUSE Acute Rejection GRF FAIL. CAUSE Chronic Rejectio GRF FAIL. CAUSE. Other GROUPING COROLLING GROUPING CONTROLLING GROUPING Obstructive GROUPING Pulmonary vascular GROUPING Personary vascular	JUDIOR ETHINICITY CATEGORY Valtev Howasan/other Pacific Islander, Non-Hispanic DONOR ETHINICITY CATEGORY White, Non-Hispanic DONOR ETHINICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FALURE Control Rejection/Alherosclerosis CAUSE OF GRAFT FALURE Control CAUSE OF GRAFT FALURE Primary Non-Function LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR, TGMTRR, DGNI Cystic Fibrosis LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR, TGMTRR, DGNI) Obstructive LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR, TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular LUHE, DIAGNOSIS GROUPING ON WILGON THORACIC DONTCR. TGMTRR, DGNI Pulmonary Vascular	At time of transplant	Yes	Yes Yes Yes Yes Yes Yes Yes	No No No No No No No No	No No No No No No No No	No No No No No No No	No No No No No No No	No No No No No No No
ETHCAT DON. White, Non-Hispanic GRF FAIL. CAUSE Acute Rejection GRF FAIL. CAUSE Chronic Rejectio GRF FAIL. CAUSE. Chronic Rejectio GRF FAIL. CAUSE. Primary Non-Fur GROUPING. Obstructive GROUPING Pulmonary vascular GROUPING Petentitive MED. COND. TRR. HOSPITALIZED. MED. COND. TRR. HOSPITALIZED.	JUDIORIE ETHNICITY CATEGORY VIAINE Non-Hispanic DONGR ETHNICITY CATEGORY VIAINE, Non-Hispanic DONGR ETHNICITY CATEGORY VIAINE, Non-Hispanic CAUSE OF GRAFT FALLURE Charle Rejection CAUSE OF GRAFT FALLURE Charle CAUSE OF GRAFT FALLURE Charle CAUSE OF GRAFT FALLURE Primary Hon-Function LUHL DIAGNOSIS GROUPING ON WIJON THORACIC_DONTCR, TGMTRR_DGN) Cystic Fibrosis LUHL DIAGNOSIS GROUPING ON WIJON THORACIC DGNTCR, TGMTRR_DGN) Opstructive LUHL DIAGNOSIS GROUPING ON WIJON THORACIC DGNTCR TGMTRR_DGN) Pulmonary Vascular LUHL DIAGNOSIS GROUPING ON WIJON THORACIC DGNTCR TGMTRR DGN) Pulmonary Vascular LUHL DIAGNOSIS GROUPING ON WIJON THORACIC DGNTCR TGMTRR DGN) Particular LUHL DIAGNOSIS GROUPING ON WIJON THORACIC DGNTCR TGMTRR DGN) Restrictive RECIPIENT MEDICAL CONDITION PRE-TRANSPLANT OF TRANSPLANT NOT IN ICU	At time of transplant	Yes	Yes	No No No No No No No No No No Yes	No No No No No No No No No No	No No No No No No No No No Yes	No No No No No No No No No No No Yes	No No No No No No No No Yes
ETHCAT DON, White, Non-Hispanic GRF, FAIL, CAUSE, Chronic Rejection GRF, FAIL, CAUSE, Chronic Rejectio GRF, FAIL, CAUSE, Chronic Rejectio GRF, FAIL, CAUSE, Chronic Rejection GRF, FAIL, CAUSE, Chronic Region GROUPING, Company, Vancular GROUPING, Pulmonary, vascular GROUPING, Restrictive GROUPING, Restrictive MED, COND, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZ	LUNION ET HINDITY CATEGORY WINE. Non-Hispanic DONOR ETHNICITY CATEGORY WINE. Non-Hispanic DONOR ETHNICITY CATEGORY WINE. Non-Hispanic CAUSE OF GRAFT FALUER CAUSE Registion CAUSE OF GRAFT FALUER CHIEF Registion/Alteroslerasis CAUSE OF GRAFT FALUER CHIEF CAUSE OF GRAFT FALUER CHIEF CAUSE OF GRAFT FALUER CHIEF LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Cystic Fibrosis LUNE. DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Palmonary Vascular LUNE. DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Palmonary Vascular LUNE. DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Palmonary Vascular LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Restrictive RECIPIENT MEDICAL CONDITION PRE-TRANSIPANT (© TRANSPANT TOVI FILO RECIPIENT MEDICAL CONDITION PRE-TRANSIPANT (© TRANSPANT TOVI FILO RECIPIENT MEDICAL CONDITION PRE-TRANSPANT	At time of transplant	Yes	Yes	No Yes Yes	No Yes Yes	No No No No No No No Ves Yes	No No No No No No No No No Yes Yes	No No No No No No No No No No Yes Yes
ETHCAT DON, White, Non-Hispanic GRF, FAIL, CAUSE, Chronic Rejection GRF, FAIL, CAUSE, Chronic Rejectio GRF, FAIL, CAUSE, Chronic Rejectio GRF, FAIL, CAUSE, Chronic Rejection GRF, FAIL, CAUSE, Chronic Region GROUPING, Company, Vancular GROUPING, Pulmonary, vascular GROUPING, Restrictive GROUPING, Restrictive MED, COND, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZ	LUNION ET HINDITY CATEGORY WINE. Non-Hispanic DONOR ETHNICITY CATEGORY WINE. Non-Hispanic DONOR ETHNICITY CATEGORY WINE. Non-Hispanic CAUSE OF GRAFT FALUER CAUSE Registion CAUSE OF GRAFT FALUER CHIEF Registion/Alteroslerasis CAUSE OF GRAFT FALUER CHIEF CAUSE OF GRAFT FALUER CHIEF CAUSE OF GRAFT FALUER CHIEF LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Cystic Fibrosis LUNE. DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Palmonary Vascular LUNE. DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Palmonary Vascular LUNE. DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Palmonary Vascular LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR. TOWTRR. DON Restrictive RECIPIENT MEDICAL CONDITION PRE-TRANSIPANT (© TRANSPANT TOVI FILO RECIPIENT MEDICAL CONDITION PRE-TRANSIPANT (© TRANSPANT TOVI FILO RECIPIENT MEDICAL CONDITION PRE-TRANSPANT	At time of transplant	Yes	Yes	No No No No No No No No No Yes Yes Yes	No No No No No No No No No Yes Yes Yes	No No No No No Yes Yes Yes	No No No No No No No No No Yes Yes	No No No No No No No Yes Yes Yes
ETHCAT DON, White, Non-Hispanic GRF, FAIL, CAUSE, Chronic Rejection GRF, FAIL, CAUSE, Chronic Rejectio GRF, FAIL, CAUSE, Chronic Rejectio GRF, FAIL, CAUSE, Chronic Rejection GRF, FAIL, CAUSE, Chronic Region GROUPING, Company, Vancular GROUPING, Pulmonary, vascular GROUPING, Restrictive GROUPING, Restrictive MED, COND, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZED I MED, TIRR, MOSPITALIZ	LIONIOR ETHNICITY CATEGORY Marke Hawasavisther Pacific Islander, Non-Hispanic DONOR ETHNICITY CATEGORY White, Non-Hispanic CAUSE OF GRAFT FALUER CAMER, Non-Hispanic CAUSE OF GRAFT FALUER CAUSE AND RESPONSIVE AND	At time of transplant	Yes	Yes	No No No No No No No No Yes Yes Yes No	No No No No No No No No No Yes Yes Yes No	No No No No No No No Ves Yes	No No No No No No No Yes Yes No	No No No No No No No No No No Yes Yes

	NO. TO A DESCRIPTION OF THE PROPERTY OF THE PR	1200	-	-	77-07				
PERFUSED_BY_Transplant Program	TRR LUNG(S) PERFUSION PERFORMED BY Transplant Program	At time of transplant	Yes	Yes	No	No	No	No	No.
PRI_PAYMENT_TRR_Other	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Other	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
PRI_PAYMENT_TRR_Private	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Private	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
PRI_PAYMENT_TRR_Public	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Public	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
PRIOR_LUNG_SURG_TYPE_TRR_L	TRR LUNG SURGERY TYPE BETWEEN LISTING AND TRANSPLANT (NON-TRANSPLANT) Lobectomy	At time of transplant	Yes	Yes.	Yes	Yes	Yes.	Yes	Yes
PRIOR_LUNG_SURG_TYPE_TRR_(	TRR LUNG SURGERY TYPE BETWEEN LISTING AND TRANSPLANT (NON-TRANSPLANT) Other	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
PRIOR LUNG SURG TYPE TRR I	TRR LUNG SURGERY TYPE BETWEEN LISTING AND TRANSPLANT (NON-TRANSPLANT) Pneumoredu	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
PRIOR LUNG SURG TYPE TRR 1	TRR LUNG SURGERY TYPE BETWEEN LISTING AND TRANSPLANT (NON-TRANSPLANT) Thoracotomy	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
PX_STAT_Alive	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Alive	At time of transplant	Yes	Yes	No	No	No		No
PX STAT Dead	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Dead	At time of transplant	Yes	Yes	No	No	No	No	No
PX STAT Retransplanted	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Retransplanted	At time of transplant	Yes	Yes	No	No	No	-	No
SHARE_TY_Foreign Donor	ALLOCATION TYPE Foreign Donor	At time of transplant	Yes	Yes	No	No	No	No	No
	ALLOCATION TYPE Local	At time of transplant	Yes	Yes	No	No	No		No
SHARE_TY_Local SHARE_TY_National	ALLOCATION TYPE National	At time of transplant			No	No			1000
		At time of transplant	Yes	Yes			No		No
SHARE TY Regional	ALLOCATION TYPE Regional  CANDIDATE DIAGNOSIS AT LISTING Alpha 1 Antitrypsin Deficiency	At time of transplant	Yes	Yes	No	No	No	No	No
TCR_DGN_A1AT		At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_BRONCHIECTASIS	CANDIDATE DIAGNOSIS AT LISTING Bronchiectasis	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_CF	CANDIDATE DIAGNOSIS AT LISTING Cystic Fibrosis		Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_COPD	CANDIDATE DIAGNOSIS AT LISTING COPD	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_COVID_ARDS	CANDIDATE DIAGNOSIS AT LISTING COVID ARDS	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_COVID_PF	CANDIDATE DIAGNOSIS AT LISTING COVID Pulmonary Fibrosis	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_HP	CANDIDATE DIAGNOSIS AT LISTING Hypersensitivity Pneumonitis	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR DGN IPF	CANDIDATE DIAGNOSIS AT LISTING Idiopathic Pulmonary Fibrosis.	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	CANDIDATE DIAGNOSIS AT LISTING LYMPHANGIOLEIOMYOMATOSIS	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR DGN NSIP	CANDIDATE DIAGNOSIS AT LISTING Nonspecific interstitial pneumonia	At time of transplant	Yes	Yes	Yes	Yes	Yes		Yes
TCR_DGN_OB	CANDIDATE DIAGNOSIS AT LISTING Obliterative bronchiolitis	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		At time of transplant	-	100000000000000000000000000000000000000					
TCR_DGN_OCCUPATIONAL	CANDIDATE DIAGNOSIS AT LISTING Occupational	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_OTHER	CANDIDATE DIAGNOSIS AT LISTING Other	THE RESIDENCE OF THE PARTY OF T	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_PF_OTHER	CANDIDATE DIAGNOSIS AT LISTING Pulmonary fibrosis - other	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_PULM_HTN	CANDIDATE DIAGNOSIS AT LISTING Pulmonary hypertension	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_RHEUMATOID	CANDIDATE DIAGNOSIS AT LISTING Rheumatoid	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TCR_DGN_SARCOIDOSIS	CANDIDATE DIAGNOSIS AT LISTING Sarcoidesis	At time of transplant	Yes	Yes	Yes	Yes	Yes.	Yes	Yes
TCR DGN SCLERODERMA MIXED	CANDIDATE DIAGNOSIS AT LISTING Scleroderma mixed connective tissue disease	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	CANDIDATE DIAGNOSIS AT LISTING Scleroderma pulmonary hypertension	At time of transplant	Yes	Yes		Yes	Yes		Yes
	CANDIDATE DIAGNOSIS AT LISTING Scleroderma restrictive	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	CANDIDATE DIAGNOSIS AT LISTING Secondary pulmonary hypertension	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	Waitlist CANDIDATE DIAGNOSIS AIr DISTING Secondary pulmonary hypertension	At time of transplant							
THORACIC_DGN_A1AT		At time of transplant	Yes	Yes	No	No	No	No	No
	Waitlist CANDIDATE DIAGNOSIS Bronchiectasis		Yes	Yes	No	No	No		No
THORACIC DGN_CF	Wartlist CANDIDATE DIAGNOSIS Cystic Fibrosis	At time of transplant	Yes	Yes.	No	No	No		No
THORACIC_DGN_COPD	Waitlist CANDIDATE DIAGNOSIS COPD	At time of transplant	Yes	Yes	No	No	No	No	No
THORACIC_DGN_COVID_ARDS	Waitlist CANDIDATE DIAGNOSIS COVID ARDS	At time of transplant	Yes	Yes	No	No	No	No	No
THORACIC_DGN_COVID_PF	Waitlist CANDIDATE DIAGNOSIS COVID Pulmonary Fibrosis	At time of transplant	Yes	Yes	No	No	No	No	No
THORACIC_DGN_HP	Waitlist CANDIDATE DIAGNOSIS Hypersensitivity Pneumonitis	At time of transplant	Yes	Yes	No.	No	No		No
THORACIC_DGN_IPF	Waitlist CANDIDATE DIAGNOSIS Idiopathic Pulmonary Fibrosis	At time of transplant	Yes	Yes	No	No	No	No	No
	Waitlist CANDIDATE DIAGNOSIS LYMPHANGIOLEIOMYOMATOSIS	At time of transplant	Yes	Yes	No	No	No		No
THORACIC_DGN_NSIP	Waitlist CANDIDATE DIAGNOSIS Nonspecific interstitial pneumonia	At time of transplant	Yes		No	No	No		No
		At time of transplant		Yes	No	No	No		
THORACIC DGN OB	Waltist CANDIDATE DIAGNOSIS Obliterative bronchiolitis	At time of transplant	Yes	Yes					No
	Waitist CANDIDATE DIAGNOSIS Occupational		Yes	Yes	No	No	No	177	No
THORACIC_DGN_OTHER	Waitlist CANDIDATE DIAGNOSIS Other	At time of transplant	Yes	Yes	No	No	No	No	No
THORACIC_DGN_PF_OTHER	Waitlist CANDIDATE DIAGNOSIS Pulmonary fibrosis - other	At time of transplant	Yes	Yes	No	No	No	No	No
THORACIC_DGN_PULM_HTN	Waitlist CANDIDATE DIAGNOSIS Pulmonary hypertension	At time of transplant	Yes	Yes	No	No	No	No	No
THORACIC_DGN_RHEUMATOID	Waitlist CANDIDATE DIAGNOSIS Rheumatoid	At time of transplant	Yes	Yes	No	No	No	No	No
				Yes	No	No	No	No	No
		At time of transplant	Yes						
THORACIC_DGN_SARCOIDOSIS	Waitlist CANDIDATE DIAGNOSIS Sarcoidosis	At time of transplant At time of transplant	Yes				No		1111
THORACIC_DGN_SARCOIDOSIS THORACIC_DGN_SCLERODERMA	Waitlist CANDIDATE DIAGNOSIS Sarcoidosis Waitlist CANDIDATE DIAGNOSIS Scleroderma mixed connective tissue disease	At time of transplant	Yes	Yes	No	No	No No	No	No
THORACIC_DGN_SARCOIDOSIS THORACIC_DGN_SCLERODERMA THORACIC_DGN_SCLERODERMA	Waltist CANDIDATE DIAGNOSIS Sarcoidosis Waltist CANDIDATE DIAGNOSIS Scleroderma mixed connective tissue disease Waltist CANDIDATE DIAGNOSIS Scleroderma pulmonary hypertension	At time of transplant At time of transplant	Yes Yes	Yes Yes	No No	No No	No	No No	No No
THORACIC_DGN_SARCOIDOSIS THORACIC_DGN_SCLERODERMA THORACIC_DGN_SCLERODERMA THORACIC_DGN_SCLERODERMA	Waltist CANDDATE DIAGNOSIS Surceidosis Wattet CANDDATE DIAGNOSIS Scleroderma mixed connective tissue disease Waltist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Waltist CANDDATE DIAGNOSIS Scleroderma restrictive	At time of transplant At time of transplant At time of transplant	Yes Yes Yes	Yes Yes Yes	No No No	No No No	No No	No No No	No No No
THORACIC DGN SARCOIDOSIS THORACIC DGN SCLERODERMA THORACIC DGN SCLERODERMA THORACIC DGN SCLERODERMA THORACIC DGN SCLERODERMA THORACIC DGN SECONDARY PI	Waltist CANDDATE DIAGNOSIS Surcidosis Waltist CANDDATE DIAGNOSIS Scleroderma mixed connective tissue disease Waltist CANDDATE DIAGNOSIS Scleroderma polimonary hypertension Waltist CANDDATE DIAGNOSIS Scleroderma restrictive Waltist CANDDATE DIAGNOSIS Scenoder audinosory hypertension	At time of transplant At time of transplant At time of transplant At time of transplant	Yes Yes Yes Yes	Yes Yes Yes Yes	No No No No	No No No No	No No	No No No	No No No
THORACIC DGN SARCOIDOSIS THORACIC DGN SCLERODERMA THORACIC DGN SCLERODERMA THORACIC DGN SCLERODERMA THORACIC DGN SECONDARY PL THORACIC DGN SECONDARY PL TO SEC	Waltist CANDDATE DIAGNOSIS Succidensis Waltist CANDDATE DIAGNOSIS Scleroderma mixed connective tissue disease Waltist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Waltist CANDDATE DIAGNOSIS Scleroderma restrictive Waltist CANDDATE DIAGNOSIS Scleroderma restrictive Waltist CANDDATE DIAGNOSIS Secondary pulmonary hypertension RECIPIENT PROCEDURE TYPE Blatteral Secondial June	At time of transplant	Yes Yes Yes Yes Yes	Yes Yes Yes Yes	No No No No No	No No No No No	No No No	No No No No No	No No No No No
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLORODERMA THORACIC DON SECONDARY PL TX PROCEDUR TY Bilateral Sequence TX PROCEDUR TY Bilateral Sequence TX PROCEDUR TY BILE DONALD	Waltist CANDDATE DIAGNOSIS Secrotionis Waltist CANDDATE DIAGNOSIS Sclenoderma mixed connective tissue disease Waltist CANDDATE DIAGNOSIS Sclenoderma pulmonary hypertension Waltist CANDDATE DIAGNOSIS Sclenoderma restrictive Waltist CANDDATE DIAGNOSIS Sclenoderma restrictive Waltist CANDDATE DIAGNOSIS Scoondary pulmonary hypertension RECIPENT PROCEDURE TYPE Blatted Sequential Lung RECIPENT PROCEDURE TYPE File Dice Double Lung	At time of transplant	Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes	No No No No No No	No No No No No No	No No No No	No No No No No No	No No No No No No
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SECONDARY PI TX PROCEDUR TY Bilateral Seque TX PROCEDUR TY En-Bioc Double TX PROCEDUR TY LINE BOTH TY TX PROCEDUR TY LINE BOTH THE TX PROCEDUR TY LINE TX	Waltist CANDDATE DIAGNOSIS Scienderina mixed connective tissue disease Waltist CANDDATE DIAGNOSIS Scienderina mixed connective tissue disease Waltist CANDDATE DIAGNOSIS Scienderina polimonary hypertension Waltist CANDDATE DIAGNOSIS Scienderina restrictive Waltist CANDDATE DIAGNOSIS Scienderina restrictive Marilist CANDDATE DIAGNOSIS Scienderina pulmonary hypertension RECIPENT PROCEDURE TYPE Enterel Sequential Lung RECIPENT PROCEDURE TYPE Enterel Sequential Lung RECIPENT PROCEDURE TYPE Enterel Sequential Lung RECIPENT PROCEDURE TYPE Lote Both Left & Right	At time of transplant	Yes Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	No No No No No No No	No No No No No No No	No No No No No No	No N	No No No No No No
THORACIC DON SARCOPOSIS THORACIC DGN SCLERODERIMA THORACIC DGN SCLERODERIMA THORACIC DGN SCLERODERIMA THORACIC DGN SCLERODERIMA THORACIC DGN SECONDARY PT TX PROCEDUR TV Bildateral Sequi TX PROCEDUR TV En-Bloc Doubl TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TV Lobe, Left	Walist CANDDATE DIAGNOSIS Succidensis Walist CANDDATE DIAGNOSIS Selenderma mixed connective tissue disease Walist CANDDATE DIAGNOSIS Sclenderma primonary hypertension Walist CANDDATE DIAGNOSIS Sclenderma restrictive Walist CANDDATE DIAGNOSIS Sclenderma restrictive Walist CANDDATE DIAGNOSIS Sclenderma restrictive Richard Procedure TYPE Cateval Sequential Long RICHARD PROCEDURE TYPE Call Coll Coulde Long RICHARD PROCEDURE TYPE Call Coll Coulde Long RICHARD PROCEDURE TYPE Lobe, Both Let & Right RICHARD PROCEDURE TYPE Lobe, Both Let & Right RICHARD PROCEDURE TYPE Lobe, Let	At time of transplant	Yes Yes Yes Yes Yes Yes Yes Yes	Yes	No No No No No No No	No No No No No No No No No No	No No No No No No	No N	No No No No No No No No
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SECONDARY, PI TX PROCEDUR TY Bilderal Segu TX PROCEDUR TY Lobe Both Left TX PROCEDUR TY Lobe RIght	Wastist CANDDATE DIAGNOSIS Scienderina mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scienderina mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scienderina pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scienderina restrictive Wastist CANDDATE DIAGNOSIS Scienderina restrictive Mastist CANDDATE DIAGNOSIS Scienderina restrictive RICHERIT PROCEDURE TYPE Batterial Sequential Lung RICHERIT PROCEDURE TYPE Bello Coulde Lung RICHERIT PROCEDURE TYPE Bello Coulde Lung RICHERIT PROCEDURE TYPE Lobe, Both Left & Right RICHERIT PROCEDURE TYPE Lobe, Left RICHERIT PROCEDURE TYPE Lobe, Left	At time of transplant	Yes Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	No No No No No No No	No No No No No No No	No No No No No No	No N	No No No No No No
THORACIC DON SARCODOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SECONDARY PI X PROCEDUR TV Briller Doubl TX PROCEDUR TV Briller Doubl TX PROCEDUR TV Briller Doubl TX PROCEDUR TV Lobe, Bible TX PROCEDUR TV Lobe, Bible TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Stope Lett Litt X PROCEDUR TV STOPE	Wallist CANDDATE DIAGNOSIS Succidensis Wallist CANDDATE DIAGNOSIS Schededima mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclendedima primonary hypertension Wallist CANDDATE DIAGNOSIS Sclendedima restrictive Wallist CANDDATE DIAGNOSIS Sclenderima restrictive Wallist CANDDATE DIAGNOSIS Sclenderima primonary hypertension RICCIPILIT PROCEDURE TYPE Endered Sequential Lung RICCIPILIT PROCEDURE TYPE Ender Diodublic lung RICCIPILIT PROCEDURE TYPE Ender Diodublic lung RICCIPILIT PROCEDURE TYPE Lobe, Both Left & Right RICCIPILIT PROCEDURE TYPE Lobe, Ide RICCIPILIT PROCEDURE TYPE Lobe, Right RICCIPILIT	At time of transplant	Yes Yes Yes Yes Yes Yes Yes Yes	Yes	No No No No No No No	No No No No No No No No No No	No No No No No No	No N	No No No No No No No No
THORACIC DON SARCODOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SECONDARY PI X PROCEDUR TV Briller Doubl TX PROCEDUR TV Briller Doubl TX PROCEDUR TV Briller Doubl TX PROCEDUR TV Lobe, Bible TX PROCEDUR TV Lobe, Bible TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Stope Lett Litt X PROCEDUR TV STOPE	Wastist CANDDATE DIAGNOSIS Sercidosis Wastist CANDDATE DIAGNOSIS Schederima mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Schederima pulmonary hypertension Wastist CANDDATE DIAGNOSIS Schederima pulmonary hypertension Wastist CANDDATE DIAGNOSIS Schederima restrictive Martist CANDDATE DIAGNOSIS Schederima restrictive Research Canddate Control of the Canddate	At time of transplant	Yes	Yes	No No No No No No No No No	No N	No No No No No No	No No No No No No No No No	No No No No No No No
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA HORACIC DON SCLERODERMA THORACIC DON SECONDARY PI X PROCEDUR TV Britisher Sequence TX PROCEDUR TV Enible Doubl TX PROCEDUR TV Lobe, Both Left TX PROCEDUR TV Lobe, Britisher TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Stripple Left Lut X PROCEDUR TV Stripple Left Lut X PROCEDUR TV Stripple Left Lut X PROCEDUR TV Stripple Right X PROCEDUR TV STRIPPLE RIGH	Wastist CANDDATE DIAGNOSIS Scienderina mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scienderina mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scienderina pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scienderina restrictive Wastist CANDDATE DIAGNOSIS Scienderina restrictive Mastist CANDDATE DIAGNOSIS Scienderina restrictive RICHERIT PROCEDURE TYPE Batterial Sequential Lung RICHERIT PROCEDURE TYPE Bello Coulde Lung RICHERIT PROCEDURE TYPE Bello Coulde Lung RICHERIT PROCEDURE TYPE Lobe, Both Left & Right RICHERIT PROCEDURE TYPE Lobe, Left RICHERIT PROCEDURE TYPE Lobe, Left	At time of transplant	Yes	Yes	No No No No No No No No No No No No No N	No N	No N	No N	No N
THORACIC DON SARCODOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SECONDARY PI X PROCEDUR TV Briller Doubl TX PROCEDUR TV Briller Doubl TX PROCEDUR TV Briller Doubl TX PROCEDUR TV Lobe, Bible TX PROCEDUR TV Lobe, Bible TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Stope Lett Litt X PROCEDUR TV STOPE	Wastist CANDDATE DIAGNOSIS Secoldosis Wastist CANDDATE DIAGNOSIS Secledosima mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scoendary pulmonary hypertension RECIPENT PROCEDURE TYPE Endocodary pulmonary hypertension RECIPENT PROCEDURE TYPE Telloc Double lung RECIPENT PROCEDURE TYPE To Fallo Chouble lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Left RECIPENT PROCEDURE TYPE Lobe, Right RECIPENT PROCEDURE TYPE Single Left Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Double	At time of transplant	Yes	Yes	No No No No No No No No No No	No N	No No No No No No No No No No	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCOURNOAPY, PI TX PROCEDUR TY En-Bloc Doubl TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Single Right Li TX PROCEDUR TY Single Right Li TX TYPE, Double TX TYPE Single	Wastist CANDDATE DIAGNOSIS Secretorisis Wastist CANDDATE DIAGNOSIS Scleroderma mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scleroderma restrictive Wastist CANDDATE DIAGNOSIS Scoondary pulmonary hypertension RECIPENT PROCEDURE TYPE Batteral Sequential Lung RECIPENT PROCEDURE TYPE Bello Double Lung RECIPENT PROCEDURE TYPE Bello Double Lung RECIPENT PROCEDURE TYPE Lobe, Italy RECIPENT PROCEDURE TYPE Lobe, Italy RECIPENT PROCEDURE TYPE Lobe, Right RECIPENT PROCEDURE TYPE Lobe, Right RECIPENT PROCEDURE TYPE Single Left Lung RECIPENT PROCEDURE TYPE Single Left Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT TO LOBE LUNG DOUBLE TYPE Single Left Lung LIVE OF TRANSPLANT TO RIGHT LUNG DOUBLE TYPE SINGle LIVE LUNG LUNG DOUBLE TYPE SINGLE LUNG LUNG DO	At time of transplant	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCOURNOAPY, PI TX PROCEDUR TY En-Bloc Doubl TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Single Right Li TX PROCEDUR TY Single Right Li TX TYPE, Double TX TYPE Single	Wastist CANDDATE DIAGNOSIS Secretorisis Wastist CANDDATE DIAGNOSIS Scleroderma mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Scleroderma restrictive Wastist CANDDATE DIAGNOSIS Scoondary pulmonary hypertension RECIPENT PROCEDURE TYPE Batteral Sequential Lung RECIPENT PROCEDURE TYPE Bello Double Lung RECIPENT PROCEDURE TYPE Bello Double Lung RECIPENT PROCEDURE TYPE Lobe, Italy RECIPENT PROCEDURE TYPE Lobe, Italy RECIPENT PROCEDURE TYPE Lobe, Right RECIPENT PROCEDURE TYPE Lobe, Right RECIPENT PROCEDURE TYPE Single Left Lung RECIPENT PROCEDURE TYPE Single Left Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT TO LOBE LUNG DOUBLE TYPE Single Left Lung LIVE OF TRANSPLANT TO RIGHT LUNG DOUBLE TYPE SINGle LIVE LUNG LUNG DOUBLE TYPE SINGLE LUNG LUNG DO	At time of transplant	Yes	Yes	No No No No No No No No No No No No No N	No N	No N	No N	No N
THORACIC DON SARCODOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SECONDARY PI X PROCEDUR TV Enlist Doubl TX PROCEDUR TV Enlist Doubl TX PROCEDUR TV Enlist Doubl TX PROCEDUR TV Lobe, Bight TX PROCEDUR TV Lobe, Bight TX PROCEDUR TV Lobe, Right TX PROCEDUR TV Single Fight Li TX PROCEDUR TV Single Left Lur X PROCEDUR TV Single Left Lur X PROCEDUR TV Single Fight Li TX TYPE Double GROUPMG initial Obstructive GROUPMG initial Pulmenary variet.	Waitist CANDDATE DIAGNOSIS Secondosis Waitist CANDDATE DIAGNOSIS Secondosis Waitist CANDDATE DIAGNOSIS Scleroderma primonary hypertension Waitist CANDDATE DIAGNOSIS Scleroderma primonary hypertension Waitist CANDDATE DIAGNOSIS Scleroderma restrictive Waitist CANDDATE DIAGNOSIS Scleroderma restrictive Waitist CANDDATE DIAGNOSIS Scondary pulmonary hypertension RECIPENT PROCEDURE TYPE Ende Coultie Lung RECIPENT PROCEDURE TYPE Ende Coultie Lung RECIPENT PROCEDURE TYPE Lobe, Roth Lung RECIPENT PROCEDURE TYPE Lobe, Roth RECIPENT PROCEDURE TYPE Lobe, Roth RECIPENT PROCEDURE TYPE Lobe, Roth RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLATT Coultie TYPE OF TRANSPLATT Single LUNE DIAGNOSIS GROUPING ON WLIGH THORACIC_DGNTCR_TGNTRR_DGN) Cystoc Fibresis LUNE DIAGNOSIS GROUPING ON WLIGH THORACIC_DGNTCR_TGNTRR_DGN) Obstructive	At time of transplant Waldist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA THORACIC DGN SCLERODERMA THORACIC DGN SCLERODERMA HORACIC DGN SCLERODERMA HORACIC DGN SECONDARY PI X. PROCEDUR TV. Bildered Segut X. PROCEDUR TV Lobe, Both Left TX. PROCEDUR TV Lobe, Left TX. PROCEDUR TV Lobe, Right TX. PROCEDUR TV Lobe, Right TX. PROCEDUR TV Lobe, Right TX. PROCEDUR TV Single Left Lun TX. PROCEDUR TV Single Right Li X. TYPE Double TX. TYPE. Double TX. TYPE. Single GROUPPIG initial Obstructive GROUPPIG initial Pulmonary vatics GROUPPIG initial Company valous	Waitist CANDDATE DIAGNOSIS Secoldosis Waitist CANDDATE DIAGNOSIS Secoldosis Waitist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Waitist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Waitist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension Waitist CANDDATE DIAGNOSIS Scondary pulmonary hypertension RECIPENT PROCEDURE TYPE Enscondary pulmonary hypertension RECIPENT PROCEDURE TYPE Ensic Double Lung RECIPENT PROCEDURE TYPE Lobe, Both Lut & Right RECIPENT PROCEDURE TYPE Lobe, Both Lut & Right RECIPENT PROCEDURE TYPE Lobe, Right RECIPENT PROCEDURE TYPE Single Let Lung RECIPENT PROCEDURE TYPE Single Ling TYPE OF TRANSPLANT Goods UNIT DIAGNOSIS GROUPING ON WIJON THORACIC_DGNTCR_TGNTRR_DGN) Cystic Fibrosis LUHL DIAGNOSIS GROUPING ON WIJON THORACIC_DGNTCR_TGNTRR_DGN) Cobstructive LUHL DIAGNOSIS GROUPING ON WIJON THORACIC_DGNTCR_TGNTRR_DGN) plostnuctive LUHL DIAGNOSIS GROUPING ON WIJON THORACIC_DGNTCR_TGNTRR_DGN) plostnuctive	At time of transplant	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCOUNDAY. PI TX PROCEDUR TY En-Bloc Doubl TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Single Left Lur TX PROCEDUR TY Single Left Lur TX PROCEDUR TY Single Left Lur TX PROCEDUR TY Single Right Li TX TYPE. Double TX TYPE Single GROUPING initial Obstructive GROUPING initial Obstructive GROUPING initial CF GROUPING initial CF GROUPING initial CR GROUPING initial CR GROUPING initial CF GROUPING initial CR GR GROUPING INITIAL CR GR	Waitist CANDDATE DIAGNOSIS Secondosis Waitist CANDDATE DIAGNOSIS Secondosis Waitist CANDDATE DIAGNOSIS Scleroderma primonary hypertension Waitist CANDDATE DIAGNOSIS Scleroderma primonary hypertension Waitist CANDDATE DIAGNOSIS Scleroderma restrictive Waitist CANDDATE DIAGNOSIS Scleroderma restrictive Waitist CANDDATE DIAGNOSIS Scondary pulmonary hypertension RECIPENT PROCEDURE TYPE Ende Coultie Lung RECIPENT PROCEDURE TYPE Ende Coultie Lung RECIPENT PROCEDURE TYPE Lobe, Roth Lung RECIPENT PROCEDURE TYPE Lobe, Roth RECIPENT PROCEDURE TYPE Lobe, Roth RECIPENT PROCEDURE TYPE Lobe, Roth RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLATT Coultie TYPE OF TRANSPLATT Single LUNE DIAGNOSIS GROUPING ON WLIGH THORACIC_DGNTCR_TGNTRR_DGN) Cystoc Fibresis LUNE DIAGNOSIS GROUPING ON WLIGH THORACIC_DGNTCR_TGNTRR_DGN) Obstructive	Al time of transplant Wallist Wallist Wallist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA TORACIC DON SCLERODERMA TY SPROCEDUR TY Enliste Doubt TX PROCEDUR TY Enlist Doubt TX PROCEDUR TY Lobe, Both Left TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Single Left Lut TX, PROCEDUR TY Single Left Lut TX, TYPE Double TX, TYPE Double TX, TYPE Single GROUPMG initial Obstructive GROUPMG initial Pulmonary vaict GROUPMG initial Pulmonary vaict GROUPMG initial CF GROUPMG initial CF GROUPMG initial CF GROUPMG Initial CF C CALC, METHOD initial Calc	Wastist CANDDATE DIAGNOSIS Secoldosis Wastist CANDDATE DIAGNOSIS Secoldosis Wastist CANDDATE DIAGNOSIS Selenderma mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Selenderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Selenderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Secondary pulmonary hypertension RECIPENT PROCEDURE TYPE Endoctor Secondary pulmonary hypertension RECIPENT PROCEDURE TYPE Tendic Double Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left RECIPENT PROCEDURE TYPE Senigle Left Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT South ReciPENT RECIPE	Al time of transplant Wallist Wallist Wallist	Yes	Yes	No N	No	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA HORACIC DON SCLERODERIMA HORACIC DON SCOURS TY TX PROCEDUR TY TX PROCEDUR TY Lobe Both Left TX PROCEDUR TY Lobe Both Left TX PROCEDUR TY Lobe Left TX PROCEDUR TY Lobe Left TX PROCEDUR TY Lobe Right TX PROCEDUR TY TX PROCEDUR TY Single Left Lun TX PROCEDUR TY Single Right TX TYPE Double TX TYPE Double TX TYPE GROUPING Initial Obstructive GROUPING Initial Obstructive GROUPING Initial CP GROUPING Initial CP CR GROUPING Initial CP CR	Waitist CANDDATE DIAGNOSIS Succidens mixed connective tissue disease Waitist CANDDATE DIAGNOSIS Schededisma mixed connective tissue disease Waitist CANDDATE DIAGNOSIS Schededisma primonary hypertension Waitist CANDDATE DIAGNOSIS Schededisma restrictive Waitist CANDDATE DIAGNOSIS Schededisma restrictive Waitist CANDDATE DIAGNOSIS Secondary pulmonary hypertension RECEPTENT PROCEDURE TYPE Lobe Coulte Lung RECEPTENT PROCEDURE TYPE Lobe (Both Left & Right RECEPTENT PROCEDURE TYPE Lobe, Right RECEPTENT PROCEDURE TYPE Single Right Lung TYPE OF TRAINSPLANT Double TYPE OF TRAINSPLANT Gould UNITED CONTROL OF TRAINSPLANT Single LUHE, DIAGNOSIS GROUPPING ON WLIGHT THORACIC, DIANTER, TONTRIR, DGN) Cystor Fibrosis LUHE, DIAGNOSIS GROUPPING ON WLIGH THORACIC, DIANTER, TONTRIR, DGN) Polemonary Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGH THORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGH THORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGH THORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGH THORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGH THORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGHT HORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGHT HORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGHT HORACIC, DIANTER, TONTRIR, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGHT HORACIC, DIANTER, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGHT HORACIC, DIANTER, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGHT HORACIC, DIANTER, DGN) Performany Vascular LUHE, DIAGNOSIS GROUPPING ON WLIGHT HORACIC, DIANTER, DGN) PERFORMANT PERFORMANT PERFORMANT PERFORMANT PERFORMANT PERFORMANT PERFORMANT PERFORMANT PERFORMANT P	As time of transplant Washist Washist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA THORACIC DON SCLERODERMA HORACIC DON SCLERODERMA HORACIC DON SCLERODERMA THORACIC DON SCLERODERMA TO SECONDARY PI X PROCEDUR TY Enliber DON X PROCEDUR TY Lobe, Both Left TX, PROCEDUR TY Lobe, Left TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Single Left Lun TX, PROCEDUR TY Single Right Li X PROCEDUR TY Single Right Li X PROCEDUR TY Single Right Li X TYPE Double TX, TYPE Single GROUPMG initial Obstructive GROUPMG initial Pulmonary vatics GROUPMG initial Charteria GROUPMG initial Restrictive O2 CALC, METHOD initial Calc O2 CALC METHOD initial Calc O2 CALC METHOD initial Calc GROUPMG GROUPMG ODSTRUCTURE GROUPMG GROUPMG Initial Calc O2 CALC METHOD initial Calc O2 CALC METHOD initial Calc	Wastist CANDDATE DIAGNOSIS Secondorsis Wastist CANDDATE DIAGNOSIS Secondorsis Wastist CANDDATE DIAGNOSIS Schenderma pulmonary hypertension RECIPENT PROCEDURE TYPE Endocode Diagnosis RECIPENT PROCEDURE TYPE Tendic Double lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both RECIPENT PROCEDURE TYPE Lobe, Right RECIPENT PROCEDURE TYPE Single Left Lung RECIPENT PROCEDURE TYPE Lobe, Right Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Single LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DONTOR TONTRIR DON) Obstructive LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DONTOR TONTRIR DON) Pulmonary Vascular LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DONTOR TONTRIR DON) Pulmonary Vascular LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DONTOR TONTRIR DON) Partnersely C, CALC, METHOD whether calculated at start of wastist LUHL DIAGNOSIS GROUPING ON WILLON THORACIC DONTOR TONTRIR DON) Cystic Fibrosis UNITED STATES OR CONTRIBUTED ON TONTRIBUTE DON'S CALLOR METHOD Whether calculated at start of wastist LUHL DIAGNOSIS GROUPING ON WILLON THORACIC DONTOR TONTRIR DON'S Cystic Fibrosis	As time of transplant Usacitist Usacitist Washist Washist Washist Washist Washist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA HORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA TO SECONDAY PI TX PROCEDUR TY LOBE, Both Lef TX PROCEDUR TY LOBE, Both Lef TX PROCEDUR TY LOBE, Both Lef TX PROCEDUR TY LOBE, Both TX PROCEDUR TY Single Left Lur TX PROCEDUR TY Single Right Lef TX PROCEDUR TY Single Right Lef TX PROCEDUR TY Single Right Lef TX TYPE Double TX TYPE Double TX TYPE Single GROUPING initial Pulmonary varict GROUPING initial Pulmonary varict GROUPING initial Cestrictive Cy CALC METHOD initial Read D GROUPING end Chestrictive	Waitist CANDDATE DIAGNOSIS Secologism invectorenctive tissue disease Waitist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension RECIPENT PROCEDURE TYPE Extend Sequential Lung RECIPENT PROCEDURE TYPE Lobe, Both Lut & Right RECIPENT PROCEDURE TYPE Lobe, Both Lut & Right RECIPENT PROCEDURE TYPE Lobe, Both RECIPENT PROCEDURE TYPE Songle Let Lung RECIPENT PROCEDURE TYPE Songle Right Lung TYPE OF TRANSPLANT Goods UNITED AND AND AND AND AND AND AND AND AND AN	As time of transplant Washist Washist Washist Washist Washist Washist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA THORACIC DON SECOMONAY PI X PROCEDUR TY Enlist Doubl X PROCEDUR TY Enlist Doubl X PROCEDUR TY Lobe, Bight X PROCEDUR TY Lobe, Bight X PROCEDUR TY Lobe, Right IX PROCEDUR TY Single Right IX TYPE Double TX TYPE Double TX TYPE Double GROUPING initial Pulmonary vancu GROUPING initial Pulmonary vancu GROUPING initial Restrictive O2 CALC METHOD initial Calc O2 CALC METHOD initial Calc GROUPING end Obstructive GROUPING end Obstructive GROUPING end Obstructive O2 CALC METHOD initial Calc ORCUPING end Obstructive GROUPING end Obstructive GROUPING end OPSTRUCTIVE GROUPING EN	Wallist CANDDATE DIAGNOSIS Secoldorian mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Seclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma restrictive Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension RICOPENT PROCEDURE TYPE Encountry pulmonary hypertension RICOPENT PROCEDURE TYPE Encountry pulmonary hypertension RICOPENT PROCEDURE TYPE Encountry pulmonary hypertension RICOPENT PROCEDURE TYPE Lobe, Both Left & Right RICOPENT PROCEDURE TYPE Lobe, Both Left Lung RICOPENT PROCEDURE TYPE Lobe, Both Left Lung RICOPENT PROCEDURE TYPE Lobe, Right RICOPENT PROCEDURE TYPE Lobe, Right RICOPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Single LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DGNTCR_TGNTRR_DGN) Cystoc Fibrosis LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DGNTCR_TGNTRR_DGN) Deteructive LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DGNTCR_TGNTRR_DGN) Pulmonary Viscolar LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DGNTCR_TGNTRR_DGN) Pulmonary Viscolar LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DGNTCR_TGNTRR_DGN) Cystoc Fibrosis LUNE DIAGNOSIS GROUPING ON WLON THORACIC_DGNTCR_TGNTRR_DGN) Obstructive	As time of transplant	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TO SECONDARY PI TX PROCEDUR TY LOBE, Both Left TX PROCEDUR TY Lobe, Both Left TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Lobe, Right TX PROCEDUR TY Single Left Lun TX PROCEDUR TY Single Right Li TX PROCEDUR TY Single Right Li TX PROCEDUR TY Single Right Li TX TYPE Double TX TYPE Double TX TYPE Single GROUPING initial Obstructive GROUPING initial Obstructive GROUPING initial Pulmonary vascul GROUPING Initial Restrictive OZ CALC METHOD initial Calc OZ CALC METHOD initial Read D GROUPING and Pulmonary vascul GROUPING and Restrictive	Waitist CANDDATE DIAGNOSIS Secologism mixed connective tissue disease Waitist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension RECIPENT PROCEDURE TYPE Extends Secondary pulmonary hypertension RECIPENT PROCEDURE TYPE Tensic Double Lung RECIPENT PROCEDURE TYPE Tensic Double Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Left RECIPENT PROCEDURE TYPE Sengle Left Lung TYPE OF TRANSPLANT Goods LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Cyster Fibrosis LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Detanctive LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Detanctive LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Restrictive QC, CALC, METHOD whether calcided at start of waitist LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Cyster Fibrosis LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Cyster Fibrosis LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Cyster Fibrosis LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Pythoracity Vascular LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Pythoracity Vascular LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Pythoracity Vascular LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Pythoracity Vascular LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Pythoracity Vascular LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Pythoracity Vascular LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DGN/TCR, TGN/TRR, DGN) Pythoracity Vascular LUNH, DIAGNOSIS GROU	As time of transplant Walling Washist Washist Washist Washist Washist Washist Washist Washist Washist	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA TORACIC DON SCLERODERMA TORACIC DON SCOUNTY TX PROCEDUR TY Enlist Count TX PROCEDUR TY Lobe, Both Let TX, PROCEDUR TY Lobe, Both Let TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Single Right Let TX, TYPE Double TX, TYPE Double TX, TYPE Double GROUPMG initial Pulmonary vascul GROUPMG initial Pulmonary vascul GROUPMG initial Restrictive O2 CALC METHOD initial Calc O2 CALC METHOD initial Calc GROUPMG end Obstructive GROUPMG end CFI	Wallist CANDDATE DIAGNOSIS Secologism mixed connective tissue disease  Wallist CANDDATE DIAGNOSIS Scleederma mixed connective tissue disease  Wallist CANDDATE DIAGNOSIS Scleederma pulmonary hypertension  Wallist CANDDATE DIAGNOSIS Scleederma pulmonary hypertension  Wallist CANDDATE DIAGNOSIS Scleederma pulmonary hypertension  RICOPENT PROCEDURE TYPE External Sequential Lung  RICOPENT PROCEDURE TYPE External Sequential Lung  RICOPENT PROCEDURE TYPE External Sequential Lung  RICOPENT PROCEDURE TYPE Lobe, Both Left & Right  RICOPENT PROCEDURE TYPE Lobe, Both Left Lung  RICOPENT PROCEDURE TYPE Lobe, Both Left Lung  RICOPENT PROCEDURE TYPE Lobe, Island  RICOPENT PROCEDURE TYPE Lobe, Island  RICOPENT PROCEDURE TYPE Single Right Lung  TYPE OF TRANSPLANT Double  TYPE OF TRANSPLANT Single  LUNH, DIAGNOSIS GROUPING ON WL(ON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis  LUNH, DIAGNOSIS GROUPING ON WL(ON THORACIC_DONTCR_TGNTRR_DGN) Deterricate  ULHA DIAGNOSIS GROUPING ON WL(ON THORACIC_DONTCR_TGNTRR_DGN) Pulmonary Viscolar  LUNH, DIAGNOSIS GROUPING ON WL(ON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis  LUNH, DIAGNOSIS GROUPING ON WL(ON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fi	As time of transplant Washist	Yes	Yes	No N	No N	1 Mo	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA HORACIC DON SCLERODERIMA HORACIC DON SCLERODERIMA HORACIC DON SCLERODERIMA TO SCHEROLE THO SCHEROLE THO SCHEROLE TO SCH	Waitist CANDDATE DIAGNOSIS Secologism mixed connective tissue disease Waitist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension RECIPENT PROCEDURE TYPE Extends Sequential Lung RECIPENT PROCEDURE TYPE Entile Diagnosis Continuing RECIPENT PROCEDURE TYPE Lobe, Both Lung RECIPENT PROCEDURE TYPE Lobe, Both Lung RECIPENT PROCEDURE TYPE Lobe, Both RECIPENT PROCEDURE TYPE Single Let Lung RECIPENT PROCEDURE TYPE Single Regit Lung LUNG DIAGNOSIS GROUPING ON WL(ON THORACIC_DGNTCR_TGNTRR_DGN) Cystic Fibrosis LUNE, DIAGNOSIS GROUPING ON WL(ON THORACIC_DGNTCR_TGNTRR_DGN) Construct LUNE, DIAGNOSIS GROUPING ON WL(ON THORACIC_DGNTCR_TGNTRR_DGN) Construct LUNE, DIAGNOSIS GROUPING ON WL(ON THORACIC_DGNTCR_TGNTRR_DGN) Cystic Fibrosis LUNE, DIAGNOSIS GROUPING ON WL(ON THORACIC_DGNTCR_TGNTRR_DGN) Construct LUNE, DIAGNOSIS GROUPING GNOW WL(ON THORACIC_DGNTCR_TGNTRR_DGN) Construct LUNE, DIAGNOSIS GROUPING GNOW WL(ON THORACIC_DGNTCR_TGNTRR_DGN) Construct LUNE, DIAGNOSIS GROU	As time of transplant Washist	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SECONDAY PI X PROCEDUR TY E-Bise Doubl X PROCEDUR TY E-Bise Doubl X PROCEDUR TY LObe, Bight TX PROCEDUR TY Lobe, Bight TX PROCEDUR TY Lobe, Bight TX PROCEDUR TY Single Right TX TYPE Double TX TYPE Double TX TYPE Double TX TYPE Double GROUPING initial Pulmonary vascul GROUPING initial Pulmonary vascul GROUPING on this Restrictive O2 CALC METHOD initial Restrictive GROUPING end Obstructive GROUPING end Districtive GROUPING end CF GROUPING end CREATER TYPE THOR TYPE THE TYPE THE TYPE TYPE THE TYPE THE TYPE	Wallist CANDDATE DIAGNOSIS Secondorian mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma primonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma primonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma primonary hypertension RICOPENT PROCEDURE TYPE Endered Responsible Lung RICOPENT PROCEDURE TYPE Ender Diagnosis Lung RICOPENT PROCEDURE TYPE Ender Diagnosis Lung RICOPENT PROCEDURE TYPE Lobe, Both Left & Right RICOPENT PROCEDURE TYPE Lobe, Both Left Lung RICOPENT PROCEDURE TYPE Lobe, Both Left Lung RICOPENT PROCEDURE TYPE Lobe, Island RICOPENT PROCEDURE TYPE Lobe, Island RICOPENT PROCEDURE TYPE Lobe, Island RICOPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Songle LUNH DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUNH DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Districtive LUNH DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at start of wallist UHL DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Patrictive LUNH DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUNH DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at end of wallist  LUNH DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at end of wallist  LUNH DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at end of wallist	As time of transplant Washist	Yes	Yes	No N	No N	1 Mo	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA HORACIC DON SCLERODERIMA THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCOLERODERIMA TORACIC DON SCOLERODERIMA TORACIC TY E-RIBBO SERVICE TX PROCEDUR TY Lobe, Both Left TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Single Right Li TX, PROCEDUR TY Single Right Li TX, PROCEDUR TY Single Right TX, TYPE Double TX, TYPE Double TX, TYPE Double GROUPING initial Definionary vascul GROUPING initial Pulmonary vascul GROUPING and Obstructive GROUPING and Obstructive GROUPING and Obstructive GROUPING and Obstructive GROUPING and Pulmonary vascul GROUPING and Restrictive GROUPING and Restrictive GROUPING and Restrictive GROUPING and Restrictive OZ CALC METHOD and Calc OC 2CALC METHOD and Read De COD year 1 CARDIOVASCULAR	Wastist CANDDATE DIAGNOSIS Secondorias mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension RECIPENT PROCEDURE TYPE Exposed pulmonary hypertension RECIPENT PROCEDURE TYPE fine Dice Double Lung RECIPENT PROCEDURE TYPE The fine Double Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Single Left Lung RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Single Right Lung LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Destructive LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Destructive LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Obstructive LUNH, DIAGNOSIS GROUPING ON WLION THORACIC DONTCR_TGNTRR_DGN) Obstructive LUNH, DIAGNOSIS GROUPING ON WLION T	As time of transplant Washist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA TO SCLERODERMA TO SCREEN THO SCR	Wallist CANDDATE DIAGNOSIS Secondorsis Wallist CANDDATE DIAGNOSIS Secondorsis Wallist CANDDATE DIAGNOSIS Selevederma primorary hypertension Wallist CANDDATE DIAGNOSIS Selevederma primorary hypertension Wallist CANDDATE DIAGNOSIS Selevederma primorary hypertension RECREATE DIAGNOSIS Selevederma restrictive Wallist CANDDATE DIAGNOSIS Selevederma restrictive RECREATE PROCEDURE TYPE Close Could be used to restrict the RECREATE PROCEDURE TYPE Close Could be used to restrict the RECREATE PROCEDURE TYPE Close Both Left & Right RECREATE PROCEDURE TYPE Lobe, Rom RECREATE PROCEDURE TYPE Single Right Lung TYPE OF TRAINSPLATT Double TYPE OF TRAINSPLATT Single LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Deterrictive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Deterrictive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Personal Visional LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at start of wallist LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Deterrictive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive CO_CALC_METHOD whether used device at end of wallist RECREATED THORACIA CALLES OF DEATH CREEREOVASCULAR at year 1 RECREATED TRAINSACY CAUSE OF DEATH CREEREOVASCULAR at year 1	As time of transplant Washist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA TO SCLERODERMA TO SCREEN THO SCR	Wallist CANDDATE DIAGNOSIS Secondorsis Wallist CANDDATE DIAGNOSIS Secondorsis Wallist CANDDATE DIAGNOSIS Selevederma primorary hypertension Wallist CANDDATE DIAGNOSIS Selevederma primorary hypertension Wallist CANDDATE DIAGNOSIS Selevederma primorary hypertension RECREATE DIAGNOSIS Selevederma restrictive Wallist CANDDATE DIAGNOSIS Selevederma restrictive RECREATE PROCEDURE TYPE Close Could be used to restrict the RECREATE PROCEDURE TYPE Close Could be used to restrict the RECREATE PROCEDURE TYPE Close Both Left & Right RECREATE PROCEDURE TYPE Lobe, Rom RECREATE PROCEDURE TYPE Single Right Lung TYPE OF TRAINSPLATT Double TYPE OF TRAINSPLATT Single LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Deterrictive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Deterrictive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Personal Visional LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at start of wallist LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Deterrictive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Restrictive CO_CALC_METHOD whether used device at end of wallist RECREATED THORACIA CALLES OF DEATH CREEREOVASCULAR at year 1 RECREATED TRAINSACY CAUSE OF DEATH CREEREOVASCULAR at year 1	As time of transplant Washist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TO PROCEDUR TY LOBE, Both LE TX PROCEDUR TY LOBE, Both TX PROCEDUR TY LOBE, Byth TX PROCEDUR TY Single Left Lux TX PROCEDUR TY Single Right Li TX PROCEDUR TY Single Right Li TX PROCEDUR TY Single Right Li TX TYPE Double TX TYPE Double TX TYPE Double GROUPING initial Pulmonary vascul GROUPING initial Pulmonary vascul GROUPING initial Restrictive O2 CALC METHOD initial Read O2 CALC METHOD initial Calc O3 CALC O4 CALC METHOD initial Calc O5 CALC	Wastist CANDDATE DIAGNOSIS Secondorias mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension RECIPENT PROCEDURE TYPE Exposed pulmonary hypertension RECIPENT PROCEDURE TYPE fine Dice Double Lung RECIPENT PROCEDURE TYPE The fine Double Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Single Left Lung RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Single Right Lung LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Destructive LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Destructive LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH, DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DGN) Obstructive LUNH, DIAGNOSIS GROUPING ON WLION THORACIC DONTCR_TGNTRR_DGN) Obstructive LUNH, DIAGNOSIS GROUPING ON WLION T	Al time of transplant	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TO SECONDATE THOROMET THOROMET THOROMET THOROMET THOROMET THOROMET THE SECONDATE THE SECOND	Wastist CANDDATE DIAGNOSIS Secondorias mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Schenderma pulmonary hypertension RECIPENT PROCEDURE TYPE Escendery pulmonary hypertension RECIPENT PROCEDURE TYPE The Files Couble Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left RECIPENT PROCEDURE TYPE Sengle Left Lung TYPE OF TRANSPLANT Couble TYPE OF TRANSPLANT Couble TYPE OF TRANSPLANT South LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Obstructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Restrictive QC, CALC, METHOD whether calculated at start of wastist LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Cystic Fibrosis LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Cystic Fibrosis LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Restrictive QC, CALC, METHOD whether calculated at start of wastist LUNE, DIAGNOSIS GROUPING ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive LUNE, DIAGNOSIS GROUPING ON DIAGNOSIS ON WILON THORACIC, DONTOR, TONTRR, DON) Distructive	As time of transplant Washist Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SCCURTOR TO SCREEN THOR SCREEN T	Wallist CANDDATE DIAGNOSIS Succidens an invited connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension RUMBIST CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension RECIPERT PROCEDURE TYPE Ender Diagnosis pulmonary hypertension RECIPERT PROCEDURE TYPE Ender Diagnosis pulmonary hypertension RECIPERT PROCEDURE TYPE Ender Diagnosis pulmonary hypertension RECIPERT PROCEDURE TYPE Lobe, Both Left Lung RECIPERT PROCEDURE TYPE Lobe, Both Left Lung RECIPERT PROCEDURE TYPE Lobe, Both Lung TYPE OF TRANSPLANT Single RECIPERT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Single LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Obstructive LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Obstructive LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Pelmonary Viscolar LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Pelmonary Viscolar LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Obstructive LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Pelmonary Viscolar LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Pelmonary Viscolar LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Pelmonary Viscolar LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Pelmonary Viscolar LUNH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Restrictive ULH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Restrictive ULH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Restrictive ULH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Restrictive ULH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Restrictive ULH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Restrictive ULH, DIAGNOSIS GROUPING ON WILON THORACIC, DONTCR, TGNTRR, DGN) Restrictive ULH, DIAGNOSIS GROUPING ON WILON THORA	As time of transplant Washist	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TO SERVICE TX PROCEDUR TY Lobe, Both Left TX, PROCEDUR TY Lobe, Both Left TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Single Left Lur TX, PROCEDUR TY Single Left Lur TX, PROCEDUR TY Single Right Lu TX, PROCEDUR TY Single Right Lu TX, TYPE, Single GROUPING initial Obstructive GROUPING initial Putmonary varict GROUPING initial Putmonary varict GROUPING initial Restrictive O2 CALC METHOD initial Red GROUPING end Obstructive GROUPING end Obstructive GROUPING end CF GROUPING end CF GROUPING end CF GROUPING end CF GROUPING end Restrictive O2 CALC METHOD end Calc O2 CALC METHOD end Calc O2 CALC METHOD end Calc O2 CALC METHOD end Read De COD year 1 COD MULTIORGAN COD year 1 COD DULINI COD year 1 COD DULINI COD year 1 COD PULINI COD year 1 COD PULINI COD year 1 COD FULINI CRAFT FAILURE GR.	Wallist CANDDATE DIAGNOSIS Secologism invoice connective tissue disease  Wallist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension  RICCIPIENT PROCEDURE TYPE Endered Sequential Lung  RICCIPIENT PROCEDURE TYPE Endered Sequential Lung  RICCIPIENT PROCEDURE TYPE Lobe, Both Luft & Right  RICCIPIENT PROCEDURE TYPE Lobe, Both Luft & Right  RICCIPIENT PROCEDURE TYPE Lobe, Both Luft & Right  RICCIPIENT PROCEDURE TYPE Lobe, Both Lung  RICCIPIENT PROCEDURE TYPE Lobe, Island  RICCIPIENT PROCEDURE TYPE Lobe, Island  RICCIPIENT PROCEDURE TYPE Single Right Lung  RICCIPIENT PROCEDURE TYPE Single Right Lung  TYPE OF TRANSPLANT Double  TYPE OF TRANSPLANT Double  TYPE OF TRANSPLANT Single  LUHL DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DON) Cystic Fibrosis  LUHL DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DON) Districtive  LUHL DIAGNOSIS GROUPING ON WLION THORACIC_DONTCR_TGNTRR_DON) Cystic Fibrosis  LUHL D	As time of transplant Washist	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERMA THORACIC DON SECONDAY PI X PROCEDUR TY GRIBLE DON TX PROCEDUR TY Enlist DON TX PROCEDUR TY Lobe, Both Left X PROCEDUR TY Lobe, Both Left X PROCEDUR TY Lobe, Right TX PROCEDUR TY Single Right Left TX PROCEDUR TY Single Right Left TX PROCEDUR TY Single Right TX PROCEDUR TY Single Right TX PROCEDUR TY Single Right TX TYPE Double TX TYPE Double TX TYPE Double GROUPING initial Pulmonary varice GROUPING initial Pulmonary varice GROUPING initial Restrictive O2 CALC METHOD initial Calc TO UP WAS A CARDIOVASCULAR TO DEAT TO CALC METHOD INITIAL TO COD YEAR TO COD GRAFT FABLURE TO DEAT TABLURE TO THE TRAILER TO THE TRAIL TRAIL TRAIL TRAIL TRAIL TRAIL TRAIL TRAIL TRAIL TO DEAT TABLURE TO THE TRAIL TRAIL TRAIL TRAIL TRAIL TRAIL TRAIL TO THE TRAIL TRAIL TRAIL TRAIL TRAIL TO THE TRAIL TRAIL TRAIL TRAIL TO THE TRAIL TRAIL TRAIL TO THE TRAIL TRAIL TO THE TRAIL T	Wallist CANDDATE DIAGNOSIS Secondoria Wallist CANDDATE DIAGNOSIS Secondoria Wallist CANDDATE DIAGNOSIS Sclendorma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclendorma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclendorma restrictive Wallist CANDDATE DIAGNOSIS Sclendorma restrictive Wallist CANDDATE DIAGNOSIS Sclendorma restrictive Robert PROCEDURE TYPE Call Could be used to restrict the Robert Robert Procedure of the Robert Rober	As time of transplant Washist Wash	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TO PROCEDUR TY LOBE BOTH TX PROCEDUR TY LOBE BOTH TX PROCEDUR TY LOBE BOTH TX PROCEDUR TY LOBE Right TX PROCEDUR TY LOBE Right TX PROCEDUR TY Single Refunt TX PROCEDUR TY Single Right TX TYPE Double TX TYPE Double TX TYPE Double TX TYPE DOUBLE GROUPING initial Pulmonany valice GROUPING initial Pulmonany valice GROUPING initial Pulmonany valice GROUPING and Obstructive GROUPING CORP TY CARBON OBSTRUCTIVE TO CORP TY CARBON OBSTRUCTIVE TO CORP TY	Wallist CANDDATE DIAGNOSIS Succidensia mixed connective tissue disease  Wallist CANDDATE DIAGNOSIS Scleenderma pulmonary hypertension  RICCIPIENT PROCEDURE TYPE Endered Sequential Lung  RICCIPIENT PROCEDURE TYPE Endered Sequential Lung  RICCIPIENT PROCEDURE TYPE Ender Diagnosis Lung  RICCIPIENT PROCEDURE TYPE Lobe, Both Left & Right  RICCIPIENT PROCEDURE TYPE Lobe, Both Left & Right  RICCIPIENT PROCEDURE TYPE Lobe, Island  RICCIPIENT PROCEDURE TYPE Single Right Lung  TYPE OF TRANSPLANT Double  TYPE OF TRANSPLANT Single  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DIANTER, TENTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DIANTER, TONTRE, DGN) Obstructive  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DIANTER, TONTRE, DGN) Pulmonary Vascular  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC DIANTER, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN) Cystoc Fibrosis  LUHH DIAGNOSIS GROUPING ON WILLON THORACIC, DONTCR, TONTRE, DGN)	As time of transplant Washist	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SECONDARY PT X PROCEDUR TY GRIBLE COUNTY X PROCEDUR TY En Bits CountY X PROCEDUR TY Lobe, Bight X PROCEDUR TY Lobe, Right X PROCEDUR TY Lobe, Right X PROCEDUR TY Single Right Let TX, PROCEDUR TY Single Right Let TX, PROCEDUR TY Single Right X PROCEDUR TY Single Right X TYPE Double GROUPING initial Pulmonary varice GROUPING initial Pulmonary varice GROUPING initial Pulmonary Varice GROUPING end Pulmonary Varice GROUPING end Pulmonary Vasice GROUPING end Cost GROUPING end	Wallist CANDDATE DIAGNOSIS Secondaria Wallist CANDDATE DIAGNOSIS Secondaria Wallist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma perincipal Wallist CANDDATE DIAGNOSIS Secondary pulmonary hypertension RECEPTER PROCEDURE TYPE Lose of The Coulting RECEPTER PROCEDURE TYPE Lose Both Left Ling RECEPTER PROCEDURE TYPE Lose, Both RECEPTER PROCEDURE TYPE Single Right Ling RECEPTER PROCEDURE TYPE Single Left Ling LING LING RECEPTER TO LING RECEPTER LONG RECEPTER LON	As time of transplant Washist Follow-up	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SECONDAY PI TX PROCEDUR TY LOBE Both LE TX PROCEDUR TY LOBE Both LE TX PROCEDUR TY LOBE BOTH TX PROCEDUR TY LOBE Right TX PROCEDUR TY LOBE Right TX PROCEDUR TY Single Left LIN TYPE Double TX TYPE Double TX TYPE Double TX TYPE DOUBLE GROUPING initial Pulmonary vascus GROUPING initial Pulmonary vascus GROUPING initial Pulmonary vascus GROUPING Initial Pulmonary vascus GROUPING ENGLISHED INITIAL CAR TO CALC METHOD INITIAL CAR GROUPING ENGLISHED GROUPING ENGLISHED GROUPING ENGLISHED GROUPING ENGLISHED GROUPING ENGLISHED GROUPING ENGLISHED GROUPING COD SERVICE TO CALC METHOD ENGLISHED GROUPING COD SERVICE TO COD VIEW TO COD MULTIORACIUNA COD year 1 COP MULTIORACI COD year 1 GRAFT FABLURE GR COD year 1 GRAFT FABLURE FRE COD year 1 GRAFT FABLURE RE COD YEAR 1 GRAFT FABLURE CO	Wallist CANDDATE DIAGNOSIS Secondorius mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension RECIPENT PROCEDURE TYPE Endered Sequential Lung RECIPENT PROCEDURE TYPE Endered Sequential Lung RECIPENT PROCEDURE TYPE Ender Diagnosis (Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Iden RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Single LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Detrictive LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Pulmonary Vascular LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Pulmonary Vascular LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Poteriocine LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Poteriocine LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costicitive OZ_CALC_METHOD whether calculated at site of wallist LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Poteriocine LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costicitive OZ_CALC_METHOD whether calculated at and of wastist RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE REJECTION-CHRONIC at year 1 RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE REJECTION SEQUENT 1 RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE REJECTION SEQUENT 1 RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE	As time of transplant Washist Fallow-up Follow-up	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TO SCREEN TO SECONDAY TO SINGLE SECONDAY TO SECONDAY TO SECONDAY TO SECONDAY TO SECONDAY THOROUGH THO SECONDAY THOROUGH THO SECONDAY THE SEC	Wallist CANDDATE DIAGNOSIS Secondaria Wallist CANDDATE DIAGNOSIS Secondaria Wallist CANDDATE DIAGNOSIS Schenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Schenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Schenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Secondary pulmonary hypertension Wallist CANDDATE DIAGNOSIS Secondary pulmonary hypertension RECEPENT PROCEDURE TYPE To file Coulife Lung RECEPENT PROCEDURE TYPE To file Coulife Lung RECEPENT PROCEDURE TYPE To file Coulife Lung RECEPENT PROCEDURE TYPE To be, Royt RECEPENT PROCEDURE TYPE Single Royt Lung TYPE OF TRAINSPLANT Goulde TYPE OF TRAINSPLANT Goulde UNIT DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Dystre Fibrosis LUHE, DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Destructive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN Perstrictive LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN PERSTRICTIVE LUHE DIAGNOSIS GROUPING ON WIJON THORACIC DIAGNOST TONTRE DIAN PERSTRICTIVE LUHE DIAGNOSIS GROUPING ON WIJON	As time of transplant Washist Washist Washist Washist Washist Washist Washist Washist Washist Follow-up	Yes	Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SECONDATY PI X PROCEDUR TY LOBE, Both Left TX PROCEDUR TY LOBE, Both Left TX PROCEDUR TY LOBE, Both TX PROCEDUR TY LOBE, Both TX PROCEDUR TY Single Right Li X TYPE Double TX PROCEDUR TY Single Right Li X TYPE Double OROUPING initial Pulmonary vascul GROUPING on the THORACIC CALC METHOD initial Read Do GROUPING ON THE THORACIC GROUPING ON THE THORACIC GROUPING ON THE THORACIC COD year 1 CARDIOVASCULAR GROUPING COD YEAR 1 CARDIOVASCULAR COD year 1 CARDIOVASCULAR COD year 1 CARDIOVASCULAR COD year 1 COD MULTIORICAN COD YEAR 1 COO D MULTIORICAN COD YEAR 1 COO D MULTIORICAN COD YEAR 1 GRAFT FAILURE GR COD YEAR 1 GRAFT FAILURE GR COD YEAR 1 GRAFT FAILURE GR COD YEAR 1 GRAFT FAILURE THE COD YEAR 1 GRAFT	Wallist CANDDATE DIAGNOSIS Succidensia Mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension RECIPENT PROCEDURE TYPE End File Doublis Lung RECIPENT PROCEDURE TYPE Ends Doublis Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Island RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Songle LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Detructive LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Persocial LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Persocial LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at start of wallist OZ_CALC_METHOD whether calculated at start of wallist ULH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costrictive LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costrictive CC_CALC_METHOD whether used dence at and of wallist  RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE (RECECTION CHRONIC at ye	As time of transplant Washist Fallow-up Follow-up	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SECONDATY PI X PROCEDUR TY LOBE, Both Left TX PROCEDUR TY LOBE, Both Left TX PROCEDUR TY LOBE, Both TX PROCEDUR TY LOBE, Both TX PROCEDUR TY Single Right Li X TYPE Double TX PROCEDUR TY Single Right Li X TYPE Double OROUPING initial Pulmonary vascul GROUPING on the THORACIC CALC METHOD initial Read Do GROUPING ON THE THORACIC GROUPING ON THE THORACIC GROUPING ON THE THORACIC COD year 1 CARDIOVASCULAR GROUPING COD YEAR 1 CARDIOVASCULAR COD year 1 CARDIOVASCULAR COD year 1 CARDIOVASCULAR COD year 1 COD MULTIORICAN COD YEAR 1 COO D MULTIORICAN COD YEAR 1 COO D MULTIORICAN COD YEAR 1 GRAFT FAILURE GR COD YEAR 1 GRAFT FAILURE GR COD YEAR 1 GRAFT FAILURE GR COD YEAR 1 GRAFT FAILURE THE COD YEAR 1 GRAFT	Wallist CANDDATE DIAGNOSIS Secondorius mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension RECIPENT PROCEDURE TYPE Endered Sequential Lung RECIPENT PROCEDURE TYPE Endered Sequential Lung RECIPENT PROCEDURE TYPE Ender Diagnosis (Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Iden RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Double TYPE OF TRANSPLANT Single LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Detrictive LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Pulmonary Vascular LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Pulmonary Vascular LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Poteriocine LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Poteriocine LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costicitive OZ_CALC_METHOD whether calculated at site of wallist LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Poteriocine LUNH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costicitive OZ_CALC_METHOD whether calculated at and of wastist RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE REJECTION-CHRONIC at year 1 RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE REJECTION SEQUENT 1 RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE REJECTION SEQUENT 1 RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE	As time of transplant Washist Washist Washist Washist Washist Washist Washist Washist Washist Follow-up	Yes	Yes	No N	No N	No	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC TY Lobe, Both Left TX, PROCEDUR TY Single Left TX, PROCEDUR TY Single Right LI TX, TYPE, Single GROUPING initial Obstructive GROUPING initial Definitionary vanct GROUPING initial Restrictive C2 CALC METHOD initial Read D GROUPING and Obstructive GROUPING end Costructive GROUPING end Pulmonary vancti GROUPING end Restrictive C2 CALC METHOD end Calc C2 CALC METHOD end Calc C3 CALC METHOD end Calc C3 CALC METHOD end Read De COD year 1 COD PULM COD year 1 COD FULM C3 FRAFT FABLURE FRE COD year 1 GRAFT FABLURE FRE COD year 1 GRAFT FABLURE RE COD YEAR 1 GRAFT FABLURE COD YEAR 1 GRAF	Wallist CANDDATE DIAGNOSIS Succidensia Mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wallist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension RECIPENT PROCEDURE TYPE End File Doublis Lung RECIPENT PROCEDURE TYPE Ends Doublis Lung RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Both Left & Right RECIPENT PROCEDURE TYPE Lobe, Island RECIPENT PROCEDURE TYPE Single Right Lung TYPE OF TRANSPLANT Songle LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Cystoc Fibrosis LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Detructive LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Persocial LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Persocial LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Restrictive OZ_CALC_METHOD whether calculated at start of wallist OZ_CALC_METHOD whether calculated at start of wallist ULH DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costrictive LUHL DIAGNOSIS GROUPING ON WLON THORACIC_DONTCR_TGNTRR_DGN) Costrictive CC_CALC_METHOD whether used dence at and of wallist  RECIPENT PRIMARY CAUSE OF DEATH GRAPT FAILURE (RECECTION CHRONIC at ye	As time of transplant Washist Washis	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	No N	No N	No N	No N	No
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SECONDAY PI X PROCEDUR TY GENEROLE TY SERVICE TO SERVICE TY SERVICE TY SERVICE TY SERVICE TY SERVICE TY SERVICE TY SINGLE TY SINCLE TY	Wastist CANDDATE DIAGNOSIS Secondorias mixed connective tissue disease  Wastist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension  RICCIPIENT PROCEDURE TYPE Endocreal Sequential Lung  RICCIPIENT PROCEDURE TYPE Indice Double Lung  RICCIPIENT PROCEDURE TYPE Indice Double Lung  RICCIPIENT PROCEDURE TYPE Lobe, Both Luft & Right  RICCIPIENT PROCEDURE TYPE Lobe, Indi  RICCIPIENT PROCEDURE TYPE Lobe, Indi  RICCIPIENT PROCEDURE TYPE Single Left Lung  RICCIPIENT PROMONIES GROUPING ON WILLON THORACIC_DONTCR_TGNTRR_DON) Cystic Fibrosis  LUNH DIAGNOSIS GROUPING ON WILLON THORACIC_DONTCR_TGNTRR_DON) Cystic Fibrosis  LUNH DIAGNOSIS GROUPING ON WILLON THORACIC_DONTCR_TGNTRR_DON) Cystic Fibrosis  LUNH DIAGNOSIS GROUPING ON WILLON THORACIC_DONTCR_TGNTRR_DON) Restrictive  1 LUNH DIAGNOSIS GROUPING ON WILLON THORACIC_DONTCR_TGNTRR_DON) R	As time of transplant Washist Washist Washist Washist Washist Washist Washist Washist Washist Follow-up	Yes	Yes	No N	No N	No	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TORACIC DON SCLERODERIMA TO PROCEDUR TY Lobe, Both Left TX, PROCEDUR TY Lobe, Both Left TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Lobe, Right TX, PROCEDUR TY Single Right TX, PROCEDUR TY Single Right TX, TYPE, Single GROUPING initial Definition TX, TYPE, Single GROUPING initial Pulmonary valice GROUPING initial Pulmonary valice GROUPING and Obstructive GROUPING COPENIES GROUPING GROUPING COPENIES GROUPING GROUPING COPENIES GROUPING GROUPING COPENIES GROUPING	Wallist CANDDATE DIAGNOSIS Secondomia invoice connective tissue disease  Wallist CANDDATE DIAGNOSIS Scleroderma pulmonary hypertension  RICCIPIENT PROCEDURE TYPE Endered Sequential Lung  RICCIPIENT PROCEDURE TYPE Endered Sequential Lung  RICCIPIENT PROCEDURE TYPE Endered Sequential Lung  RICCIPIENT PROCEDURE TYPE Lobe, Both Left & Right  RICCIPIENT PROCEDURE TYPE Lobe, Both Left & Right  RICCIPIENT PROCEDURE TYPE Lobe, Isle  RICCIPIENT PROCEDURE TYPE Single Right Lung  LUNH DIAGNOSIS GROUPING ON WLION THORACIC DIATRE TIGNITIRE DONI Distinctive  LUNH DIAGNOSIS GROUPING ON WLION THORACIC DIATRE TIGNITIRE DONI Pulmonary Vascular  LUNH DIAGNOSIS GROUPING ON WLION THORACIC DIATRE TIGNITIRE DONI Pulmonary Vascular  LUNH DIAGNOSIS GROUPING ON WLION THORACIC DIATRE TIGNITIRE DONI Restrictive  OZ CALC, METHOD whether used desce at start of wallist  OZ CALC, METHOD whether used desce at start of washist  OZ CALC, METHOD whether used desce at start of washist  OZ CALC, METHOD whether used desce at and of washist  OZ CALC, METHOD whether used desce at and of washi	As time of transplant Washist Washist Washist Washist Washist Washist Washist Washist Washist Follow-up	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes	Mo	No N	No N	No N	No N
THORACIC DON SARCOIDOSIS THORACIC DON SCLERODERIMA THORACIC DON SECONDAY PI X PROCEDUR TY GENEROLE TY SERVICE TO SERVICE TY SERVICE TY SERVICE TY SERVICE TY SERVICE TY SERVICE TY SINGLE TY SINCLE TY	Wastist CANDDATE DIAGNOSIS Secondoma mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Sclenderma mixed connective tissue disease Wastist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Wastist CANDDATE DIAGNOSIS Sclenderma pulmonary hypertension Ricciperty Procedure TYPE Diagnosis scendery pulmonary hypertension Ricciperty Procedure TYPE Lobe, Both Left Ling Ricciperty Procedure TYPE Lobe, Right Ling TYPE OF TRANSPLANT Single LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Cystic Fibrosis LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Districtive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Districtive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN) Pulmonary Viscolar LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN Destructive LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DONTCR_TGNTRR_DGN Cystic Fibrosis LUHE DIAGNOSIS GROUPING ON WILON THORACIC_DON	As time of transplant Washist Wa	Yes	Yes	No N	No N	No	No N	No N

COD_year_1_SUICIDE	RECIPIENT PRIMARY CAUSE OF DEATH SUICIDE at year 1	Follow-up	Yes	Yes	No	No	No	No	No
COD year 3 CARDIOVASCULAR	RECIPIENT PRIMARY CAUSE OF DEATH CARDIOVASCULAR at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD year 3 CEREBROVASCULAT	RECIPIENT PRIMARY CAUSE OF DEATH CEREBROVASCULAR at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD year 3 COD GRAFT FAILUR	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION-CHRONIC at year	ear 3 Follow-up	Yes	Yes	No	No	No	No	No
COD year 3 COD MULTIORGAN	RECIPIENT PRIMARY CAUSE OF DEATH MULTIORGAN at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD_year_3_COD_PULM	RECIPIENT PRIMARY CAUSE OF DEATH PULMONARY at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD year 3 COVID 19	RECIPIENT PRIMARY CAUSE OF DEATH COVID-1 at year 3	Follow-up	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: GRAFT INFECTION at year	The state of the s	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: NON, SPECIFIC at year 3	Follow-up	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE. PRIMARY FAILURE at year	- International Contract Contr			No				
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: PRIMARY FAILURE IS YOUR RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: RECURRENT DISEASE IS YOUR RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: RECURRENT DISEASE IS YOUR		Yes	Yes		No No	No No	No	No
							1000	No	No
COD year 3 GRAFT FAILURE: RE.	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE. REJECTION-ACUTE at year		Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION-HYPERACUTE	as year o	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: TECHNICAL at year 3	Fallow-up	Yes	Yes	No	No	No	No	No
COD_year_3_HEMORRHAGE	RECIPIENT PRIMARY CAUSE OF DEATH HEMORRHAGE at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD_year_3_INFECTION	RECIPIENT PRIMARY CAUSE OF DEATH IMMUNOSUPPRESSIVE at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD_year_3_MALIG	RECIPIENT PRIMARY CAUSE OF DEATH INFECTION at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD year 3 MULTIORGAN	RECIPIENT PRIMARY CAUSE OF DEATH MALIGNANCY at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD_year_3_OTHER	RECIPIENT PRIMARY CAUSE OF DEATH OTHER at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD year 3 SUICIDE	RECIPIENT PRIMARY CAUSE OF DEATH SUICIDE at year 3	Follow-up	Yes	Yes	No	No	No	No	No
COD WARE E CARRIOVASCULIAR	RECIPIENT PRIMARY CAUSE OF DEATH CARDIOVASCULAR at year 5	Follow-up	Yes	Yes	No	No	No	No	No
COD year 5 CEREBROVASCULA	RECIPIENT PRIMARY CAUSE OF DEATH CEREBROVASCULAR at year 5	Follow-up	Yes	Yes	No	No	No	No	No
COD YES 5 COD CRAFT CALLER	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION-CHRONIC at year	ear 5 Follow-up			No				
	RECIPIENT PRIMARY CAUSE OF DEATH MULTIORGAN at year 5	Follow-up	Yes	Yes		No	No	No	No
COD year 5 COD MULTIORGAN	RECIPIENT PRIMARY CAUSE OF DEATH PULMONARY at year 5	Follow-up	Yes	Yes	No	No	No	No	No
COD_year_5_COD_PULM			Yes	Yes	No	No	No	No	No
COD_year_5_COVID_19	RECIPIENT PRIMARY CAUSE OF DEATH COVID-1 at year 5	Follow-up	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: GRAFT INFECTION at year 5		Yes	Yes	No	No	No	No	No
COD_year_5_GRAFT FAILURE: NO	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: NON_SPECIFIC at year 5	Follow-up	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: PRIMARY FAILURE at year		Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION-ACUTE at year	5 Follow-up	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY CAUSE OF DEATH GRAFT FAILURE: REJECTION HYPERACUTE		Yes	Yes	No	No	No	No	No
COD_year_5_HEMORRHAGE	RECIPIENT PRIMARY CAUSE OF DEATH HEMORRHAGE at year 5	Follow-up	Yes	Yes	No	No	No	No	No
COD_year_5_INFECTION	RECIPIENT PRIMARY CAUSE OF DEATH IMMUNOSUPPRESSIVE at year 5	Follow-up	Yes	Yes	No		No		
	RECIPIENT PRIMARY CAUSE OF DEATH INFECTION at year 5	Follow-up	Yes		No	No No	No	No	No.
COD_year_5_MALIG	RECIPIENT PRIMARY CAUSE OF DEATH MALIGNANCY at year 5	Follow-up	7.44	Yes	1100	110	1.00	No	100
COD_year_5_MULTIORGAN	RECIPIENT PRIMARY CAUSE OF DEATH MALIGNANCY at year 5 RECIPIENT PRIMARY CAUSE OF DEATH OTHER at year 5	Follow-up	Yes	Yes	No	No	No	No	No
COD_year_5_OTHER			Yes	Yes	No	No	No	No	No
COD_year_5_SUICIDE	RECIPIENT PRIMARY CAUSE OF DEATH SUICIDE at year 5	Follow-up	Yes	Yes	No	No	No	No	No
COD_CAD_DON_ANOXIA	DONOR CAUSE OF DEATH ANOXIA	At time of transplant	Yes	Yes	No	No	No	No	No
COD CAD DON CEREBROVASCI	DONOR CAUSE OF DEATH CEREBROVASCULAR/STROKE	At time of transplant	Yes	Yes	No	No	No	No	No
COD_CAD_DON_CNS TUMOR	DONOR CAUSE OF DEATH CNS TUMOR	At time of transplant	Yes	Yes	No	No	No	No	No
COD CAD DON HEAD TRAUMA	DONOR CAUSE OF DEATH HEAD TRAUMA	At time of transplant	Yes	Yes	No	No	No	No	No
COD CAD DON OTHER	DONOR CAUSE OF DEATH OTHER	At time of transplant	Yes	Yes	No	No	No	No	No
	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Alive at year 1	Follow-up			No		No		
PX_STAT_year_1_Alive	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Dead at year 1	Follow-up	Yes	Yes		No	1000	No	No
PX_STAT_year_1_Dead			Yes	Yes	No	No	No	No	No
PX_STAT_year_1_Retransplanted	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Retransplanted at year 1	Follow-up	Yes	Yes	No	No	No	No	No
PX_STAT_year_3_Alive	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Alive at year 3	Follow-up	Yes	Yes	No	No	No	No	No
PX_STAT_year_3_Dead	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Dead at year 3	Follow-up	Yes	Yes	No	No	No	No	No
PX_STAT_year_3_Retransplanted	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Retransplanted at year 3	Follow-up	Yes	Yes	No	No	No	No	No
PX_STAT_year_5_Alive	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Alive at year 5	Follow-up	Yes	Yes	No	No	No	No	No
PX_STAT_year_5_Dead	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Dead at year 5	Follow-up	Yes	Yes		No	No		No
PX_STAT_year_5_Retransplanted	RECIPIENT STATUS(Died, ReTX, Lost, Alive) Retransplanted at year 5	Follow-up	Yes	Yes		No.	No		No
		At time of transplant							
	TUNOS REGION WHERE TRANSPLANTED/LISTED REGION 1		Yes	Yes		Yes	Yes		Yes
REGION_1	UNOS REGION WHERE TRANSPLANTED/LISTED REGION 1	At time of transplant							
REGION_10	UNOS REGION WHERE TRANSPLANTED/LISTED REGION 10	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REGION_10 REGION_11	UNOS REGION WHERE TRANSPLANTED/LISTED REGION 10 UNOS REGION WHERE TRANSPLANTED/LISTED REGION 11	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REGION_10 REGION_11 REGION_2	UNOS REGION WHERE TRANSPLANTED/LISTED REGION 10 UNOS REGION WHERE TRANSPLANTED/LISTED REGION 11 UNOS REGION WHERE TRANSPLANTED/LISTED REGION 2	At time of transplant At time of transplant	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes
REGION 10 REGION 11 REGION 2 REGION 3	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3	At time of transplant At time of transplant At time of transplant	Yes	Yes	Yes Yes Yes	Yes Yes Yes	Yes	Yes Yes Yes	Yes
REGION_10 REGION_11 REGION_2	UNOS REGION WHERE TRANSPLANTED/LISTED REGION 10 UNOS REGION WHERE TRANSPLANTED/LISTED REGION 11 UNOS REGION WHERE TRANSPLANTED/LISTED REGION 2	At time of transplant	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes
REGION 10 REGION 11 REGION 2 REGION 3	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3	At time of transplant	Yes Yes Yes	Yes Yes Yes	Yes Yes Yes	Yes Yes Yes	Yes Yes Yes	Yes Yes Yes	Yes Yes Yes
REGION_10 REGION 11 REGION 2 REGION_3 REGION_4 REGION_5	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5	At time of transplant	Yes Yes Yes Yes Yes	Yes Yes Yes Yes	Yes Yes Yes Yes Yes	Yes Yes Yes Yes	Yes Yes Yes Yes	Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 16	At time of transplant	Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes
REGION_10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7	At time of transplant	Yes Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes	Yes	Yes Yes Yes Yes Yes Yes Yes	Yes Yes Yes Yes Yes Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 7 REGION 6 REGION 7 REGION 8	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7	At time of transplant	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes	Yes	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 8 REGION 9	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9	At time of transplant	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1.1.0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 18 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 RECIPIET WHERE TRANS	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yes Yos Yes Yos Yos Yos	Yes
REGION 10 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 7 REGION 9 PERM STATE year 1, 1.0 PERM STATE year 1, 1.0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 14 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION PHERE TRANSPLANTEDLISTED REGION 11 REGION PHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 12 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 12 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 12 REGION WHERE TRANSPLANTEDLISTED	At time of transplant Follow-up Follow-up Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yos No	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 9 REGION 9 PERM STATE year 1 10 PERM STATE year 1 10 PERM STATE year 1 10	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 9 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION PROMPT REGION PROMPT REGION 11 REGION REGION REGION PROMPT	Al time of bransplant. At time of transplant. Follow-up Follow-up Follow-up Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No	Yes Yes Yes Yes Yes Yes Yes Yes Yes You Yes Yes Yes Yes No No No
REGION 10 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 9 REGION 9 REGION 9 REGION 9 REGION 110 PERM STATE year 1 10 PERM STATE year 1 110 PERM STATE year 1 110 PERM STATE year 1 110	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIED WHERE TRANSPLANTEDLISTED REGION 9 RECIPIED WHERE TRANSPLANTEDLISTED REGION 9 RECIPIED WHERE TRANSPLANTEDLISTED REGION 19 RECIPIED WHERE TRANSPLANTEDLISTED REGION 19 RECIPIED WHERE TRANSPLANTEDLISTED REGION 19 RECIPIED FERMANER RESIDENTIAL STATE GROUP BY UNIOS Region 1 at year 1 RECIPIED FERMANER RESIDENTIAL STATE GROUP BY UNIOS Region 1 at year 1 RECIPIED FERMANER RESIDENTIAL STATE GROUP BY UNIOS Region 1 at year 1	Al time of transplant At time of transplant Follow-up Follow-up Follow-up Follow-up Follow-up	Yes	Yes	Yes	Yes Yes Yas Yas Yas Yes Yes Yes Yos No No No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 7 REGION 9 PERM STATE year 1.1.0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION PERMANEL WHERE TRANSPLANTEDLISTED REGION 10 REGION PERMANEL STANTEDLISTED REGION 10 REGION PERMANEL REGION PERMANEL STANTEDLISTED REGION 10 REGION PERMANEL REGION PERMANEL STANTED REGION 11 REGION PERMANEL REGION PERMANEL STANTED REGION 12 REGION PERMANEL REGION PERMANEL STANTED REGION PERMANEL PE	Al time of transplant At time of transplant Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yos No No No No	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes Yos No No No No	Yes
REGION 10 REGION 11 REGION 2 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 7 REGION 9 PERM STATE year 1 1.0 PERM STATE year 1 1.10 PERM STATE year 1 2.0 PERM STATE year 1 3.0 PERM STATE year 1 3.0 PERM STATE year 1 4.0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION Permanent Residential State Grouped by UNOS Region 12 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 2 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 2 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 2 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 2 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 3 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 3 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 3 st year 1 Recipient Permanent Residential State Grouped by UNOS Region 3 st year 1	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yas Yas Yas Yes Yes Yes Yos No No No No No No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No No No	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1,1.0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 14 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION PERMANENT REGION PROBLEM TO 11 REGION PERMANENT REGION PROBLEM TO 11 REGION PERMANENT REGION PROBLEM TO 11 REGION PERMANENT REGION 11 REGION PERMANE	Al time of transplant At time of transplant Follow-up	Yes	Yes Yes Yes Yas Yes Yes Yes Yes Yes Yes Yes Yes Yes Ye	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yos No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 7 REGION 9 PERM STATE year 1 10	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNOS REGION WHERE TRANSPLANTEDLISTED REGION 19 Recipier Permanert Residential State Grouped by UNOS Region 1 at year 1 Recipier Permanert Residential State Grouped by UNOS Region 10 at year 1 Recipier Permanert Residential State Grouped by UNOS Region 2 at year 1 Recipier Permanert Residential State Grouped by UNOS Region 2 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 3 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 3 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 3 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 5 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 5 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 5 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 5 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 5 at year 1 Recipiert Permanert Residential State Grouped by UNOS Region 5 at year 1	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes You Yes You No	Yes Yes Yes Yes Yes Yes Yes Yes Yes You No	Yes	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1 10 0 PERM STATE year 1, 10 0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 REGION WHERE TRANSPLANTEDLISTED REGION 9 REGION WHERE TRANSPLANTEDLISTED REGION 9 REGION WHERE TRANSPLANTEDLISTED REGION 1 REGION 1 REGION WHERE TRANSPLANTEDLISTED REGION 1 REGI	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yes You No	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1.10 PERM STATE year 1.00	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1 10 PERM STATE year 1 110 PERM STATE year 1 110 PERM STATE year 1 100	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGI	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 REGION 10 REGION 11 REGION 10 REGION 11 REGION 10 REGION 11 REGION 12 REGIO	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION MERCHANTER REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 11 REGION 12 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1 10 PERM STATE year 1 110 PERM STATE year 1 110 PERM STATE year 1 100	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT WHERE TRANSPLANTEDLISTED REGION 1 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1	Al time of transplant At time of transplant follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 REGION 9 REGION 9 REGION 110 PERM STATE year 1 10	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION MERCHANTER REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 11 REGION 12 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes 'Yes 'Yes 'Yes 'Yes 'Yes 'Yes 'Yes '	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 4 REGION 6 REGION 6 REGION 7 REGION 9 PERM STATE year 1, 1,0 PERM STATE year 1, 2,0 PERM STATE year 1, 3,0 PERM STATE year 1, 6,0 PERM STATE year 1, 6,0 PERM STATE year 1, 6,0 PERM STATE year 1, 1,0 PERM STATE year 3, 1,0 PERM STATE year 3, 1,0 PERM STATE year 3, 1,0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT WHERE TRANSPLANTEDLISTED REGION 1 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes	Yes
REGION 10 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 10 PERM STATE year 1 10 PERM STATE year 1 110 PERM STATE year 1 10	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 14 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION THE WHERE TRANSPLANTEDLISTED REGION 19 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 18 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 18 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 18 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGION 11 REGION MAY 11 REGION WHERE TRANSPLANTEDLISTED REGION 19 REGI	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1,10 PERM STATE YEAR 3,10	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 2 year 3 Recipient Permanent Residential State Grouped by UNIOS Region 2 year 3 Recipient Permanent Residential State Grouped by UNIOS Region 2 year 3 Recipient Permanent Residential State Grouped by UNIOS Region 2 year 3 Recipient Permanent Residential State Grouped by UNIOS Region 2 year 3	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes
REGION 10 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 110 REGION 9 REGION 10 REGION	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 10 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 11 REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 12 REGION 11 REGION 11 REGION WHERE TRANSPLANTEDLISTED REGION 11 REGI	Al time of bransplant. At time of transplant. Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Old No	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 7 REGION 8 REGION 8 REGION 9 PERM STATE year 1 1.0 PERM STATE year 1 1.10 PERM STATE year 1 1.10 PERM STATE year 1 1.0 PERM STATE year 3 1.0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 REGION WHERE TRANSPLANTEDLISTED REGION 9 REGION PERMANENT REGION PROVINCE WHERE TRANSPLANTEDLISTED REGION 9 REGION PERMANENT REGION PROVINCE REGION 9 REGION PERMANENT REGION PERMANENT REGION 9 R	Al time of transplant At time of transplant follow-up	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 4 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 7 REGION 8 REGION 7 REGION 8 REGION 9 REGION 10 REGION 9 REGION 110 PERM STATE year 1,10 PERM STATE year 1,10 PERM STATE year 1,10 PERM STATE year 1,10 PERM STATE year 1,50 PERM STATE year 1,50 PERM STATE year 1,50 PERM STATE year 1,60 PERM STATE year 1,10 PERM STATE year 1,10 PERM STATE year 3,10 PERM STATE year 3,00	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes Yes Yes Yes Yes Yes Yes No	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 5 REGION 6 REGION 6 REGION 7 REGION 8 REGION 8 REGION 9 PERM STATE year 1 10 PERM STATE YEAR 3 3 0 PERM STATE YEAR 3 3 0 PERM STATE YEAR 3 6 0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes Yes Ne	Yes	Yes	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 8 REGION 9 PERM STATE year 1, 10 PERM STATE year 3, 70	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 RECIPENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 1 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 3 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 3 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 3 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 3 Reciperer Permanent Residential State Grouped by UNIOS Region 1 at year 3 Reciperer Permanent Residential State Grouped by UNIOS Region 2 at year 3 Reciperer Permanent Residential State Grouped by UNIOS Region 3 at year	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 9 REGION 1 REGION 1 REGION 1 REGION 9 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 110 REGION 11	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Rec	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Ne	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 9 REGION 1 REGION 1 REGION 1 REGION 9 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 110 REGION 11	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 14 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 15 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 16 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at	Al time of transplant At time of transplant	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Ne	Yes	Yes	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 9 REGION 1 REGION 1 REGION 1 REGION 9 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 110 REGION 11	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 9 REGION 1 REGION 1 REGION 1 REGION 9 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 10 REGION 11	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 14 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 15 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 16 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 17 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at	Al time of transplant At time of transplant	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes One Ne	Yes	Yes Yes Yes Yes Yes Yes Yes Yes A Yes Yes A No	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 8 REGION 9 PERM STATE year 1 1.0 PERM STATE year 1 1.10 PERM STATE year 1 1.10 PERM STATE year 1 1.00 PERM STATE year 3 1.00	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes	Yes   Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 PERM STATE year 1.10 PERM STATE year 3.10	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Reci	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes Yes Yes Yes Yes Yes Yes A Yes Yes Yes A No	Yes
REGION 10 REGION 1 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 8 REGION 9 PERM STATE year 1 1.0 PERM STATE year 1 1.10 PERM STATE year 1 1.10 PERM STATE year 1 1.0 PERM STATE year 3 1.0 PERM STATE year 5 2.0 PERM STATE YEAR 5 2.0 PERM STATE YEAR 5 2.0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No
REGION 10 REGION 11 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 8 REGION 8 REGION 9 REGION 9 REGION 9 REGION 9 REGION 10	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 14 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 19 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 2 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at ye	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes AN Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes Yes Yes Yes Yes Yes Yes No	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 1100 PERM STATE year 1 10 0 PERM STATE year 3 10 0 PERM STATE year 5 10 0 PERM STATE year 5 10 0 PERM STATE year 5 30 0 PERM STATE year 5 30 0 PERM STATE year 5 50 0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 3 Recipient Permanent Residen	Al time of transplant At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Ne	Yes	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 8 REGION 8 REGION 9 PERM STATE year 1 10 PERM STATE YEAR 3 10 PERM STATE YEAR 5 5 0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIED REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIED Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 5 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 7 at year 3 Recipient Permanent Reside	Al time of transplant At time of transplant	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 11 10 0 PERM STATE year 1 10 0 PERM STATE year 3 10 0 PERM STATE year 5 10 0 PERM STATE year 5 3 0 PERM STATE year 5 4 0 PERM STATE year 5 4 0 PERM STATE year 5 5 0 PERM STATE year 5 6 0 PERM STATE year 5 6 0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 10 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped	At time of transplant Follow-up	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes One Ne	Yes	Yes Yes Yes Yes Yes Yes Yes A Yes A Yes A Yes A Yes A No	Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 8 REGION 8 REGION 9 PERM STATE year 1 1.0 PERM STATE year 1 1.10 PERM STATE year 1 1.10 PERM STATE year 1 1.00 PERM STATE year 3 1	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 2 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 7 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIED REGION 1 REGION WHERE TRANSPLANTEDLISTED REGION 1 RECIPIED REGION 1	Al time of transplant At time of transplant	Yes	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes	Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes
REGION 10 REGION 11 REGION 2 REGION 3 REGION 3 REGION 4 REGION 6 REGION 6 REGION 7 REGION 8 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 9 REGION 11 10 0 PERM STATE year 1 10 0 PERM STATE year 3 10 0 PERM STATE year 5 10 0 PERM STATE year 5 3 0 PERM STATE year 5 4 0 PERM STATE year 5 4 0 PERM STATE year 5 5 0 PERM STATE year 5 6 0 PERM STATE year 5 6 0	UNOS REGION WHERE TRANSPLANTEDLISTED REGION 10 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 11 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 12 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 3 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 4 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 5 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 6 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 1 UNIOS REGION WHERE TRANSPLANTEDLISTED REGION 9 RECIPIENT Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 10 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 3 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 6 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 1 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped by UNIOS Region 1 at year 3 Recipient Permanent Residential State Grouped	At time of transplant Follow-up	Yes	Yes	Yes Yes Yes Yes Yes Yes Yes Yes No	Yes Yes Yes Yes Yes Yes Yes No	Yes	Yes Yes Yes Yes Yes Yes Yes A Yes Yes Yes A No	Yes

VENT_USE_NEW_initial_CPAP	Assisted Ventilator Use CPAP at start of waitlist	Waitlist	Yes	Yes	No	No	No.	No.	No.
VENT_USE_NEW_initial_Continuous	Assisted Ventilator Use Continuous mechanical at start of waitlist	Waitlist	Yes	Yes	No	No	No	No	No
VENT_USE_NEW_initial_Continuous	Assisted Ventilator Use Continuous mechanical hospitalized at start of waitlist	Waitlist	Yes	Yes	No	No	No	No	No
VENT_USE_NEW_initial_Continuous	Assisted Ventilator Use Continuous mechanical not hospitalized at start of waitlist	Waitlist	Yes	Yes	No	No	No	No	No
VENT_USE_NEW_initial_ECMO	Assisted Ventilator Use ECMO at start of waitlist	Waitlist	Yes	Yes	No	No	No	No	No
VENT USE NEW initial Intermittent	Assisted Ventilator Use Intermittent mechanical at start of waitlist	Waitlist	Yes	Yes	No	No	No	No	No
VENT_USE_NEW_initial_No assisted	Assisted Ventilator Use No assisted ventilation needed at start of waitlist	Waitlist	Yes	Yes	No	No	No	No	No
VENT_USE_NEW_end_BiPAP	Assisted Ventilator Use BiPAP at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	No
VENT_USE_NEW_end_CPAP	Assisted Ventilator Use CPAP at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	No
VENT_USE_NEW_end_Continuous r	Assisted Ventilator Use Continuous mechanical at end of waitlist	Wartlist	Yes	Yes	Yes	Yes	Yes	Yes	No
VENT USE NEW end Continuous r	Assisted Ventilator Use Continuous mechanical hospitalized at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	No
VENT USE NEW end Continuous r	Assisted Ventilator Use Continuous mechanical not hospitalized at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	No
VENT USE NEW end ECMO	Assisted Ventilator Use ECMO at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	No
VENT USE NEW end Intermittent n	Assisted Ventilator Use Intermittent mechanical at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	No
VENT USE NEW end No assisted	Assisted Ventilator Use No assisted ventilation needed at end of waitlist	Waitlist	Yes	Yes	Yes	Yes	Yes	Yes	No
EDUCATION ASSOCIATE/BACHELO	RECIPIENT HIGHEST EDUCATIONAL LEVEL @ REGISTRATION ASSOCIATE/BACHELOR DEGREE	At time of transplant	Yes	Yes	No	No	No	No	No
EDUCATION ATTENDED COLLEGE	RECIPIENT HIGHEST EDUCATIONAL LEVEL @ REGISTRATION ATTENDED COLLEGE/TECHNICAL SC	At time of transplant	Yes	Yes	No	No	No	No	No
EDUCATION GRADE SCHOOL (0.8	RECIPIENT HIGHEST EDUCATIONAL LEVEL @ REGISTRATION GRADE SCHOOL (0-8)	At time of transplant	Yes	Yes	No	No	No	No	No
EDUCATION HIGH SCHOOL (9-12)	RECIPIENT HIGHEST EDUCATIONAL LEVEL @ REGISTRATION HIGH SCHOOL (9-12) or GED	At time of transplant	Yes	Yes	No	No	No	No	No
EDUCATION NONE	RECIPIENT HIGHEST EDUCATIONAL LEVEL @ REGISTRATION NONE	At time of transplant	Yes	Yes	No	No	No	No	No
EDUCATION POST-COLLEGE GRA	RECIPIENT HIGHEST EDUCATIONAL LEVEL @ REGISTRATION POST COLLEGE GRADUATE DEGREE	At time of transplant	Yes	Yes	No	No	No	No	No
EDUCATION BINARIZED	RECIPIENT HIGHEST EDUCATIONAL LEVEL @ REGISTRATION BINARIZED (0 for High School/GED or I		Yes	Yes	Yes	Yes	Yes	Yes	Yes
DIAG A1AT	RECIPIENT PRIMARY DIAGNOSIS Alpha 1 Antitrypsin Deficiency	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG BRONCHIECTASIS	RECIPIENT PRIMARY DIAGNOSIS Bronchiectasis	At time of transplant	Yes	Yes	No		No	No	No
DIAG CF		At time of transplant	Yes	Yes	No	No	No	No	No
DIAG COPD	RECIPIENT PRIMARY DIAGNOSIS COPD	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG COVID ARDS	RECIPIENT PRIMARY DIAGNOSIS COVID ARDS	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG COVID PF	RECIPIENT PRIMARY DIAGNOSIS COVID Pulmonary Fibrosis	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG HP	RECIPIENT PRIMARY DIAGNOSIS Hypersensitivity Pneumonitis	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG IPF	RECIPIENT PRIMARY DIAGNOSIS Idiopathic Pulmonary Fibrosis	At time of transplant	Yes	Yes	No	No	No	No	No
		At time of transplant	Yes	Yes	No	No	No	No	No
DIAG MIXED CTD	RECIPIENT PRIMARY DIAGNOSIS Nonspecific interstitial pneumonia	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG NSIP	RECIPIENT PRIMARY DIAGNOSIS Notispecial interstital predictional	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG OB	RECIPIENT PRIMARY DIAGNOSIS Occupational	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG OCCUPATIONAL	RECIPIENT PRIMARY DIAGNOSIS Other	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG OTHER	RECIPIENT PRIMARY DIAGNOSIS Pulmonary fibrosis - other	At time of transplant	Yes	Yes	No	No	No	No	No
DIAG PF OTHER	RECIPIENT PRIMARY DIAGNOSIS Pulmonary hypertension	At time of transplant	Yes	Yes	No		No	No	No
DIAG PULM HTN		At time of transplant	Yes		No	No	No	No	1000
DIAG RHEUMATOID	RECIPIENT PRIMARY DIAGNOSIS Rheumatoid RECIPIENT PRIMARY DIAGNOSIS Sarcoidosis	At time of transplant	Yes	Yes	No	No	No	No.	No No
DIAG SARCOIDOSIS	RECIPIENT PRIMARY DIAGNOSIS Salcoidosis RECIPIENT PRIMARY DIAGNOSIS Sclerodorma mixed connective tissue disease	At time of transplant	Yes	Yes	No	No	No	No.	No
		At time of transplant		The second secon	No		1000		-
	RECIPIENT PRIMARY DIAGNOSIS Scleroderma pulmonary hypertension	At time of transplant	Yes	Yes	No	No	No	No	No
	RECIPIENT PRIMARY DIAGNOSIS Scienoderma restrictive	At time of transplant	Yes	Yes		No	No	No	No
	RECIPIENT PRIMARY DIAGNOSIS Secondary pulmonary hypertension RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Other at year 1	Follow-up	Yes	Yes	No No	No	No	No	No
PRI_PAYMENT_year_1_Other	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Private at year 1	Follow-up	1144	Yes		No	No	No	No
PRI_PAYMENT_year_1_Private	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Public at year 1	Follow-up	Yes	Yes	No	No	No	No	No
PRI_PAYMENT_year_1_Public	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Public at year 1 RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Other at year 3		Yes	Yes	No	No	No	No	No
PRI_PAYMENT_year_3_Other		Follow-up Follow-up	Yes	Yes	No	No	No	No	No
PRI_PAYMENT_year_3_Private	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Private at year 3		Yes	Yes	No	No	No	No	No
PRI_PAYMENT_year_5_Public	RECIPIENT PRIMARY PAYMENT SOURCE @ TRANSPLANT Public at year 5	Follow-up	Yes	Yes	No	No	No	No	No
	RECIPIENT VENTILATOR SUPPORT POST TRANSPLANT Timeframe ordinalized (NoVentilator support for		Yes	No	No	Yes	Yes	No	No
T GOT THE TELL GOT I GITT DIT	RECIPIENT VENTILATOR SUPPORT POST TRANSPLANT Timeframe binarized (NoVentilator support, Ver		Yes	No	No	Yes	Yes	No	No
GRF STAT year 5	Graft Status at Time of Follow-Up (Y=Functioning, N=Failed) at year 5	Follow-up	Yes	No	No	No	No	No	No

**Table S1: Data dictionary of all UNOS features used for analysis.** The columns indicate which features were used for data exploration and which features were used in various models.